

CITATION REPORT

List of articles citing

Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence

DOI: 10.1161/circulationaha.105.595140
Circulation, 2006, 114, 119-25.

Source: <https://exaly.com/paper-pdf/39706174/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2066	Reviews : VON KNUD KRAKAU. Die Harmon Doktrin : Eine These der Vereinigten Staaten zum internationalen Flubrecht. Hamburg, Institut ft.Auswärtige Politik, 1966. Pp. 139. Price not indicated. 1967 , 9, 372-373		
2065	Computational approaches to structural and functional analysis of plastocyanin and other blue copper proteins. 2004 , 61, 1123-42		21
2064	Study of molecular events in cells by fluorescence correlation spectroscopy. 2005 , 62, 535-50		79
2063	Innovative approaches to anti-arrhythmic drug therapy. 2006 , 5, 1034-49		155
2062	Transvenous radiofrequency catheter ablation for atrial flutter and atrial fibrillation: the end of the beginning?. <i>Circulation</i> , 2006 , 114, 1670-2	16.7	3
2061	The number of US citizens with AF could top 10 million by 2050. 2006 , 3, 642-643		
2060	Advances in the prevention and treatment of cardiovascular disease. 2007 , 26, 25-37		44
2059	Left atrial appendage closure for stroke prevention in atrial fibrillation: state of the art and current challenges. 2007 , 4, 428-35		25
2058	Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. <i>Circulation</i> , 2007 , 115, e69-171	16.7	2297
2057	Maintaining sinus rhythm--making treatment better than the disease. 2007 , 357, 1039-41		11
2056	Kinematic characterization of a cardiac ablation catheter. 2007 ,		9
2055	A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. 2007 , 93, 606-12		119
2054	Atrial fibrillation--the growing epidemic. 2007 , 93, 542-3		50
2053	Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. <i>Circulation</i> , 2007 , 115, 2689-96	16.7	814
2052	High prevalence of paroxysmal atrial fibrillation and/or atrial flutter in metabolic syndrome. 2007 , 71, 252-5		53
2051	Novel pharmacological therapies for atrial fibrillation. 2007 , 22, 450-7		3
2050	Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence. 2007 , 2007, 440-441		

2049	Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. 2007 , 2007, 381-383	
2048	Is there any hope for angiotensin-converting enzyme inhibitors in atrial fibrillation?. 2007 , 154, 403-6	18
2047	Shedding new light on the pathophysiology of conversion of paroxysmal atrial fibrillation into persistent atrial fibrillation. 2007 , 154, 801-4	2
2046	Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure. 2007 , 154, 1140-5	49
2045	Post-stenting antithrombotic drug therapy in patients with atrial fibrillation. 2007 , 120, 920-2	1
2044	Global epidemic of atrial fibrillation including China. 2007 , 122, 160	5
2043	Management of atrial fibrillation. 2007 , 370, 604-18	164
2042	Minimally invasive surgery for atrial fibrillation. 2007 , 19, 33-8	11
2041	Adjunctive procedures in degenerative mitral valve repair: tricuspid valve and atrial fibrillation surgery. 2007 , 19, 121-6	15
2040	[Acute coronary syndrome (ACS) with elevated ST segment: consensus strategy for early reperfusion. The Public Enterprise for Health Emergencies and the ARIAM Project Andalusia]. 2007 , 31, 502-9	0
2039	Atrioventricular junction ablation combined with either right ventricular pacing or cardiac resynchronization therapy for atrial fibrillation: the need for large-scale randomized trials. 2007 , 4, 224-32	38
2038	Amiodarone for atrial fibrillation. 2007 , 356, 935-41	164
2037	Catheter ablation as first-line therapy for patients with symptomatic atrial fibrillation. 2007 , 5, 663-72	
2036	Epidemiology of atrial fibrillation: a current perspective. 2007 , 4, S1-6	97
2035	[Prevalence of atrial fibrillation in the Spanish population aged 60 years or more. The PREV-ICTUS study]. 2007 , 60, 616-24	85
2034	Atrial fibrillation--a new cardiac channelopathy. 2007 , 16, 356-60	11
2033	Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. 2007 , 49, 986-92	322
2032	The year in epidemiology, health services research, and outcomes research. 2007 , 50, 2254-62	1

2031	Atrial fibrillation. 2007 , 186, 197-202	27
2030	Economics of managing atrial fibrillation: broadening the focus to include efficiency. 2007 , 18, 634-5	1
2029	Overview of management of atrial fibrillation in symptomatic elderly patients: pharmacologic therapy versus AV node ablation. 2007 , 81, 284-7	13
2028	n-3 (omega-3) polyunsaturated fatty acids prevent acute atrial electrophysiological remodeling. 2007 , 150, 281-5	46
2027	Variants conferring risk of atrial fibrillation on chromosome 4q25. 2007 , 448, 353-7	702
2026	The new Medicare Part D prescription drug benefit: an estimation of its effect on prescription drug costs in a Medicare population with atrial fibrillation. 2007 , 55, 1038-43	11
2025	Cardioversion of atrial fibrillation: from guidelines to contemporary clinical practice. 2007 , 61, 714-6	
2024	Atrial fibrillation in end-stage renal disease. 2007 , 30, 1391-7	35
2023	About arrhythmogenic triggers and substrates in aging atria: partners in crime for atrial fibrillation development?. 2007 , 18, 532-3	3
2022	Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. 2007 , 18, 628-33	99
2021	Atrial fibrillation and stroke prevention. 2007 , 6, 981-93	174
2020	Dual antiplatelet and oral anticoagulant therapy: increasing use and precautions for a hazardous combination. 2008 , 1, 62-4	4
2019	Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician. 2008 , 26, 167-74	11
2018	Regenerative therapies in electrophysiology and pacing. 2008 , 22, 87-98	3
2017	[Rate versus rhythm control with and without heart failure]. 2008 , 33, 568-79	0
2016	Innovation focus: the patient with arrhythmia. 2008 , 1, 258-72	1
2015	New developments in anticoagulation for atrial fibrillation. 2008 , 10, 388-97	10
2014	Nonpharmacologic therapy of atrial fibrillation. 2008 , 2, 365-371	

2013	Examining warfarin underutilization rates in patients with atrial fibrillation: Detailed chart review essential to capture contraindications to warfarin therapy. 2008 , 6, 6	41
2012	Progress in secondary stroke prevention. 2008 , 63, 418-27	19
2011	Update on atrial fibrillation: part I. 2008 , 31, 55-62	77
2010	Case studies with the experts: management decisions in atrial fibrillation. 2008 , 19 Suppl 1, S1-12; quiz S13-5	5
2009	Radiofrequency catheter ablation of atrial fibrillation and thromboembolic risk. 2008 , 15, 1261-2	
2008	Warfarin for atrial fibrillation in community-based practise. 2008 , 6, 1647-54	90
2007	Initiation and persistence of warfarin or aspirin as thromboprophylaxis in chronic atrial fibrillation in general practice. 2008 , 6, 1622-4	
2006	Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database. 2008 , 28, 540-8	54
2005	Risk stratification for recurrent heart failure in patients post-myocardial infarction with electrocardiographic and echocardiographic left atrial abnormality. 2008 , 101, 1373-8	9
2004	Changing trends of hospital utilization in patients after their first episode of atrial fibrillation. 2008 , 102, 568-72	51
2003	Self-management of atrial fibrillation: a new frontier for nursing research. 2008 , 23, 37-40	13
2002	ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults with Nonvalvular Atrial Fibrillation or Atrial Flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation) Developed in Collaboration with the Heart Rhythm Society. 2008 , 51, 865-84	99
2001	Damage assessment after ablation role of cardiovascular magnetic resonance. 2008 , 52, 1272-3	3
2000	Economic Costs Associated with Atrial Fibrillation. 2008 , 13-26	4
1999	Pharmacotherapy for atrial arrhythmias: present and future. 2008 , 5, S26-31	16
1998	Treatment of atrial fibrillation. 2008 , 88, 75-94	31
1997	Knowledge and self-management behaviors of patients with recently detected atrial fibrillation. 2008 , 37, 79-90	60
1996	Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005. 2008 , 155, 829-40	14

1995	Oral anticoagulant therapy for patients with atrial fibrillation--an update. 2008 , 123 Suppl 1, S46-9	2	
1994	Clinical predictors and relationship between early and late atrial tachyarrhythmias after pulmonary vein antrum isolation. 2008 , 5, 679-85	125	
1993	Prevalence of early-onset atrial fibrillation in congenital long QT syndrome. 2008 , 5, 704-9	131	
1992	Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation. 2008 , 22, 815-25	35	
1991	Reducing the risk for stroke in patients who have atrial fibrillation. 2008 , 26, 267-75, vii	13	
1990	Anticoagulation control in atrial fibrillation: optimizing risks and benefits. 2008 , 1, 72-3	1	
1989	New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I _{Kur}): rationale, pharmacology and evidence for potential therapeutic value. 2008 , 52, 105-20	73	
1988	Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals. 2008 , 10, 15-20	198	
1987	The significance of preoperative atrial fibrillation in patients undergoing cardiac surgery: preoperative atrial fibrillation--still underestimated opponent. 2008 , 10, 1266-70	32	
1986	Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 2008 , 133, 546S-592S	595	
1985	Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. 2009 , 30, 813-9	165	
1984	Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. <i>Circulation</i> , 2008 , 117, 1255-60	16.7	308
1983	Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation. 2008 , 336, 614-5	34	
1982	Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. <i>Circulation</i> , 2008 , 117, e25-146	16.7	2438
1981	ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation): Vernakalant (RSD1235) in the management of atrial fibrillation: a review of pharmacological properties, clinical efficacy and safety. 2008 , 4, 559-67	16.7	63
1980		2	
1979	The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy. 2008 , 2, 507-13	15	
1978	Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. 2008 , 5, 30-41	64	

1977	Pharmacotherapy of atrial fibrillation: an old option with new possibilities. 2008 , 9, 913-25		4
1976	Minimally invasive cardiothoracic surgery for atrial fibrillation: a combined Japan-US experience. 2008 , 72, 434-6		23
1975	Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan: analysis of 41,436 non-employee residents in Kurashiki-city. 2008 , 72, 909-13		104
1974	Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective. 2008 , 11, 281-98		90
1973	Clinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States. 2008 , 14, 143-50		36
1972	Spectral analysis of ultrasound backscatter for characterization of HIFU lesions in cardiac tissue high-frequency imaging. 2009 ,		3
1971	Atrial fibrillation: pathogenesis, medical-surgical management and dental implications. 2009 , 140, 167-77; quiz 248		9
1970	Patient perspectives on taking vitamin K antagonists: a qualitative study in the UK, USA and Spain. 2009 , 9, 467-74		19
1969	Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. <i>Circulation</i> , 2009 , 119, 2146-52	16.7	213
1968	The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. 2009 , 2, 474-80		598
1967	Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. 2009 , 32, 1851-6		127
1966	New therapies for stroke prevention in atrial fibrillation: the long road to enhanced efficacy. <i>Circulation</i> , 2009 , 120, 1024-6	16.7	3
1965	Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. 2009 , 11, 860-85		84
1964	Big men and atrial fibrillation: effects of body size and weight gain on risk of atrial fibrillation in men. 2009 , 30, 1113-20		139
1963	Targeting of cardiac autonomic plexus for modulation of intracardiac neural tone. 2009 , 11, 1090-6		8
1962	Atrial Fibrillation: A4 study: proof of concept?. 2009 , 6, 332-4		0
1961	Dronedronone. <i>Circulation</i> , 2009 , 120, 636-44	16.7	119
1960	Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. 2009 , 30, 1038-45		365

1959	Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population. 2009 , 22, 538-44		41
1958	Atrial arrhythmias: a "call to arms" for congenital heart disease caregivers. <i>Circulation</i> , 2009 , 120, 1649-50.	16.7	2
1957	Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. <i>Circulation</i> , 2009 , 119, 606-18	16.7	378
1956	Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. 2009 , 2, 297-304		77
1955	Factor II- and factor Xa-inhibitors for prevention and treatment of thromboses / Faktor II- und Faktor Xa-Inhibitoren in der Prävention und Therapie von Thrombosen. 2009 , 33, 121-127		
1954	Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. <i>Circulation</i> , 2009 , 119, 2516-25	16.7	367
1953	Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation. 2009 , 43, 840-8		21
1952	Cardima Surgical Ablation System: a novel tool for cardiac ablation in the treatment of atrial fibrillation. 2009 , 6, 231-6		
1951	Left atrial appendage occlusion eliminates the need for warfarin. <i>Circulation</i> , 2009 , 120, 1919-26; discussion 1926	16.7	37
1950	Atrial fibrillation: A risk score for AF-burning the haystack to find the needle. 2009 , 6, 394-5		2
1949	Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. <i>Circulation</i> , 2009 , 119, e21-181	16.7	1705
1948	Can the NICE guidelines on the management of atrial fibrillation improve its management?. 2009 , 9, 207-9		
1947	Sleep-disordered breathing and atrial fibrillation. 2009 , 51, 411-5		53
1946	Point: Minimally invasive bipolar radiofrequency ablation of lone atrial fibrillation: early multicenter results. 2009 , 137, 521-6		77
1945	Can we improve outcomes in AF patients by early therapy?. 2009 , 7, 72		15
1944	Prevalence, functional impact, and mortality of atrial fibrillation in an older Italian population (from the Pro.V.A. study). 2009 , 104, 1092-7		52
1943	Increasing prevalence of atrial fibrillation and flutter in the United States. 2009 , 104, 1534-9		608
1942	Acute weight gain and diastolic dysfunction as a potent risk complex for post stem cell transplant atrial fibrillation. 2009 , 84, 499-503		18

1941	Quality of life in older people with atrial fibrillation. 2009 , 25, 37-42	30
1940	Pharmacotherapy for rhythm management in elderly patients with atrial fibrillation. 2009 , 25, 25-9	13
1939	Epidemiology of atrial fibrillation. 2009 , 25, 3-8	70
1938	Radiofrequency catheter ablation of atrial fibrillation in older patients: outcomes and complications. 2009 , 25, 31-5	50
1937	Perioperative management of anticoagulation: guidelines translated for the clinician. 2009 , 28, 16-22	7
1936	Hypertension and atrial fibrillation. 2009 , 11, 430-5	20
1935	Non-invasive atrial fibrillation organization follow-up under successive attempts of electrical cardioversion. 2009 , 47, 1247-55	7
1934	Relationship between adiponectin and left atrium size in uncomplicated obese patients: adiponectin, a link between fat and heart. 2009 , 19, 1324-32	35
1933	National assessment of Medicare prescription plan coverage gaps among patients with atrial fibrillation in the US. 2009 , 26, 784-94	1
1932	Cost of atrial fibrillation in United States managed care organizations. 2009 , 26, 847-57	64
1931	Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects. 2009 , 68, 77-88	50
1930	Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. 2009 , 41, 879-81	307
1929	Cardioversion for atrial fibrillation: treatment options and advances. 2009 , 32, 1073-84	14
1928	Percutaneous epicardial left atrial appendage closure: preliminary results of an electrogram guided approach. 2009 , 20, 908-15	55
1927	Safe and rapid isolation of pulmonary veins using a novel circular ablation catheter and duty-cycled RF generator. 2009 , 20, 1097-101	51
1926	Reduced peak atrial systolic mitral annular velocity predicts the development of nonvalvular atrial fibrillation. 2009 , 26, 645-50	3
1925	Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet-based expert system. 2009 , 7, 1284-90	61
1924	Pulmonary vein stenosis complicating ablation for atrial fibrillation: clinical spectrum and interventional considerations. 2009 , 2, 267-76	152

1923	Atrial fibrillation in the elderly. 2009 , 27, 417-27, table of contents	3
1922	Atrial fibrillation: mechanistic insights and treatment options. 2009 , 20, 672-81	51
1921	Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. 2009 , 124, 37-41	213
1920	Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. 2009 , 137, 102-7	258
1919	Is significance of atrial fibrillation in acute aortic dissection underestimated?. 2009 , 37, 168-70	7
1918	Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. 2009 , 158, 111-7	378
1917	Rationale and design of the Duke Electrophysiology Genetic and Genomic Studies (EPGEN) biorepository. 2009 , 158, 719-25	7
1916	Amiodarone or dronedarone for atrial fibrillation: too early to know the winner?. 2009 , 54, 1096-8	5
1915	Triggering of nocturnal arrhythmias by sleep-disordered breathing events. 2009 , 54, 1797-804	185
1914	Management of atrial fibrillation in Chinese patients. 2009 , 4, 79-83	6
1913	Surgery for atrial fibrillation. 2009 , 6, 505-13	27
1912	Atrial Fibrillation: Is it an Epidemic?. 2009 , 62, 10-14	2
1911	Novel approaches for pharmacological management of atrial fibrillation. 2009 , 69, 757-74	58
1910	Molecular genetics of atrial fibrillation. 2009 , 1, 54	17
1909	Burden of atrial fibrillation. 2009 , 25, 1261-3	10
1908	Stroke prevention in atrial fibrillation: WATCHMAN versus warfarin. 2009 , 7, 727-9	11
1907	Incidence and temporal pattern of hospital readmissions for patients with atrial fibrillation. 2009 , 25, 1215-20	21
1906	Delirium cordis: can we predict the onset of atrial fibrillation?. 2009 , 373, 698-700	5

1905	Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. 2009 , 373, 739-45	715
1904	Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. 2009 , 374, 534-42	1373
1903	[Atrial fibrillation: are we faced with an epidemic?]. 2009 , 62, 10-4	17
1902	Bridging of chronic oral anticoagulation with enoxaparin in patients with atrial fibrillation: results from the prospective BRAVE registry. 2009 , 27, 230-8	22
1901	Echocardiography in cardiovascular public health: the Feigenbaum Lecture 2008. 2009 , 22, 649-56; quiz 751-2	14
1900	Milestones in the management of atrial fibrillation. 2009 , 6, S62-7	32
1899	Genetics of atrial fibrillation. 2009 , 27, 25-33, vii	21
1898	Trends in utilization and complications of catheter ablation for atrial fibrillation in Medicare beneficiaries. 2009 , 6, 1267-73	82
1897	The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. 2009 , 25, 563-77, vii	299
1896	The need for new oral anticoagulants in clinical practice. 2009 , 10, 605-9	15
1895	What can ongoing clinical trials of anticoagulants demonstrate?. 2009 , 10, 610-5	1
1894	2) Irregular Pulse Especially Treatment of Atrial Fibrillation. 2009 , 98, 2181-2187	
1893	Measuring quality of oral anticoagulation care: extending quality measurement to a new field. 2009 , 35, 146-55	41
1892	Pulse check as a screen for atrial fibrillation. 2009 , 20, 310-313	4
1891	Pulse check as a screen for atrial fibrillation. 2009 , 4, 426-429	
1890	Electrocardiographic markers of cardioversion success in patients with atrial fibrillation. 2009 , 102, 885-9	2
1889	Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. 2009 , 30, 2969-77c	136
1888	Ablation strategies for atrial fibrillation. 2009 , 7, 1091-101	2

1887	Racial/ethnic differences in the prevalence of atrial fibrillation among older adults--a cross-sectional study. 2010 , 102, 906-13	73
1886	Treatment strategies for atrial fibrillation. 2010 , 35, 25-9	2
1885	Optimal imaging for planning and guiding interventions in structural heart disease: a multi-modality imaging approach. 2010 , 12, E10-E23	2
1884	Psychological distress in patients diagnosed with atrial fibrillation: the state of the science. 2010 , 25, 40-51	66
1883	The burden of atrial fibrillation and other cardiac arrhythmias in an employed population: associated costs, absences, and objective productivity loss. 2010 , 52, 383-91	25
1882	Persistent atrial fibrillation: current approach and controversies. 2010 , 25, 1-7	32
1881	The 2010 update of the ESC guidelines for the management of atrial fibrillation. Beyond the rate or rhythm strategy debate. 2010 , 74, 2538-41	2
1880	Atrial fibrillation in women. 2010 , 7, 139-146	1
1879	Body size and atrial fibrillation in Japanese outpatients. 2010 , 74, 66-70	21
1878	Dronedarone (Multaq): a new option in atrial fibrillation. 2010 , 21, 30-34	
1877	Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States. 2010 , 33, 270-9	51
1876	Inhibition of IK _{ACh} current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation. 2010 , 381, 251-9	38
1875	Atrial Ca ²⁺ signaling in atrial fibrillation as an antiarrhythmic drug target. 2010 , 381, 195-206	33
1874	Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. 2010 , 381, 1-13	38
1873	Cardiovascular function and the veteran athlete. 2010 , 110, 459-78	24
1872	Simulations of reduced conduction reserve in the diabetic rat heart: response to uncoupling and reduced excitability. 2010 , 38, 1415-25	10
1871	Umstellung einer oralen Antikoagulation vor einem großen gefäßchirurgischen Eingriff. 2010 , 15, 615-617	
1870	Sex Differences in Atrial Fibrillation and Its Complications. 2010 , 4, 237-243	1

1869	Left atrial appendage closure. 2010 , 12, 413-21	23
1868	Emerging therapies for atrial fibrillation: is the paradigm shifting?. 2010 , 28, 1-4	
1867	Atrial fibrillation in the Malmö Diet and Cancer study: a study of occurrence, risk factors and diagnostic validity. 2010 , 25, 95-102	207
1866	Atrial fibrillation. 2010 , 38, 507-514	3
1865	Dronedronone: a new antiarrhythmic agent. 2010 , 30, 904-15	24
1864	The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. 2010 , 105, 687-93	84
1863	Annual incidence of atrial fibrillation and related factors in adults. 2010 , 106, 1129-33	38
1862	[Atrial fibrillation in 2010: an increasing morbidity and mortality burden]. 2010 , 59 Suppl 1, S4-13	7
1861	[Current management of atrial fibrillation: rhythm or rate control and thoughts about a new treatment paradigm]. 2010 , 59 Suppl 1, S33-6	
1860	Meeting the unmet needs in anticoagulant therapy. 2010 , 85, 1-28	61
1859	Chronic augmentation of the parasympathetic tone to the atrioventricular node: a nonthoracotomy neurostimulation technique for ventricular rate control during atrial fibrillation. 2010 , 21, 193-9	25
1858	A prospective study evaluating the role of obesity and obstructive sleep apnea for outcomes after catheter ablation of atrial fibrillation. 2010 , 21, 521-5	85
1857	The impact of new and emerging clinical data on treatment strategies for atrial fibrillation. 2010 , 21, 946-58	19
1856	The effects of rate and rhythm control on blood pressure and antihypertensive drug usage in patients with atrial fibrillation and hypertension enrolled in the AFFIRM trial. 2010 , 21, 1094-8	6
1855	Dronedronone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy. 2010 , 6, 517-23	15
1854	New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. 2010 , 104, 1099-105	91
1853	Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects. 2010 , 103, 234-41	50
1852	Atherothrombosis and atrial fibrillation: Important and often overlapping clinical syndromes. 2010 , 104, 657-63	57

1851	Selective molecular potassium channel blockade prevents atrial fibrillation. <i>Circulation</i> , 2010 , 121, 2263-70.	73
1850	Challenges in the classification of atrial fibrillation. 2010 , 7, 451-60	30
1849	Caffeine consumption and incident atrial fibrillation in women. 2010 , 92, 509-14	54
1848	Pericardial fat is associated with prevalent atrial fibrillation: the Framingham Heart Study. 2010 , 3, 345-50	283
1847	Augmenting maintenance of sinus rhythm in the control of atrial fibrillation by antiarrhythmic drug combinations. 2010 , 15, 31S-5S	4
1846	Outcome of atrial fibrillation among patients with end-stage renal disease. 2010 , 25, 1225-30	13
1845	Optimizing the management of atrial fibrillation: focus on current guidelines and the impact of new agents on future recommendations. 2010 , 15, 244-56	1
1844	Vernakalant: A novel agent for the termination of atrial fibrillation. 2010 , 67, 1157-64	10
1843	Recent advances in oral anticoagulation for atrial fibrillation. 2010 , 4, 395-407	5
1842	Birth weight is a significant risk factor for incident atrial fibrillation. <i>Circulation</i> , 2010 , 122, 764-70	16.7 49
1841	Who receives anticoagulant treatment with warfarin and why? A population-based study in Finland. 2010 , 28, 237-41	19
1840	Treatment of atrial fibrillation in 2010 and beyond. 2010 , 15, 5	1
1839	Improvements in symptoms and quality of life in patients with paroxysmal atrial fibrillation treated with radiofrequency catheter ablation versus antiarrhythmic drugs. 2010 , 3, 615-23	86
1838	Prevalence, pathogenesis, and impact of atrial fibrillation. 2010 , 67, S11-6	12
1837	Stroke risk in AF: do AF patterns matter?. 2010 , 31, 908-10	9
1836	A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. 2010 , 31, 1730-6	104
1835	Atrial fibrillation: is the prevalence rising?. 2010 , 12, 451-2	23
1834	Evaluation of non-synonymous NPPA single nucleotide polymorphisms in atrial fibrillation. 2010 , 12, 1078-83	22

1833	Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. <i>Circulation</i> , 2010 , 121, 200-7	16.7	211
1832	Stroke risk and antithrombotic strategies in atrial fibrillation. 2010 , 41, 2705-13		59
1831	The evolving field of stroke prevention in patients with atrial fibrillation. 2010 , 41, S17-20		13
1830	Warfarin versus new agents: interpreting the data. 2010 , 2010, 221-8		29
1829	Validation of an atrial fibrillation risk algorithm in whites and African Americans. 2010 , 170, 1909-17		104
1828	Stroke prevention in atrial fibrillation patients. 2010 , 11, 2331-50		4
1827	Myocardial perfusion imaging does not adequately assess the risk of coronary artery disease in patients with atrial fibrillation. 2010 , 12, 643-8		14
1826	Beyond PV isolation for ablation of persistent AF. 2010 , 7, 121-2		1
1825	Atrial fibrillation in congestive heart failure. 2010 , 6, 187-200		89
1824	Epidemiología de las taquiarritmias preoperatorias en la cirugía cardíaca. 2010 , 17, 131-141		
1823	Genetics of atrial fibrillation. 2010 , 6, 239-47		27
1822	Future Developments in Nonsurgical Epicardial Therapies. 2010 , 2, 135-146		2
1821	Hypertension and atrial fibrillation: evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model. 2010 , 7, 1282-90		132
1820	Fibrilación auricular. Generalidades. indicación de la ablación. 2010 , 17, 173-179		
1819	Short-term hypertension is associated with the development of atrial fibrillation substrate: a study in an ovine hypertensive model. 2010 , 7, 396-404		73
1818	Principles of Anticoagulation and New Therapeutic Agents in Atrial Fibrillation. 2010 , 2, 479-492		0
1817	Impact of genetic discoveries on the classification of lone atrial fibrillation. 2010 , 55, 705-12		70
1816	Genetic mutations as risk predictors of atrial fibrillation recurrence after catheter ablation?. 2010 , 55, 754-7		4

1815	Progression of paroxysmal to persistent atrial fibrillation factors promoting the HATCH score. 2010 , 55, 732-4	11
1814	Atrial fibrillation and obesity an association of increasing importance. 2010 , 55, 2328-9	13
1813	The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study). 2010 , 55, 2319-27	308
1812	Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. 2010 , 56, 827-37	168
1811	Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments. 2010 , 56, 2067-76	53
1810	Atrial fibrillation-the final frontier. 2010 , 15, 36S-50S	6
1809	Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). 2010 , 31, 2369-429	3452
1808	Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese. 2010 , 139, 173-80	106
1807	Androgens and atrial fibrillation: friends or foes?. 2010 , 145, 365-367	11
1806	[Management of a first recent episode of atrial fibrillation in clinical practice]. 2010 , 39, 662-8	
1805	Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. 2010 , 21, 516-23	44
1804	Proteomic and metabolomic analysis of atrial profibrillatory remodelling in congestive heart failure. 2010 , 49, 851-63	69
1803	Apixaban for reduction in stroke and other Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. 2010 , 159, 331-9	345
1802	Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. 2010 , 159, 850-6	134
1801	Impact of hospitalization on health-related quality of life in atrial fibrillation patients in Canada and the United States: results from an observational registry. 2010 , 160, 752-8	23
1800	Underuse of oral anticoagulants in atrial fibrillation: a systematic review. 2010 , 123, 638-645.e4	677
1799	Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. 2010 , 123, 646-51	150
1798	A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. 2010 , 138, 1093-100	2947

1797	Heart disease and stroke statistics--2010 update: a report from the American Heart Association. <i>Circulation</i> , 2010 , 121, e46-e215	16.7	3147
1796	Dronedarone: current evidence and future questions. 2010 , 28, 38-47		10
1795	New antithrombotics for atrial fibrillation. 2010 , 28, 278-86		12
1794	New antiarrhythmic drugs for treatment of atrial fibrillation. 2010 , 375, 1212-23		210
1793	Atrial fibrillation is a possible marker of frailty in hospitalized patients: results of the GIFA Study. 2010 , 22, 129-33		32
1792	Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). 2010 , 12, 1360-420		1120
1791	Validation of the AF-QoL, a disease-specific quality of life questionnaire for patients with atrial fibrillation. 2010 , 12, 364-70		63
1790	Predictors of warfarin use in atrial fibrillation patients in the inpatient setting. 2010 , 10, 37-48		38
1789	The pharmaceutical pipeline for atrial fibrillation. 2011 , 43, 13-32		11
1788	Home management of oral anticoagulation via telemedicine versus conventional hospital-based treatment. 2011 , 17, 169-76		29
1787	Full report from the first annual Heart Rhythm Society Research Forum: a vision for our research future, "dream, discover, develop, deliver". 2011 , 8, e1-12		1
1786	Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study. 2011 , 8, 1160-6		141
1785	Termination of sustained atrial flutter and fibrillation using low-voltage multiple-shock therapy. 2011 , 8, 101-8		36
1784	Advances in the Pharmacologic Management of Atrial Fibrillation. 2011 , 3, 157-167		
1783	Atrial fibrillation. 2011 , 29, 747-58, vi		7
1782	Mechanisms Underlying Atrial Fibrillation. 2011 , 3, 141-156		
1781	Stroke prevention versus bleeding risk in atrial fibrillation: a clinical dilemma. 2011 , 57, 181-3		16
1780	Pericardial fat is associated with atrial fibrillation severity and ablation outcome. 2011 , 57, 1745-51		281

1779	Lenient versus strict rate control in atrial fibrillation some devils in the details. 2011 , 58, 950-2	10
1778	Effect of lenient versus strict rate control on cardiac remodeling in patients with atrial fibrillation data of the RACE II (RAte Control Efficacy in permanent atrial fibrillation II) study. 2011 , 58, 942-9	34
1777	Wrinkles in the atrium: age, atrial fibrillation, or something else. 2011 , 58, 2233-5	8
1776	Epidemiology of atrial fibrillation in France: extrapolation of international epidemiological data to France and analysis of French hospitalization data. 2011 , 104, 115-24	53
1775	Heart disease and stroke statistics--2011 update: a report from the American Heart Association. <i>Circulation</i> , 2011 , 123, e18-e209	16.7 3795
1774	Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. 2011 , 13, 308-28	190
1773	Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. 2011 ,	2
1772	The epidemiology of atrial fibrillation in adults depends on locale of diagnosis. 2011 , 161, 986-992.e1	29
1771	Differential impact of race and risk factors on incidence of atrial fibrillation. 2011 , 162, 31-7	39
1770	Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. 2011 , 162, 606-612.e1	120
1769	It's health care delivery, stupid: implementing the New Canadian Cardiovascular Society atrial fibrillation treatment guidelines. 2011 , 27, 14-8	4
1768	Atrial fibrillation: a real-life observational study in the Qubec population. 2011 , 27, 794-9	5
1767	Atrial fibrillation: current knowledge and future directions in epidemiology and genomics. <i>Circulation</i> , 2011 , 124, 1982-93	16.7 197
1766	Atrial fibrillation: pathophysiology and current therapy. 2011 , 43, 425-36	3
1765	Atrial fibrillation and obesity among older Chinese: the Guangzhou Biobank Cohort Study. 2011 , 148, 48-52	42
1764	Prognostic impact of atrial fibrillation progression in a community study: AFBAR Study (Atrial Fibrillation in the Barbanza Area Study). 2011 , 153, 68-73	22
1763	Rate vs. rhythm control in patients with atrial fibrillation--an updated meta-analysis of 10 randomized controlled trials. 2011 , 153, 96-8	13
1762	TLR2 was overexpressed independent of IL-6 in patients with valvular atrial fibrillation. 2011 , 25, 178-84	4

1761	Using multiple databases to produce comprehensive follow-up in an effort to enhance evaluation of outcome measurements: surgical ablation (Maze) exemplar. 2011 , 33, 50-63	13
1760	Clinical profiles, efficacy of antiarrhythmic drug therapy, and cardiovascular prognosis in patients with first detected paroxysmal atrial fibrillation. 2011 , 52, 32-8	6
1759	Long-term efficacy of upstream therapy with lipophilic or hydrophilic statins on antiarrhythmic drugs in patients with paroxysmal atrial fibrillation: comparison between atorvastatin and pravastatin. 2011 , 52, 359-65	12
1758	Long-term efficacy of amiodarone therapy for the prevention of recurrence of paroxysmal atrial fibrillation. Analysis based on patient characteristics. 2011 , 52, 212-7	4
1757	Prevalence and Predisposing Factors of Atrial Fibrillation in a Multi-Ethnic Society: The Impact of Racial Differences in Bahrain. 2011 , 4, 9-16	2
1756	Stepwise Approach for Ablation of Persistent Atrial Fibrillation. 2011 , 304-315	
1755	Atrial fibrillation and the use of oral bisphosphonates. 2011 , 7, 131-44	8
1754	Prevention of atrial fibrillation after cardiac surgery. 2011 , 24, 58-63	16
1753	The role of obesity and sleep apnea in atrial fibrillation. 2011 , 26, 40-5	11
1752	The perils of combination antithrombotic therapy and potential resolutions. 2011 , 42, 278-81	6
1751	Fibrillation auriculaire. 2011 , 6, 1-13	
1750	Clinical management of atrial fibrillation: need for a comprehensive patient-centered approach. 2011 , 140, 843-845	6
1749	Role of atrioventricular nodal ablation and pacemaker therapy in elderly patients with recurrent atrial fibrillation. 2011 , 3, 713-720	1
1748	Current and emerging therapies for stroke prophylaxis in atrial fibrillation. 2011 , 1, 1019-1037	
1747	Association between lipid profile and risk of atrial fibrillation. 2011 , 75, 2767-74	86
1746	High-resolution endocardial and epicardial optical mapping in a sheep model of stretch-induced atrial fibrillation. 2011 ,	11
1745	Improved anticoagulant control in patients using home international normalized ratio testing and decision support provided through the Internet. 2011 , 41, 332-7	14
1744	Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification. 2011 , 9, 441-9	26

1743	Effects of metoprolol therapy on cardiac gap junction remodelling and conduction in human chronic atrial fibrillation. 2011 , 164, 607-16	27
1742	Atrial fibrillation: what have recent trials taught us regarding pharmacologic management of rate and rhythm control?. 2011 , 34, 247-59	9
1741	Quality of life with atrial fibrillation: do the spouses suffer as much as the patients?. 2011 , 34, 804-9	16
1740	Atrial fibrillation hospitalization is not increased with short-term elevations in exposure to fine particulate air pollution. 2011 , 34, 1475-9	31
1739	Percutaneous epicardial left atrial appendage closure: intermediate-term results. 2011 , 22, 64-70	32
1738	Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. 2011 , 22, 839-45	259
1737	The impact of dronedarone on lone atrial fibrillation: perhaps not such a "benign" arrhythmia?. 2011 , 22, 777-80	0
1736	Non-surgical left atrial appendage closure for stroke prevention in atrial fibrillation. 2011 , 22, 1184-91	10
1735	Assessment of atrial electromechanical delay by tissue Doppler echocardiography in obese subjects. 2011 , 19, 779-83	19
1734	Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. 2011 , 9 Suppl 1, 344-51	67
1733	The "missing" link in atrial fibrillation heritability. 2011 , 44, 641-4	14
1732	Novel pharmacological targets for the rhythm control management of atrial fibrillation. 2011 , 132, 300-13	24
1731	Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] study). 2011 , 108, 1272-6	81
1730	Rhythm control for management of patients with atrial fibrillation: balancing the use of antiarrhythmic drugs and catheter ablation. 2011 , 34, 23-9	8
1729	Effect of spironolactone on patients with atrial fibrillation and structural heart disease. 2011 , 34, 415-9	29
1728	Catheter ablation for atrial fibrillation. 2011 , 365, 2296-304	71
1727	The burden of atrial fibrillation in the Netherlands. 2011 , 19, 373-8	25
1726	Inflammation-sensitive proteins and risk of atrial fibrillation: a population-based cohort study. 2011 , 26, 449-55	28

1725	Dabigatran in atrial fibrillation: pharmacology and clinical trials. 2011 , 32, 173-80	6
1724	Progression of new onset to established persistent atrial fibrillation: an implantable device-based analysis with implications for clinical classification of persistent atrial fibrillation. 2011 , 32, 7-15	7
1723	How to use implantable loop recorders in clinical trials and hybrid therapy. 2011 , 32, 227-32	8
1722	Stroke prevention in atrial fibrillation. 2011 , 25, 561-70	4
1721	Remodeling bei Vorhofflimmern. 2011 , 25, 379-384	
1720	Antiarrhythmic and antioxidant activity of novel pyrrolidin-2-one derivatives with adrenolytic properties. 2011 , 383, 13-25	10
1719	What is the role of the cardiologist in future management of stroke prevention in atrial fibrillation?. 2011 , 28, 1-12	3
1718	Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors. 2011 , 28, 907-26	12
1717	Prevention of cardioembolic stroke. 2011 , 8, 488-502	21
1716	Rhythm control strategies and the role of antiarrhythmic drugs in the management of atrial fibrillation: focus on clinical outcomes. 2011 , 26, 531-7	9
1715	Prediction of stroke risk in atrial fibrillation, prevention of stroke in atrial fibrillation, and the impact of long-term monitoring for detecting atrial fibrillation. 2011 , 13, 290-7	7
1714	Stroke prevention in atrial fibrillation: atrial appendage closure. 2011 , 13, 159-66	29
1713	Troponin utilization in patients presenting with atrial fibrillation/flutter to the emergency department: retrospective chart review. 2011 , 4, 25	11
1712	In vivo evaluation and proof of radiofrequency safety of a novel diagnostic MR-electrophysiology catheter. 2011 , 65, 770-7	26
1711	Atrial fibrillation in the aging heart: pharmacological therapy and catheter ablation in the elderly. 2011 , 7, 415-23	4
1710	Regulatory pathways for development of antiarrhythmic drugs for management of atrial fibrillation/flutter. 2011 , 13, 1063-76	7
1709	Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence. 2011 , 39, 7-16	1
1708	Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. 2011 , 13, 1110-7	125

1707	Dronedaron for atrial fibrillation therapy. 2011 , 9, 675-83	2
1706	Dietary factors and incident atrial fibrillation: the Framingham Heart Study. 2011 , 93, 261-6	88
1705	Surgical treatment for isolated atrial fibrillation: minimally invasive vs. classic cut and sew maze. 2011 , 6, 373-7	23
1704	The impact of comorbidities on stroke prophylaxis strategies in atrial fibrillation patients. 2011 , 18, 510-7	2
1703	Defects in ankyrin-based membrane protein targeting pathways underlie atrial fibrillation. <i>Circulation</i> , 2011 , 124, 1212-22	16.7 78
1702	Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial fibrillation. 2011 , 4, 15-25	219
1701	Importance of evaluating conduction block in radiofrequency ablation for atrial fibrillation. 2012 , 41, 113-8	7
1700	Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. 2011 , 305, 2080-7	237
1699	Frequent early cardiac complications contribute to worse stroke outcome in atrial fibrillation. 2011 , 32, 454-60	30
1698	Left Atrial Appendage Closure in Atrial Fibrillation: A World without Anticoagulation?. 2011 , 2011, 752808	18
1697	Rationale and current perspective for early rhythm control therapy in atrial fibrillation. 2011 , 13, 1517-25	41
1696	Low-energy multistage atrial defibrillation therapy terminates atrial fibrillation with less energy than a single shock. 2011 , 4, 917-25	31
1695	Atrial fibrillation and death after myocardial infarction: a community study. <i>Circulation</i> , 2011 , 123, 2094-1009	163
1694	Recent advances in the molecular pathophysiology of atrial fibrillation. 2011 , 121, 2955-68	369
1693	Teaching the pharmacology of antiarrhythmic drugs. 2011 , 75, 139	5
1692	Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. 2011 , 4, 313-20	500
1691	Quality of stroke prevention care in atrial fibrillation: many moving targets. 2011 , 4, 5-8	3
1690	An epidemic of atrial fibrillation?. 2011 , 13, 1059-60	5

1689	The perils of combination antithrombotic therapy and potential resolutions. <i>Circulation</i> , 2011 , 123, 232-56.7	10
1688	A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices. 2011 , 42, 3316-22	24
1687	Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation. 2011 , 89, 754-65	151
1686	Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries. 2011 , 13, 23-30	35
1685	Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. 2011 , 13, 329-45	147
1684	What are the costs of atrial fibrillation?. 2011 , 13 Suppl 2, ii9-12	22
1683	Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. 2011 , 13, 1118-26	26
1682	Should heart failure and atrial fibrillation be considered in determining the risk of noncardiac surgery?. <i>Circulation</i> , 2011 , 124, 276-7	16.7
1681	Physical activity and the risk of incident atrial fibrillation in women. 2011 , 4, 321-7	74
1680	Atrial fibrillation and death after myocardial infarction: risk marker or causal mediator?. <i>Circulation</i> , 2011 , 123, 2063-5	16.7 8
1679	Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. <i>Circulation</i> , 2011 , 123, 1501-8	16.7 378
1678	Atrial fibrillation pathophysiology: implications for management. <i>Circulation</i> , 2011 , 124, 2264-74	16.7 464
1677	Antioxidant vitamins in the prevention of atrial fibrillation: what is the evidence?. 2011 , 2011, 164078	18
1676	Atrial Fibrillation Ablation without Interruption of Anticoagulation. 2011 , 2011, 837841	19
1675	Management of patients with atrial fibrillation: specific considerations for the old age. 2011 , 2011, 854205	2
1674	Association of plasma phospholipid long-chain Ω fatty acids with incident atrial fibrillation in older adults: the cardiovascular health study. <i>Circulation</i> , 2012 , 125, 1084-93	16.7 112
1673	Reactive oxygen species-targeted therapeutic interventions for atrial fibrillation. 2012 , 3, 311	40
1672	Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities. <i>Circulation</i> , 2012 , 125, 2933-43	16.7 118

1671 Is dronedarone really safer than amiodarone?. **2012**, 44, 805-6

1670 Polyunsaturated Fatty acids in atrial fibrillation: looking for the proper candidates. **2012**, 3, 370

3

1669 Atrial Fibrillation and Long QT Syndrome Presenting in a 12-Year-Old Girl. **2012**, 2012, 124838

4

1668 Left atrial appendage exclusion for stroke prevention in atrial fibrillation. **2012**, 2012, 610827

13

1667 Atrial fibrillation-associated remodeling does not promote atrial thrombus formation in canine models. **2012**, 5, 1168-75

11

1666 Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. *Circulation*, **2012**, 125, 159-64; discussion 164

16.7 68

1665 Why is warfarin underused for stroke prevention in atrial fibrillation? A detailed review of electronic medical records. **2012**, 28, 1407-14

21

1664 Secular trends in ischemic stroke characteristics in a rapidly developed country: results from the Korean Stroke Registry Study (secular trends in Korean stroke). **2012**, 5, 327-34

77

1663 Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. *Circulation*, **2012**, 125, 216-25

16.7 154

1662 Advances in the management of atrial fibrillation. **2012**, 12, 544-52

1661 Health outcomes with catheter ablation or antiarrhythmic drug therapy in atrial fibrillation: results of a propensity-matched analysis. **2012**, 5, 171-81

83

1660 Do the benefits of anti-arrhythmic drugs outweigh the associated risks? A tale of treatment goals in atrial fibrillation. **2012**, 5, 163-71

3

1659 Functional modeling in zebrafish demonstrates that the atrial-fibrillation-associated gene GREM2 regulates cardiac laterality, cardiomyocyte differentiation and atrial rhythm. **2013**, 6, 332-41

35

1658 Periprocedural anticoagulant management. **2012**, 40, 40-9

1

1657 Lifestyle risk reduction interventions in atrial fibrillation: a systematic review. **2012**, 19, 1091-100

14

1656 New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. **2012**, 10, 1471-80

37

1655 Review of contemporary antiarrhythmic drug therapy for maintenance of sinus rhythm in atrial fibrillation. **2012**, 17, 12-20

17

1654 Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. **2012**, 98, 195-201

87

1653	Accuracy of oscillometric blood pressure monitors for the detection of atrial fibrillation: a systematic review. 2012 , 9, 635-40	17
1652	Irregular rhythm adversely influences calcium handling in ventricular myocardium: implications for the interaction between heart failure and atrial fibrillation. 2012 , 5, 786-93	41
1651	Antioxidant therapy for atrial fibrillation: lost in translation?. 2012 , 98, 1615-6	9
1650	Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry. 2012 , 46, 149-53	144
1649	Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark. 2012 , 15, 695-703	43
1648	Bridging evidence-based practice and practice-based evidence in periprocedural anticoagulation. <i>Circulation</i> , 2012 , 126, 1573-6	16.7 37
1647	Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk. 2012 , 3, 133	68
1646	Stroke Prevention in Atrial Fibrillation: Where are We Now?. 2012 , 6, 65-78	8
1645	The use of cardiac magnetic resonance imaging in the diagnostic workup and treatment of atrial fibrillation. 2012 , 2012, 658937	4
1644	Novel anticoagulants in atrial fibrillation stroke prevention. 2012 , 3, 123-36	15
1643	Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study. 2012 , 59, 198-204	97
1642	Progress for stroke prevention with atrial fibrillation: emergence of alternative oral anticoagulants. <i>Circulation</i> , 2012 , 125, 1577-83	16.7 16
1641	Progress for stroke prevention with atrial fibrillation: emergence of alternative oral anticoagulants. 2012 , 43, 1179-85	7
1640	Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. 2012 , 14, 666-74	79
1639	Oral anticoagulants versus antiplatelet therapy for preventing stroke and systemic embolic events in patients with atrial fibrillation. 2012 ,	1
1638	Stroke prevention in atrial fibrillation: concepts and controversies. 2012 , 8, 290-301	8
1637	Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation. 2012 , 13, 86-96	8
1636	Medical treatment of atrial fibrillation. 2012 , 13, 97-107	16

1635	Catheter ablation of atrial fibrillation: state-of-the-art techniques and future perspectives. 2012 , 13, 108-24	11
1634	Stroke risk assessment in atrial fibrillation. 2012 , 10-29	1
1633	Atrial fibrillation. 2012 , 379, 648-61	287
1632	Discovery of ((S)-5-(methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S)-2-(3-methyl-1H-indol-5-yl)-2-oxoethyl)phosphonic acid as a potent and selective I(Kur) inhibitor. 2012 , 55, 3036-48	1
1631	Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. 2012 , 11, 1066-81	62
1630	Sleep, stroke and poststroke. 2012 , 30, 1275-84	13
1629	Can we predict the occurrence of atrial fibrillation?. 2012 , 35 Suppl 1, 5-9	12
1628	Systems biology and cardiac arrhythmias. 2012 , 380, 1498-508	25
1627	Management of atrial fibrillation: direct factor IIa and Xa inhibitors or "warfarin shotgun"?. 2012 , 79, 705-20	1
1626	Association between KCNE1 (G38S) genetic polymorphism and non-valvular atrial fibrillation in an Uyghur population. 2012 , 124, 737-41	2
1625	Should rhythm control be preferred in younger atrial fibrillation patients?. 2012 , 35, 71-80	6
1624	Atrial Fibrillation Ablation in Obese Patients. 2012 , 4, 327-34	
1623	Prise en charge de la fibrillation atriale lors de la période périopératoire. 2012 , 16, 285-295	
1622	An Approach to Catheter Ablation of Atrial Fibrillation in the Elderly. 2012 , 4, 119-25	4
1621	Fibrillation atriale (FA): une exigence d'efficacité anticoagulante pour une pathologie grave. 2012 , 2012, 11-12	
1620	Atrial Fibrillation Ablation Strategy: "Ready Made" or "Tailored"?. 2012 , 4, 353-61	1
1619	Prevalence of atrial fibrillation in US nursing homes: results from the National Nursing Home Survey, 1985-2004. 2012 , 13, 529-34	10
1618	[Epidemiology of thromboembolic diseases: atrial fibrillation, venous thromboembolic disease and acute coronary syndrome]. 2012 , 139 Suppl 2, 4-9	3

1617	Atrial fibrillation and the risk of incident dementia: a meta-analysis. 2012 , 9, 1761-8	172
1616	Expanding the role of statins in postoperative atrial fibrillation. 2012 , 9, 170-1	1
1615	Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications. 2012 , 26, 563-9	56
1614	Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial. 2012 , 13, 1101-11	6
1613	[Stroke risk--atrial fibrillation]. 2012 , 154, 53-6	
1612	Efficacia e sicurezza dei nuovi farmaci anticoagulanti orali rispetto al warfarin nella profilassi cardioembolica del paziente con fibrillazione atriale non valvolare. Più luci che ombre. 2012 , 6, 153-169	
1611	[New oral anticoagulants and chronic kidney disease]. 2012 , 53, 1431-44	4
1610	Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature. 2012 , 129, 392-400	49
1609	Arrhythmias in the coronary care unit. 2012 , 27, 267-89	3
1608	Plasma resistin, adiponectin, and risk of incident atrial fibrillation: the Framingham Offspring Study. 2012 , 163, 119-124.e1	35
1607	Assessment of the Framingham risk factors among ED patients with newly diagnosed atrial fibrillation. 2012 , 30, 151-7	
1606	Importance of physical fitness on predictive effect of body mass index and weight gain on incident atrial fibrillation in healthy middle-age men. 2012 , 110, 425-32	31
1605	Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: the ARIC study. 2012 , 155, 217-22	50
1604	Atrial fibrillation, arrhythmia burden and thrombogenesis. 2012 , 157, 318-23	23
1603	Impact of obesity on atrial fibrillation hospitalization. 2012 , 159, 241-2	6
1602	Management of atrial fibrillation in patients with structural heart disease. <i>Circulation</i> , 2012 , 125, 945-57	16.7 77
1601	Low prevalence of connexin-40 gene variants in atrial tissues and blood from atrial fibrillation subjects. 2012 , 13, 102	5
1600	Central tendency measure and wavelet transform combined in the non-invasive analysis of atrial fibrillation recordings. 2012 , 11, 46	9

1599	Role of the CHADS2 score in acute coronary syndromes: risk of subsequent death or stroke in patients with and without atrial fibrillation. 2012 , 141, 1431-1440	97
1598	The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. 2012 , 74, 744-56	71
1597	Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation. 2012 , 9, 385-91	13
1596	Proteomics of atrial fibrillation. 2012 , 5, 1036-43	1
1595	Clinical considerations of anticoagulation therapy for patients with atrial fibrillation. 2012 , 13, 609-15	3
1594	The Role of Anticoagulation in a Patient with Atrial Fibrillation and a CHADS2 Score of 1. 2012 , 4, 107-17	1
1593	The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. 2012 , 142, 1489-1498	281
1592	Current role for surgery in treatment of lone atrial fibrillation. 2012 , 24, 42-50	11
1591	Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation. 2012 , 59, 143-9	203
1590	The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. 2012 , 59, 923-9	352
1589	Repolarization recipes for atrial fibrillation: beyond single channel variants. 2012 , 59, 1026-8	2
1588	Chromosome 4q25 variants are genetic modifiers of rare ion channel mutations associated with familial atrial fibrillation. 2012 , 60, 1173-81	65
1587	Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) trial. 2012 , 60, 628-36	766
1586	Type 2 diabetes mellitus and risk of incident atrial fibrillation in women. 2012 , 60, 1421-8	70
1585	Feasibility, accuracy, and reproducibility of real-time full-volume 3D transthoracic echocardiography to measure LV volumes and systolic function: a fully automated endocardial contouring algorithm in sinus rhythm and atrial fibrillation. 2012 , 5, 239-51	92
1584	Factors associated with the epidemic of hospitalizations due to atrial fibrillation. 2012 , 110, 1496-9	37
1583	Trends in atrial fibrillation in patients hospitalized with an acute coronary syndrome. 2012 , 125, 1076-84	42
1582	[Atrial fibrillation: from cardiology to perioperative management]. 2012 , 31, 897-910	5

1581	Left atrial appendage occlusion for stroke prevention. 2012 , 37, 405-41	16
1580	Quality of life and costs of conventional therapy in patients treated by catheter ablation for atrial fibrillation. 2012 , 54, e421-e427	1
1579	Catheter ablation of atrial fibrillation: Past, present, and future directions. 2012 , 28, 83-90	7
1578	Prevalence of atrial fibrillation in Asia and the world. 2012 , 28, 330-337	24
1577	[Atrial fibrillation in elderly. That long wayâ] 2012 , 138, 246-8	0
1576	[The new medicine and the new anticoagulants]. 2012 , 138, 438-40	1
1575	Atrial fibrillation in heart failure. 2012 , 9, 309-18	7
1574	An update on the prognosis of patients with atrial fibrillation. <i>Circulation</i> , 2012 , 126, e143-6	16.7 95
1573	Epidemiolog� de la fibrilaci� auricular y comorbilidades asociadas. 2012 , 12, 3-10	1
1572	The risk stratification in atrial fibrillation. 2012 , 7 Suppl 3, S233-40	6
1571	Cardioversion in atrial fibrillation. Focus on recent-onset atrial fibrillation. 2012 , 7 Suppl 3, S241-50	3
1570	Mechanisms of arrhythmias and conduction disorders in older adults. 2012 , 28, 555-73	48
1569	Atrial fibrillation and atrial flutter: nonpharmacologic therapy. 2012 , 28, 649-63	1
1568	Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. 2012 , 15, 776-85	74
1567	Computational mapping identifies localized mechanisms for ablation of atrial fibrillation. 2012 , 7, e46034	75
1566	Overview of sleep and stroke. 1-10	
1565	A review of current surgical treatment of patients with atrial fibrillation. 2012 , 25, 218-23	14
1564	Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin?. 2012 , 27, 445-52	1

1563	Avoiding adverse events with dabigatran by careful selection of eligible patients. 2012 , 196, 431-2	2
1562	Patterns of warfarin use and subsequent outcomes in atrial fibrillation in primary care practices. 2012 , 8, 587-98	16
1561	Atrial fibrillation in pigs induces left atrial endocardial transcriptional remodelling. 2012 , 108, 742-9	4
1560	Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 2012 , 141, e531S-e575S	763
1559	Heart disease and stroke statistics--2012 update: a report from the American Heart Association. <i>Circulation</i> , 2012 , 125, e2-e220	16.7 3532
1558	Impatto ospedaliero e management pratico delle emorragie cerebrali intraparenchimali spontanee associate a terapia anticoagulante orale nel corso degli anni. 2012 , 8, 84-93	
1557	Atrial fibrillation and heart failure in the elderly. 2012 , 17, 597-613	26
1556	Anatomical analysis of the left atrial appendage using segmented, three-dimensional cardiac CT: a comparison of patients with paroxysmal and persistent forms of atrial fibrillation. 2012 , 34, 173-9	18
1555	Percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation. 2012 , 20, 161-6	9
1554	P wave indices, obesity, and the metabolic syndrome: the atherosclerosis risk in communities study. 2012 , 20, 666-72	45
1553	Continuous versus intermittent monitoring of ventricular rate in patients with permanent atrial fibrillation. 2012 , 35, 598-604	9
1552	Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter. 2012 , 23, 462-72	10
1551	Anticoagulation management in clinical practice: preventing stroke in patients with atrial fibrillation. 2012 , 41, 146-56	6
1550	CHADS2 and CHA2DS2-VASc risk factors to predict first cardiovascular hospitalization among atrial fibrillation/atrial flutter patients. 2012 , 109, 1526-33	50
1549	Electrical cardioversion of persistent atrial fibrillation: acute and long-term results stratified according to arrhythmia duration. 2012 , 35, 1126-34	12
1548	Catheter ablation of atrial fibrillation in octogenarians: safety and outcomes. 2012 , 23, 687-93	90
1547	Catheter ablation of atrial fibrillation in octogenarians: the right "medicine?". 2012 , 23, 694-6	
1546	Low rate of atrial fibrillation recurrence verified by implantable loop recorder monitoring following a convergent epicardial and endocardial ablation of atrial fibrillation. 2012 , 23, 1059-66	47

1545	The influence of stroke risk factors and comorbidities on assessment of stroke therapies in humans and animals. 2012 , 7, 386-97	29
1544	Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. 2012 , 23, 233-45	35
1543	Incomplete occlusion of the left atrial appendage with the percutaneous left atrial appendage transcatheter occlusion device is not associated with increased risk of stroke. 2012 , 33, 69-75	44
1542	Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation. 2013 , 16, 1193-202	11
1541	Supraventricular and ventricular arrhythmias. 2013 , 40, 43-71	4
1540	Catheter ablation of atrial fibrillation in the elderly: does the benefit outweigh the risk?. 2013 , 11, 697-704	15
1539	Epidemiology of atrial fibrillation in Spain in the past 20 years. 2013 , 66, 561-5	2
1538	Racial differences in the incidence of and risk factors for atrial fibrillation in older adults: the cardiovascular health study. 2013 , 61, 276-80	49
1537	US health care policy and reform: implications for cardiac electrophysiology. 2013 , 36, 129-36	3
1536	Drug-Drug Interactions with Anticoagulants and Antiplatelets. 2013 , 2, e130-e141	
1535	Oral anticoagulation during atrial fibrillation ablation: Facts and controversies. 2013 , 55, e101-e106	2
1534	Intracerebral hemorrhage during anticoagulation with vitamin K antagonists: a consecutive observational study. 2013 , 260, 2046-51	33
1533	Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study. 2013 , 21, 354-63	23
1532	Bleeding risk in atrial fibrillation patients taking vitamin K antagonists: systematic review and meta-analysis. 2013 , 94, 367-75	17
1531	Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. 2013 , CD008980	27
1530	Mechanical closure of the left atrial appendage: is it time to be more aggressive?. 2013 , 146, 1018-1027.e2	22
1529	Lone atrial fibrillation: a disease threatened with extinction. 2013 , 10, 1270-1	
1528	Transcatheter left atrial appendage occlusion. 2013 , 31, 363-84	1

1527	Target specific oral anticoagulants in the management of thromboembolic disease in the elderly. 2013 , 36, 203-11	1
1526	The future of inpatient anticoagulation management. 2013 , 35, 375-86	
1525	Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. 2013 , 112, 1142-7	726
1524	Bleeding as an outcome among patients with nonvalvular atrial fibrillation in a large managed care population. 2013 , 35, 1536-45.e1	16
1523	Women hospitalized with atrial fibrillation: gender differences, trends and outcome from a 20-year registry in a Middle Eastern country (1991-2010). 2013 , 168, 975-80	16
1522	Common threads in atrial fibrillation and heart failure. 2013 , 9, 373-83, vii	4
1521	Atrial fibrillation in the 21st century: a current understanding of risk factors and primary prevention strategies. 2013 , 88, 394-409	100
1520	Atrial fibrillation and atrial flutter in human immunodeficiency virus-infected persons: incidence, risk factors, and association with markers of HIV disease severity. 2013 , 61, 2288-95	70
1519	[New oral anticoagulants in nonvalvular atrial fibrillation]. 2013 , 42, 1225-31	2
1518	Human atrial fibrillation substrate: towards a specific fibrotic atrial cardiomyopathy. 2013 , 34, 2731-8	199
1517	Novel anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly. 2013 , 6, 677-89	5
1516	Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. 2013 , 310, 2050-60	411
1515	Novel percutaneous left atrial appendage closure. 2013 , 14, 164-7	13
1514	Atrial fibrillation management in Asia: from the Asian expert forum on atrial fibrillation. 2013 , 164, 21-32	25
1513	Periprocedural management of oral anticoagulation in patients with atrial fibrillation: approach in the era of new oral anticoagulants. 2013 , 29, S54-9	11
1512	Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study. 2013 , 62, 1674-1679	109
1511	Does CHA2DS2-VASc improve stroke risk stratification in postmenopausal women with atrial fibrillation?. 2013 , 126, 1143.e1-8	13
1510	A magnetic-resonance-imaging-compatible remote catheter navigation system. 2013 , 60, 899-905	18

1509	Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants. 2013 , 31, 971-80	32
1508	I left my smartphone at home and can't tell if I'm in atrial fibrillation. 2013 , 10, 320-1	2
1507	Atrial fibrillation and congestive heart failure: a cost analysis of rhythm-control vs. rate-control strategies. 2013 , 29, 1256-62	9
1506	Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. 2013 , 36, 163-74	15
1505	Review of challenges in optimizing oral anticoagulation therapy for stroke prevention in atrial fibrillation. 2013 , 13, 87-102	3
1504	A POINT-CORRESPONDENCE APPROACH TO DESCRIBING THE DISTRIBUTION OF IMAGE FEATURES ON ANATOMICAL SURFACES, WITH APPLICATION TO ATRIAL FIBRILLATION. 2013 , 2013, 226-229	5
1503	Determination of dronedarone in the pharmaceutical dosage form by a stability-indicating micellar electrokinetic chromatography method. 2013 , 5, 3106	3
1502	Obesity and atrial fibrillation. 2013 , 14, 929-38	25
1501	Risk assessment for incident heart failure in individuals with atrial fibrillation. 2013 , 15, 843-9	60
1500	Ethnic differences in atrial fibrillation identified using implanted cardiac devices. 2013 , 24, 381-7	43
1499	Wall-motion based analysis of global and regional left atrial mechanics. 2013 , 32, 1765-76	6
1498	Heart disease and stroke statistics--2013 update: a report from the American Heart Association. <i>Circulation</i> , 2013 , 127, e6-e245	16.7 3837
1497	Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. <i>Circulation</i> , 2013 , 127, 720-9	16.7 445
1496	Epidemiologia de la fibrilaci3n auricular en Espa1a. 2013 , 13, 3-8	
1495	Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. 2013 , 61, 2079-87	83
1494	[Which anticoagulation therapy in old atrial fibrillation patients?]. 2013 , 42, 1015-8	
1493	[New oral anticoagulant agents: the quandary of anticoagulation in the elderly]. 2013 , 141, 346-8	4
1492	Interventions for the treatment of atrial fibrillation: a systematic literature review and meta-analysis. 2013 , 165, 229-36	17

1491	Initial experience with a novel percutaneous left atrial appendage exclusion device in patients with atrial fibrillation, increased stroke risk, and contraindications to anticoagulation. 2013 , 111, 869-73	92
1490	Prolonged Rhythm Monitoring in the Patient with Stroke and Transient Ischemic Attack. 2013 , 5, 349-356	
1489	Introducci3n. 2013 , 13, 1-2	0
1488	Trends in mortality after first hospitalization with atrial fibrillation diagnosis in Sweden 1987 to 2006. 2013 , 170, 75-80	8
1487	Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. 2013 , 166, 935-40.e1	27
1486	Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. 2013 , 10, 90-100	233
1485	Fine tuning risk stratification for atrial fibrillation. 2013 , 61, 2285-7	5
1484	Atrial fibrillation outcomes: changing the paradigm. 2013 , 166, 545-7	4
1483	Trends in stroke incidence after hospitalization for atrial fibrillation in Sweden 1987 to 2006. 2013 , 167, 733-8	14
1482	Herpes simplex virus infection and risk of atrial fibrillation: a nationwide study. 2013 , 164, 201-4	20
1481	Interpreting changes in quality of life in atrial fibrillation: how much change is meaningful?. 2013 , 166, 381-387.e8	55
1480	Epidemiolog3a de la fibrilaci3n auricular en Espa1a en los 1ltimos 20 a1os. 2013 , 66, 561-565	27
1479	Thromboembolism in patients with nonvalvular atrial fibrillation: comparison between Asian and Western countries. 2013 , 61, 1-7	20
1478	The change in the atrial fibrillation type as a prognosis marker in a community study: long-term data from AFBAR (Atrial Fibrillation in the BARbanza) study. 2013 , 168, 2146-52	13
1477	Is emergency department cardioversion of recent-onset atrial fibrillation safe and effective?. 2013 , 45, 117-27	12
1476	Losartan affects the substrate for atrial fibrillation maintenance in a rabbit model. 2013 , 22, 383-8	7
1475	Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population. 2013 , 35, 1201-10	31
1474	Predictors of late recurrence of atrial fibrillation after catheter ablation. 2013 , 164, 82-7	61

1473 Has the dream come through?. **2013**, 46, 36-7

1472 Presence of left atrial diverticula, accessory appendages, and normal variant pulmonary venous anatomy diagnosed using MDCT and adverse outcomes following radiofrequency catheter ablation therapy in patients with drug-refractory atrial fibrillation: an exploratory study. **2013**, 68, 762-9 7

1471 Left atrial appendage occlusion: single center experience with PLAATO LAA Occlusion System(®) and AMPLATZER® Cardiac Plug. **2013**, 62, 44-9 10

1470 Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation. **2013**, 166, 871-8 10

1469 Low-level transcutaneous electrical stimulation of the auricular branch of the vagus nerve: a noninvasive approach to treat the initial phase of atrial fibrillation. **2013**, 10, 428-35 108

1468 [Improvements in oral anticoagulant therapy for atrial fibrillation]. **2013**, 141, 487-93 2

1467 Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. **2013**, 167, 1807-24 374

1466 New directions in antiarrhythmic drug therapy for atrial fibrillation. **2013**, 9, 71-88 36

1465 Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. **2013**, 15, 486-93 226

1464 Evaluating the HATCH score for predicting progression to sustained atrial fibrillation in ED patients with new atrial fibrillation. **2013**, 31, 792-7 12

1463 Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation. **2013**, 33, 409-18 38

1462 Selection of Medications to Prevent Stroke Among Individuals With Atrial Fibrillation : Update on Prevention of Stroke in Patients with AF. **2013**, 15, 583-92

1461 Atrial fibrillation and stroke: the evolving role of rhythm control. **2013**, 15, 299-312 0

1460 Recent developments in understanding epidemiology and risk determinants of atrial fibrillation as a cause of stroke. **2013**, 29, S4-S13 23

1459 Review of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the US. **2013**, 47, 671-85 5

1458 Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. **2013**, 106, 303-23 40

1457 Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. **2013**, 73, 715-39 13

1456 Application of randomized clinical trial data to actual practice: apixaban therapy for reduction of stroke risk in non-valvular atrial fibrillation patients. **2013**, 29, 1253-61 7

1455	Deep sedation during catheter ablation for atrial fibrillation in elderly patients. 2013 , 38, 115-21	16
1454	Atrial fibrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. 2013 , 173, 29-35	135
1453	Obesity and atrial fibrillation: the evidence is gaining weight. 2013 , 15, 771-2	2
1452	Decreased glomerular filtration rate and markers of left atrial stasis in patients with nonvalvular atrial fibrillation. 2013 , 124, 3-10	25
1451	Cardiovascular and non-cardiovascular hospital admissions associated with atrial fibrillation: a Danish nationwide, retrospective cohort study. 2013 , 3,	16
1450	Stroke prevention for patients with atrial fibrillation: improving but not perfect yet. 2013 , 99, 1141-2	2
1449	Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis. 2013 , 44, 1329-36	77
1448	All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. 2013 , 34, 1061-7	260
1447	Novel genetic markers improve measures of atrial fibrillation risk prediction. 2013 , 34, 2243-51	100
1446	Impact of ageing on presentation and outcome of mitral regurgitation due to flail leaflet: a multicentre international study. 2013 , 34, 2600-9	18
1445	Changing epidemiology of atrial fibrillation. 2013 , 15, 465-6	4
1444	Incidence, prevalence, and antithrombotic management of atrial fibrillation in elderly Germans. 2013 , 15, 1436-44	27
1443	Ten-year trends in the use of catheter ablation for treatment of atrial fibrillation vs. the use of coronary intervention for the treatment of ischaemic heart disease in Australia. 2013 , 15, 1702-9	44
1442	Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation. 2013 , 41, 49-60	
1441	Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation. 2013 , 41, 26-36	1
1440	Factors associated with warfarin discontinuation, including bleeding patterns, in atrial fibrillation patients. 2013 , 29, 761-71	17
1439	Prevalence of unknown atrial fibrillation in patients with risk factors. 2013 , 15, 657-62	45
1438	Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers. 2013 , 16, 1190-2	

1437	Advances in stroke prevention in atrial fibrillation: enhanced risk stratification combined with the newer oral anticoagulants. 2013 , 36, 312-22	4
1436	Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review. 2013 , 13, 29-42	6
1435	Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. 2013 , 125, 301-9	80
1434	Relationship between left atrial tissue structural remodelling detected using late gadolinium enhancement MRI and left ventricular hypertrophy in patients with atrial fibrillation. 2013 , 15, 1725-32	27
1433	Characterization of incidental cardiac masses in oncological patients using a new CT-based tumor volume perfusion technique. 2013 , 54, 895-903	1
1432	The Relationship between Obstructive Sleep Apnea and Atrial Fibrillation: A Complex Interplay. 2013 , 2013, 621736	35
1431	Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. 2013 , 6, 461-9	61
1430	Comparison of Atrial Fibrillation in the Young versus That in the Elderly: A Review. 2013 , 2013, 976976	36
1429	eComment. Atrial ablation in high-risk cardiac surgery patients: pipe dream or sensible strategy?. 2013 , 16, 494	
1428	Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. 2013 , 34, 2746-51	638
1427	Addressing the controversy of rate-versus-rhythm control in atrial fibrillation. 2013 , 125, 7-18	93
1426	Oral anticoagulation improves the prognosis of octogenarian patients with atrial fibrillation undergoing percutaneous coronary intervention and stenting. 2013 , 42, 70-5	11
1425	Association between panic disorder and risk of atrial fibrillation: a nationwide study. 2013 , 75, 30-5	21
1424	How to ablate long-standing persistent atrial fibrillation?. 2013 , 28, 26-35	44
1423	Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry. 2013 , 2, e000110	45
1422	Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. <i>Circulation</i> , 2013 , 128, 2192-2017	167 206
1421	Gene therapy to treat cardiovascular disease. 2013 , 2, e000119	43
1420	Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era. 2013 , 125, 34-44	10

1419	Stroke prevention in patients with atrial fibrillation: focus on new oral anticoagulants. 2013 , 125, 155-61	0
1418	Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. <i>Circulation</i> , 2013 , 128, 1085-93	16.7 202
1417	National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries. 2013 , 47, 35-42	31
1416	Secular trends, treatments, and outcomes of Middle Eastern Arab and South Asian patients hospitalized with atrial fibrillation: insights from a 20-year registry in Qatar (1991-2010). 2013 , 64, 498-504	8
1415	Stroke prenotification is associated with shorter treatment times for warfarin-associated intracerebral hemorrhage. 2013 , 36, 383-7	4
1414	Placing a value on new technologies. <i>Circulation</i> , 2013 , 127, 2375-7	16.7 2
1413	Surgical minimally invasive pulmonary vein isolation for lone atrial fibrillation: midterm results of a multicenter study. 2013 , 8, 410-5	12
1412	Managing atrial fibrillation in the global community: The European perspective. 2013 , 2013, 173-84	6
1411	Which is the best approach for ablation of long-standing persistent atrial fibrillation?. 2013 , 36, 1198-201	5
1410	Outcomes after kidney transplantation of patients previously diagnosed with atrial fibrillation. 2013 , 13, 1566-75	31
1409	Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation. 2013 , 11, 1619-29	12
1408	Seek and ye shall find: cardiac arrhythmias in the horse. 2013 , 45, 270-2	6
1407	Revisiting the prehypertension debate: increasing evidence for treatment yet randomized clinical trials are lacking. 2013 , 22, 340-3	1
1406	Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary. 2013 , 11, 1461-71	2
1405	A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE. 2013 , 11, 1105-14	6
1404	Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients â and . 2013 , 16, 1163-8	14
1403	A novel NKX2.5 loss-of-function mutation responsible for familial atrial fibrillation. 2013 , 31, 1119-26	53
1402	Catheter ablation in combination with left atrial appendage closure for atrial fibrillation. 2013 , e3818	6

1401	A novel PITX2c loss-of-function mutation underlies lone atrial fibrillation. 2013 , 32, 827-34	26
1400	Temporal trends in stroke admissions in Denmark 1997-2009. 2013 , 13, 156	16
1399	Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. 2013 , CD008600	34
1398	Surgical pathology of atrial appendages removed during the cox-maze procedure: a review of 86 cases (2004 to 2005) with implications for prognosis. 2013 , 37, 890-7	17
1397	Treatment patterns associated with stroke prevention in patients with atrial fibrillation in three major cities in the People's Republic of china. 2013 , 7, 29-35	1
1396	Avoiding permanent atrial fibrillation: treatment approaches to prevent disease progression. 2014 , 10, 1-12	19
1395	Estimating the prevalence of atrial fibrillation in a general population using validated electronic health data. 2013 , 5, 475-81	45
1394	Changes in left ventricular filling in patients with persistent atrial fibrillation. 2013 , 10, 1876-9	6
1393	Prevalence and spectrum of Nkx2.5 mutations associated with idiopathic atrial fibrillation. 2013 , 68, 777-84	38
1392	Epicardial adipose tissue is associated with prevalent atrial fibrillation in patients with hypertrophic cardiomyopathy. 2013 , 54, 297-303	21
1391	Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. 2013 , 8, e57183	119
1390	Mitochondrial hyperfusion during oxidative stress is coupled to a dysregulation in calcium handling within a C2C12 cell model. 2013 , 8, e69165	30
1389	Frequent periodic leg movement during sleep is an unrecognized risk factor for progression of atrial fibrillation. 2013 , 8, e78359	21
1388	Orthostatic change in blood pressure and incidence of atrial fibrillation: results from a bi-ethnic population based study. 2013 , 8, e79030	19
1387	Screening to identify unknown atrial fibrillation. A systematic review. 2013 , 110, 213-22	207
1386	Arrhythmias in Women: Atrial Fibrillation and Sudden Cardiac Death. 2013 , 1039-1053	
1385	Hemostatic Aspects of Cardiovascular Medicine. 2013 , 342-394	
1384	Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation. 2013 , 7, 8	2

1383	Dental Procedures in Patients with Atrial Fibrillation and New Oral Anticoagulants. 2014 , 3, 85-9	3
1382	Atrial Ischemia and Fibrillation. 2014 , 443-448	
1381	Percutaneous methods of left atrial appendage exclusion: an alternative to the internist. 2014 , 4,	3
1380	Rezidivierend kryptogene Posteriorinfarkte. 2014 , 25, 42-52	1
1379	Computational Shape Models Characterize Shape Change of the Left Atrium in Atrial Fibrillation. 2014 , 8, 99-109	16
1378	Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation. 2014 , 8, 167-77	21
1377	Comparison of the clinical features and outcomes in two age-groups of elderly patients with atrial fibrillation. 2014 , 9, 1335-42	7
1376	Statin Therapy for Primary Prevention of Atrial Fibrillation: Guided by CHADS2/CHA2DS2VASc Score. 2014 , 44, 205-9	6
1375	Role of atrial fibrillation burden in assessing thromboembolic risk. 2014 , 7, 1223-9	17
1374	Effects of renal denervation on atrial arrhythmogenesis. 2014 , 10, 813-22	5
1373	Incidence and predictors of atrial fibrillation and its impact on long-term survival in patients with supraventricular arrhythmias. 2014 , 16, 1508-14	21
1372	Prevalence of atrial fibrillation in patients with high CHADS2- and CHA2DS2VASc-scores: anticoagulate or monitor high-risk patients?. 2014 , 37, 1651-7	25
1371	Incidence, mortality, and sex differences of non-valvular atrial fibrillation: a population-based study. 2014 , 3, e001402	24
1370	Atrial fibrillation as a cause of death increased steeply in England between 1995 and 2010. 2014 , 16, 797-802	12
1369	Hybrid approach to atrial fibrillation ablation using bipolar radiofrequency devices epicardially and cryoballoon endocardially. 2014 , 19, 590-4	18
1368	Atrial fibrillation in the elderly: a review. 2014 , 10, 745-58	9
1367	Epicardial and perivascular adipose tissues and their influence on cardiovascular disease: basic mechanisms and clinical associations. 2014 , 3, e000582	193
1366	Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders. 2014 , 4, 619-639	1

1365	Effect of ECG episodes on parameters extraction for paroxysmal atrial fibrillation classification. 2014 ,		1
1364	Cardioembolic stroke: practical considerations for patient risk management and secondary prevention. 2014 , 126, 55-65		8
1363	Transcription factors and atrial fibrillation. 2014 , 101, 194-202		25
1362	Atrial fibrillation in Indigenous and non-Indigenous Australians: a cross-sectional study. 2014 , 4, e006242		22
1361	Evaluation of the WATCHMAN left atrial appendage closure device. 2014 , 11, 541-51		5
1360	Use of oral anticoagulants in atrial fibrillation is highly variable and only weakly associated with estimated stroke risk: cross-sectional population database study. 2014 , 20, 181-9		11
1359	Shared decision making in atrial fibrillation: where we are and where we should be going. <i>Circulation</i> , 2014 , 129, 704-10	16.7	73
1358	Initial independent outcomes from focal impulse and rotor modulation ablation for atrial fibrillation: multicenter FIRM registry. 2014 , 25, 921-929		151
1357	What tissue does circumferential PV Isolation actually modulate?. 2014 , 25, 119-21		1
1356	Emergence of atrial repolarization alternans at late stages of remodeling: the "second factor" in atrial fibrillation progression?. 2014 , 25, 428-430		1
1355	Heart disease and stroke statistics--2014 update: a report from the American Heart Association. <i>Circulation</i> , 2014 , 129, e28-e292	16.7	3912
1354	Differences of two cryoballoon generations: insights from the prospective multicentre, multinational FREEZE Cohort Substudy. 2014 , 16, 1434-42		41
1353	Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. 2014 , 64, 2222-31		507
1352	Predictive value of atrial high-rate episodes for arterial stiffness and endothelial dysfunction in dual-chamber pacemaker patients. 2014 , 44, 13-21		3
1351	Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines. 2014 , 16, 162-73		55
1350	Atrial fibrillation and stroke - Coexistence and attitude to preventive therapy on the basis of Szczecin and Szczecin region patients. 2014 , 48, 410-5		3
1349	Pericardial fat is associated with atrial conduction: the Framingham Heart Study. 2014 , 3, e000477		53
1348	Brachial flow-mediated dilation and incident atrial fibrillation: the multi-ethnic study of atherosclerosis. 2014 , 34, 2717-20		25

1347	Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study. 2014 , 9, 861-70	21
1346	Automatic online detection of atrial fibrillation based on symbolic dynamics and Shannon entropy. 2014 , 13, 18	82
1345	Prediction and personalised treatment of atrial fibrillation-stroke prevention: consolidated position paper of CVD professionals. 2014 , 5, 15	14
1344	The atrial fibrillation epidemic is approaching the physician's door: will mobile technology improve detection?. 2014 , 12, 180	6
1343	Oral anticoagulant therapy and clinical outcomes in patients with atrial fibrillation: a pilot study from a single center registry. 2014 , 25, 688-94	
1342	Genetic basis of atrial fibrillation. 2014 , 29, 220-6	15
1341	Estimation of potential cost savings associated with reduced rates of cardiovascular hospitalization among atrial fibrillation/flutter patients treated with dronedarone in the ATHENA trial. 2014 , 21, 500-8	0
1340	Atrial fibrillation in the elderly: management strategies to achieve performance measures. 2014 , 25, 205-12	3
1339	A computer-aided diagnostic algorithm improves the accuracy of transesophageal echocardiography for left atrial thrombi: a single-center prospective study. 2014 , 33, 83-91	11
1338	New oral anticoagulant agents - general features and outcomes in subsets of patients. 2014 , 111, 575-82	42
1337	Atrial Fibrillation. 2014 , 739-754	
1336	Atrial fibrillation and cognitive decline-the role of subclinical cerebral infarcts: the atherosclerosis risk in communities study. 2014 , 45, 2568-74	82
1335	EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. 2014 , 16, 1397-416	185
1334	Management of atrial fibrillation in critically ill patients. 2014 , 2014, 840615	31
1333	Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute. 2014 , 2014, 901586	5
1332	Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation. 2014 , 7, 300-6	45
1331	Improved understanding of the pathophysiology of atrial fibrillation through the lens of discrete pathological pathways. 2014 , 2014, 24-36	11
1330	Atrial fibrillation epidemic and hospitalizations: how to turn the rising tide?. <i>Circulation</i> , 2014 , 129, 2361-67	29

1329	Left atrial anatomy and physiology: echo/Doppler assessment. 2014 , 29, 403-7	5
1328	Comparison of different approaches to atrioventricular junction ablation and pacemaker implantation in patients with atrial fibrillation. 2014 , 37, 1686-93	5
1327	Shared risk factors for anticoagulation in nonvalvular atrial fibrillation: a dilemma in clinical decision making. 2014 , 63, 2148-2150	1
1326	Direct oral anticoagulants in atrial fibrillation. 2014 , 51, 139-46	2
1325	Illustrated Atlas of Post-AF Ablation Cerebral Abnormalities. 2014 , 6, 101-10	
1324	[Warfarin switch from fluindione in elderly patients]. 2014 , 43, 221-3	
1323	The association between atrial fibrillation and sudden cardiac death: the relevance of heart failure. 2014 , 2, 221-7	38
1322	Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure. 2014 , 19, 391-401	10
1321	Atrial fibrillation and prestroke cognitive impairment in stroke. 2014 , 261, 546-53	14
1320	A cohort study examination of established and emerging risk factors for atrial fibrillation: the Busselton Health Study. 2014 , 29, 181-90	78
1319	The young patient with asymptomatic atrial fibrillation: what is the evidence to leave the arrhythmia untreated?. 2014 , 35, 1439-47	14
1318	Lone atrial fibrillation: does it exist?. 2014 , 63, 1715-23	125
1317	[Upstream therapy for atrial fibrillation]. 2014 , 25, 33-40	0
1316	Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice. 2014 , 14, 111-27	17
1315	Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting. 2014 , 28, 87-98	14
1314	Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. 2014 , 38, 150-9	51
1313	High left atrial pressures are associated with advanced electroanatomical remodeling of left atrium and independent predictors for clinical recurrence of atrial fibrillation after catheter ablation. 2014 , 11, 953-60	69
1312	Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. 2014 , 7, 113-24	54

1311	Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. 2014 , 167, 329-34	85
1310	Lone atrial fibrillation - an overview. 2014 , 68, 418-33	18
1309	The dilemma of atrial fibrillation in intracerebral haemorrhage: how to balance the risks of ischaemia and bleeding. 2014 , 21, 549-51	2
1308	Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications. 2014 , 43, 48-59	19
1307	Very early-onset lone atrial fibrillation patients have a high prevalence of rare variants in genes previously associated with atrial fibrillation. 2014 , 11, 246-51	39
1306	Left atrial appendage occlusion: opportunities and challenges. 2014 , 63, 291-8	53
1305	European experience of the convergent atrial fibrillation procedure: multicenter outcomes in consecutive patients. 2014 , 147, 1411-6	46
1304	Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. 2014 , 170, 413-8	54
1303	Atrial fibrillation and the risk of myocardial infarction. 2014 , 174, 107-14	274
1302	Atrial fibrillation and heart failure: cause or effect?. 2014 , 11, 463-70	9
1301	Associations with anticoagulation: a cross-sectional registry-based analysis of stroke survivors with atrial fibrillation. 2014 , 100, 557-62	17
1300	Prevalence of atrial fibrillation and its associated factors in Spain: An analysis of 6 population-based studies. DARIOS Study. 2014 , 214, 505-12	14
1299	Prevalence of atrial fibrillation and its associated factors in Spain: An analysis of six population-based studies. DARIOS Study. 2014 , 214, 505-512	
1298	Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications. 2014 , 74, 1587-603	27
1297	Cost-effectiveness of cryoballoon ablation for the management of paroxysmal atrial fibrillation. 2014 , 16, 652-9	19
1296	Telomere length and the risk of atrial fibrillation: insights into the role of biological versus chronological aging. 2014 , 7, 1026-32	16
1295	Comparison of clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation. 2014 , 45, 426-31	23
1294	Risk factors and genetics of atrial fibrillation. 2014 , 32, 485-94	18

1293	Diagnostic evaluation and follow-up of patients with atrial fibrillation. 2014 , 32, 507-19	2
1292	Atrial fibrillation in patients undergoing liver transplantation-a single-center experience. 2014 , 46, 1432-7	32
1291	Age-specific incidence, outcome, cost, and projected future burden of atrial fibrillation-related embolic vascular events: a population-based study. <i>Circulation</i> , 2014 , 130, 1236-44	16.7 95
1290	Novel therapeutic targets in the management of atrial fibrillation. 2014 , 14, 403-21	2
1289	Pericardial fat volume is associated with clinical recurrence after catheter ablation for persistent atrial fibrillation, but not paroxysmal atrial fibrillation: an analysis of over 600-patients. 2014 , 176, 841-6	39
1288	Risk factors for atrial fibrillation in patients with normal versus dilated left atrium (from the Atherosclerosis Risk in Communities Study). 2014 , 114, 1368-72	21
1287	Efficacy of β -blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. 2014 , 384, 2235-43	323
1286	Does health-related quality of life predict hospitalization or mortality in patients with atrial fibrillation?. 2014 , 25, 23-8	20
1285	Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project. 2014 , 127, 972-8	41
1284	Anticoagulation strategies for the management of postoperative atrial fibrillation. 2014 , 34, 537-61	28
1283	Ablation versus drugs: what is the best first-line therapy for paroxysmal atrial fibrillation? Antiarrhythmic drugs are outmoded and catheter ablation should be the first-line option for all patients with paroxysmal atrial fibrillation: pro. 2014 , 7, 739-46	16
1282	Temporal trends in the occurrence and outcomes of atrial fibrillation in patients with acute myocardial infarction (from the Atherosclerosis Risk in Communities Surveillance Study). 2014 , 114, 692-7	19
1281	Global epidemiology of atrial fibrillation. 2014 , 11, 639-54	385
1280	Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. 2014 , 17, 771-81	12
1279	The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. 2014 , 114, 1453-68	587
1278	Current approaches to antiarrhythmic therapy in heart failure. 2014 , 10, 635-52	2
1277	Prolonged cardiac monitoring for detection of paroxysmal atrial fibrillation after cerebral ischemia. 2014 , 45, 1208-14	21
1276	Atrial fibrillation. 2014 , 42, 598-603	1

1275	Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects. 2014 , 12, 1850-60	8
1274	Renal denervation: effects on atrial electrophysiology and arrhythmias. 2014 , 103, 765-74	32
1273	Atrial fibrillation and heart failure: intersecting populations, morbidities, and mortality. 2014 , 19, 285-93	16
1272	Mathematical approaches to understanding and imaging atrial fibrillation: significance for mechanisms and management. 2014 , 114, 1516-31	68
1271	A common variant on chromosome 4q25 is associated with prolonged PR interval in subjects with and without atrial fibrillation. 2014 , 113, 309-13	13
1270	Cardiac imaging for assessment of left atrial appendage stasis and thrombosis. 2014 , 11, 470-80	47
1269	Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. 2014 , 35, 233-41	67
1268	Effect of intravenous thrombolysis on stroke associated with atrial fibrillation. 2014 , 23, 2199-2205	4
1267	Economic burden and disparities in healthcare resource use among adult patients with cardiac arrhythmia. 2014 , 12, 59-71	20
1266	Outcomes associated with comorbid atrial fibrillation and heart failure in Medicare beneficiaries with acute coronary syndrome. 2014 , 14, 80	11
1265	n-3 polyunsaturated fatty acids for atrial fibrillation recurrence: is the horse already out of the barn?. 2014 , 64, 1449-51	3
1264	[Perioperative management of atrial fibrillation]. 2014 , 61, 262-71	
1263	Elevated left ventricular filling pressure estimated by E/E' ratio after exercise predicts development of new-onset atrial fibrillation independently of left atrial enlargement among elderly patients without obvious myocardial ischemia. 2014 , 63, 128-33	15
1262	Extravirgin olive oil consumption reduces risk of atrial fibrillation: the PREDIMED (Prevenci3n con Dieta Mediterr3nea) trial. <i>Circulation</i> , 2014 , 130, 18-26	16.7 141
1261	Relations between circulating microRNAs and atrial fibrillation: data from the Framingham Offspring Study. 2014 , 11, 663-9	71
1260	Atrial fibrillation therapies: lest we forget surgery. 2014 , 30, 590-7	5
1259	Atrial natriuretic peptide as a predictor of atrial fibrillation in a male population study. The Study of Men Born in 1913 and 1923. 2014 , 171, 44-8	9
1258	Atrial Fibrillation and Stroke: Increasing Stroke Risk with Intervention. 2014 , 6, 87-94	1

1257	Mechanisms of Stroke in Atrial Fibrillation. 2014 , 6, 5-15		11
1256	Trends in the pharmacologic management of atrial fibrillation: Data from the Veterans Affairs health system. 2014 , 168, 53-9.e1		9
1255	In vitro photoacoustic visualization of myocardial ablation lesions. 2014 , 11, 150-7		49
1254	Multistage electrotherapy delivered through chronically-implanted leads terminates atrial fibrillation with lower energy than a single biphasic shock. 2014 , 63, 40-8		20
1253	Prospective European survey on atrial fibrillation ablation: clinical characteristics of patients and ablation strategies used in different countries. 2014 , 25, 1074-81		16
1252	Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. <i>Circulation</i> , 2014 , 129, 837-47	16.7	2509
1251	Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning. <i>Circulation</i> , 2014 , 129, 2371-9	16.7	272
1250	Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Circulation</i> , 2014 , 130, 138-46	16.7	281
1249	A genome-wide association study to identify genomic modulators of rate control therapy in patients with atrial fibrillation. 2014 , 114, 593-600		11
1248	Breed predisposition and heritability of atrial fibrillation in the Standardbred horse: a retrospective case-control study. 2014 , 16, 173-84		20
1247	The impact of age on the epidemiology of atrial fibrillation hospitalizations. 2014 , 127, 158.e1-7		31
1246	Transesophageal Echocardiography in Atrial Fibrillation. 2014 , 6, 43-59		1
1245	Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin. 2014 , 39, 1-9		4
1244	Atrial fibrillation and its association with sudden cardiac death. 2014 , 78, 2588-93		41
1243	De Gruyter. 2014 , 22,		1
1242	Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study. 2014 , 112, 276-86		94
1241	Epidemiology of atrial fibrillation: European perspective. 2014 , 6, 213-20		637
1240	Whole blood gene expression and atrial fibrillation: the Framingham Heart Study. 2014 , 9, e96794		18

1239	Association between atrial fibrillation and silent cerebral infarctions: a systematic review and meta-analysis. 2014 , 161, 650-8	88
1238	Incidence and risk of atrial fibrillation in sleep-disordered breathing without coexistent systemic disease. 2014 , 78, 2182-7	15
1237	NKX2-6 mutation predisposes to familial atrial fibrillation. 2014 , 34, 1581-90	17
1236	Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents. 2014 , 37, 717-24	6
1235	Racial disparities in the use of catheter ablation for atrial fibrillation and flutter. 2014 , 37, 733-7	11
1234	Stroke prevention in atrial fibrillation: an Asian perspective. 2014 , 111, 789-97	181
1233	A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. 2014 , 145, 1370-1382	54
1232	A contemporary review on the genetic basis of atrial fibrillation. 2014 , 10, 18-24	14
1231	Percutaneous suture ligation of left atrial appendage using the LARIAT device: a review of technique and current data. 2014 , 6, 477-487	
1230	Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai. 2015 , 1, 203-209	2
1229	Association between hyperuricemia and atrial fibrillation in rural China: a cross-sectional study. 2015 , 15, 98	19
1228	Changes in Left Atrial Appendage Dimensions Following Volume Loading During Percutaneous Left Atrial Appendage Closure. 2015 , 8, 1935-1941	51
1227	Comparison of hemostatic dressings for superficial wounds using a new spectrophotometric coagulation assay. 2015 , 13, 375	18
1226	Age-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe: The EORP-AF General Pilot Registry (EURObservational Research Programme-Atrial Fibrillation). 2015 , 1, 326-334	37
1225	Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review. 2015 , 38, 684-91	6
1224	Circulating Fibroblast Growth Factor 23 Has a U-Shaped Association With Atrial Fibrillation Prevalence. 2015 , 79, 1742-8	11
1223	Use of warfarin in elderly patients with non-valvular atrial fibrillation -- subanalysis of the J-RHYTHM Registry. 2015 , 79, 2345-52	25
1222	Long-standing persistent atrial fibrillation ablation. 2015 , 315-322	

1221	The heavy LEGACY: Should weight management be part of every atrial fibrillation clinic?. 2015 , 2015, 57	4
1220	Acute Shrinkage of the Pulmonary Vein Ensuing From Radiofrequency and Cryoablations1. 2015 , 9,	
1219	A large left atrium thrombus extended from the right lower pulmonary vein in a patient with malignant lymphoma. 2015 , 9, 83-84	1
1218	Efficacy of ablation at the anteroseptal line for the treatment of perimitral flutter. 2015 , 31, 359-63	2
1217	Interventional Echocardiography: Current Role and Progress. 2015 , 24, 4-15	1
1216	Catheter Ablation for Atrial Fibrillation: A Review of the Literature. 2015 , 24, 16-23	4
1215	Percent Time With a Supratherapeutic INR in Atrial Fibrillation Patients Also Using an Antiplatelet Agent Is Associated With Long-Term Risk of Dementia. 2015 , 26, 1180-1186	29
1214	Novel K ⁺ Channel Targets in Atrial Fibrillation Drug Development--Where Are We?. 2015 , 66, 412-31	17
1213	Obstructive Sleep Apnea and Atrial Fibrillation: Pathophysiology and Implications for Treatment. 2015 , 14, 81-5	14
1212	Warfarin and Aspirin Use for Stroke Prevention Among Patients With Atrial Fibrillation: The US National Health and Wellness Survey. 2015 , 22, 248-56	9
1211	Statin Use and Risk of Atrial Fibrillation or Flutter: A Population-based Case-Control Study. 2015 , 22, 186-94	12
1210	A common data model to assess cardiovascular hospitalization and mortality in atrial fibrillation patients using administrative claims and medical records. 2015 , 7, 77-90	10
1209	Cardiomyocyte Remodeling in Atrial Fibrillation and Hibernating Myocardium: Shared Pathophysiologic Traits Identify Novel Treatment Strategies?. 2015 , 2015, 587361	13
1208	Estimating the current and future prevalence of atrial fibrillation in the Australian adult population. 2015 , 202, 32-5	56
1207	Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants. 2015 , 10, 1431-44	14
1206	Diagnosing Paroxysmal Atrial Fibrillation: Are Biomarkers the Solution to This Elusive Arrhythmia?. 2015 , 2015, 910267	11
1205	Prevalence of Atrial Fibrillation and Relation to Echocardiographic Parameters in a Healthy Asymptomatic Rural Korean Population. 2015 , 30, 1078-84	8
1204	How Could Pre-Procedural Imaging Guide Successful Left Atrial Appendage Closure?. 2015 , 23, 209-10	

1203	Optimal Anticoagulation Strategy for Cardioversion in Atrial Fibrillation. 2015 , 4, 44-6	2
1202	Association between left atrial appendage morphology evaluated by trans-esophageal echocardiography and ischemic cerebral stroke in patients with atrial fibrillation. 2015 , 56, 329-34	7
1201	Predictors of atrial fibrillation recurrence after cryoballoon ablation. 2015 , 6, 211-7	13
1200	Net clinical benefit of oral anticoagulants: a multiple criteria decision analysis. 2015 , 10, e0124806	19
1199	Risk and outcome after ablation of isthmus-dependent atrial flutter in elderly patients. 2015 , 10, e0127672	10
1198	Non-Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study). 2015 , 10, e0142937	83
1197	Atrial fibrillation in Sub-Saharan Africa: epidemiology, unmet needs, and treatment options. 2015 , 8, 231-42	29
1196	Surgical Left Atrial Appendage Exclusion Does Not Impair Left Atrial Contraction Function: A Pilot Study. 2015 , 2015, 318901	14
1195	Results from the Registry of Atrial Fibrillation (AFABE): Gap between Undiagnosed and Registered Atrial Fibrillation in Adults--Ineffectiveness of Oral Anticoagulation Treatment with VKA. 2015 , 2015, 134756	8
1194	Arrhythmia discrimination using a smart phone. 2015 , 19, 815-24	38
1193	Atrial Fibrillation: Pathophysiology and Therapeutic Options. 2015 , 29, 1333-40	17
1192	Obesity and atrial fibrillation: A comprehensive review of the pathophysiological mechanisms and links. 2015 , 66, 361-9	81
1191	Taking the pulse of atrial fibrillation. 2015 , 386, 113-5	14
1190	Management of atrial fibrillation in bradyarrhythmias. 2015 , 12, 337-49	23
1189	Comparisons of hospitalization rates among younger atrial fibrillation patients receiving different antiarrhythmic drugs. 2015 , 8, 292-300	7
1188	Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice. 2015 , 75, 979-98	9
1187	Cardiac CT angiography for device surveillance after endovascular left atrial appendage closure. 2015 , 16, 1198-206	85
1186	Radiofrequency ablation of accessory pathways in patients with the Wolff-Parkinson-White syndrome: the long-term mortality and risk of atrial fibrillation. 2015 , 17, 117-22	25

1185	Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses. 2015 , 15, 395-401		11
1184	Prevalence of atrial fibrillation and the HATCH score: Intensified monitoring of patients with high HATCH score. 2015 , 40, 803-8		5
1183	Left atrial appendage occlusion for prevention of stroke in nonvalvular atrial fibrillation: a meta-analysis. 2015 , 43, 79-89		3
1182	Atrial fibrillation in end stage renal disease patients: influence of hemodialysis on P wave duration and atrial dimension. 2015 , 28, 615-21		6
1181	Atrial fibrillation pathophysiology and prognosis: insights from cardiovascular imaging. 2015 , 8,		7
1180	Cardiorespiratory Fitness and Risk of Incident Atrial Fibrillation: Results From the Henry Ford Exercise Testing (FIT) Project. <i>Circulation</i> , 2015 , 131, 1827-34	16.7	127
1179	Association Between Atrial Fibrillation and Costs After Myocardial Infarction: A Community Study. 2015 , 38, 548-54		1
1178	Real-time physiologic biomarker for prediction of atrial fibrillation recurrence, stroke, and mortality after electrical cardioversion: A prospective observational study. 2015 , 170, 914-22		14
1177	Improved detection of activation timings in endoatrial electrograms through a modified sinusoidal recomposition method. 2015 ,		1
1176	Asian strategy for stroke prevention in atrial fibrillation. 2015 , 17 Suppl 2, ii31-9		21
1175	Analysis of the electrical patterns and structural remodeling in atrial fibrillation. 2015 , 2015, 7035-8		1
1174	Closing the Oval Door. 2015 , 8, 1922-1924		
1173	Atrial fibrillation in patients admitted to coronary care units in western Sweden - focus on obesity and lipotoxicity. 2015 , 48, 853-60		9
1172	Impact of Uncontrolled Hypertension on Atrial Fibrillation Ablation Outcome. 2015 , 1, 164-173		24
1171	Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. 2015 , 147, 109-119		161
1170	Early detection of atrial fibrillation is the first step to prevent cardiogenic stroke: Usefulness of B-type natriuretic peptide. 2015 , 65, 451-2		3
1169	Association of soda consumption with subclinical cardiac remodeling in the Framingham heart study. 2015 , 64, 208-12		6
1168	Atrial fibrillation and dementia. 2015 , 25, 44-51		42

1167	Optimal contact forces to minimize cardiac perforations before, during, and/or after radiofrequency or cryothermal ablations. 2015 , 12, 291-6	17
1166	Singular Value Decomposition of Optically-Mapped Cardiac Rotors and Fibrillatory Activity. 2015 , 48,	1
1165	Burden of disease and cost of illness of atrial fibrillation in Portugal. 2015 , 34, 1-11	13
1164	Évolution dans la prise en charge des accidents hémorragiques liés aux antivitamines K et traités par du concentré de complexes prothrombiniques : la gestion du traitement médicamenteux par les urgentistes s'améliore-t-elle au fil du temps ? 2015 , 5, 9-15	
1163	Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation. 2015 , 17, 331	1
1162	Vitamin D deficiency and atrial fibrillation. 2015 , 184, 159-162	34
1161	Untreated atrial fibrillation in the United Kingdom: Understanding the barriers and treatment options. 2015 , 27, 31-43	11
1160	Burden of disease and cost of illness of atrial fibrillation in Portugal. 2015 , 34, 1-11	14
1159	Atrial fibrillation incidence and risk factors in relation to race-ethnicity and the population attributable fraction of atrial fibrillation risk factors: the Multi-Ethnic Study of Atherosclerosis. 2015 , 25, 71-6, 76.e1	104
1158	Five-year outcomes of catheter ablation in patients with atrial fibrillation and left ventricular systolic dysfunction. 2015 , 26, 363-370	50
1157	Intracardiac myocardial elastography in canines and humans in vivo. 2015 , 62, 337-49	22
1156	Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. 2015 , 18, 399-409	23
1155	Prevalence of atrial fibrillation and its risk factors in rural China: a cross-sectional study. 2015 , 182, 13-7	58
1154	Long-term results of surgical minimally invasive pulmonary vein isolation for paroxysmal lone atrial fibrillation. 2015 , 17, 747-52	16
1153	Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. 2015 , 17, 194-206	30
1152	Heart disease and stroke statistics--2015 update: a report from the American Heart Association. <i>Circulation</i> , 2015 , 131, e29-322	16.7 5259
1151	Worse stroke outcome in atrial fibrillation is explained by more severe hypoperfusion, infarct growth, and hemorrhagic transformation. 2015 , 10, 534-40	73
1150	Body weight and risk of atrial fibrillation in 7,169 patients with newly diagnosed type 2 diabetes; an observational study. 2015 , 14, 5	38

1149	Decade-long trends in atrial fibrillation incidence and survival: a community study. 2015 , 128, 260-7.e1	59
1148	Low-level transcutaneous electrical vagus nerve stimulation suppresses atrial fibrillation. 2015 , 65, 867-75	180
1147	Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). 2015 , 65, 2159-69	499
1146	Anticoagulation therapy in 2015: where we are and where we are going. 2015 , 39, 264-72	10
1145	Impact of weight reduction on pericardial adipose tissue and cardiac structure in patients with atrial fibrillation. 2015 , 169, 655-662.e2	31
1144	Obesity and the Risk of Incident, Post-Operative, and Post-Ablation Atrial Fibrillation: A Meta-Analysis of 626,603 Individuals in 51 Studies. 2015 , 1, 139-152	106
1143	Atrial Fibrillation and Thrombogenesis: Innocent Bystander or Guilty Accomplice?. 2015 , 1, 218-219	1
1142	Atrial fibrillation ablation: indications, emerging techniques, and follow-up. 2015 , 58, 202-12	4
1141	ADVICE on adenosine to improve atrial fibrillation ablation. 2015 , 386, 633-4	1
1140	Evaluating the Atrial Myopathy Underlying Atrial Fibrillation: Identifying the Arrhythmogenic and Thrombogenic Substrate. <i>Circulation</i> , 2015 , 132, 278-91	16.7 138
1139	Dosing of Target-Specific Oral Anticoagulants in Special Populations. 2015 , 49, 1031-45	14
1138	Metabolic syndrome, atrial fibrillation, and stroke: Tackling an emerging epidemic. 2015 , 12, 2332-43	21
1137	Validation of a simple method for atrial fibrillation screening in patients with stroke. 2015 , 36, 1675-8	19
1136	Atrial Fibrillation. 2015 , 33, 597-612	4
1135	Bridging the gender gap in atrial fibrillation. 2015 , 13, 317-23	6
1134	Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. 2015 , 13, 907-14	2
1133	Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United States. 2015 , 116, 733-9	49
1132	Trends in hospitalization for atrial fibrillation: epidemiology, cost, and implications for the future. 2015 , 58, 105-16	56

1131	Dietary Fat Intake Is Differentially Associated with Risk of Paroxysmal Compared with Sustained Atrial Fibrillation in Women. 2015 , 145, 2092-101	8
1130	Electrophysiological, Electroanatomical, and Structural Remodeling of the Atria as Consequences of Sustained Obesity. 2015 , 66, 1-11	219
1129	SR calcium handling dysfunction, stress-response signaling pathways, and atrial fibrillation. 2015 , 6, 46	3
1128	Asymptomatic atrial fibrillation after cryptogenetic stroke: incidence, clinical significance, and therapeutic implications. 2015 , 8, 249-51	
1127	Atrial Fibrillation and Risk of ST-Segment-Elevation Versus Non-ST-Segment-Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2015 , 131, 1843-50	16.7 101
1126	Percutaneous ligation of the left atrial appendage results in atrial electrical substrate modification. 2015 , 165, 365-73	5
1125	Comparison of Medical Costs of Patients With Atrial Fibrillation Unsuitable for Warfarin Treatment With Apixaban or Aspirin Based on AVERROES Trial. 2015 , 21, 235-40	4
1124	Atrial fibrillation: recent advances in understanding the role of microRNAs in atrial remodeling with an electrophysiological overview. 2015 , 131, 58-67	14
1123	Baseline NT-ProBNP level predicts success of cardioversion of atrial fibrillation with flecainide. 2015 , 23, 182-9	4
1122	CHA ₂ DS ₂ -VASc scores predict mortality after hospitalization for atrial fibrillation. 2015 , 185, 293-6	13
1121	Alternating membrane potential/calcium interplay underlies repetitive focal activity in a genetic model of calcium-dependent atrial arrhythmias. 2015 , 593, 1443-58	18
1120	Atrial fibrillation and cycling: six year follow-up of the Taupo bicycle study. 2015 , 15, 23	8
1119	Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences. 2015 , 65, 2239-51	129
1118	Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. 2015 , 4, e001486	143
1117	Gastroparesis as a Complication of Atrial Fibrillation Ablation. 2015 , 116, 92-7	31
1116	50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. 2015 , 386, 154-62	714
1115	Stroke associated with discontinuation of warfarin therapy for atrial fibrillation. 2015 , 31, 2021-9	19
1114	Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke?. 2015 , 4, e001573	17

1113	Edoxaban: a review in nonvalvular atrial fibrillation. 2015 , 15, 351-61	4
1112	Refining the Risk for Atrial Fibrillation. 2015 , 8, e003807	
1111	LKB1 knockout mouse develops spontaneous atrial fibrillation and provides mechanistic insights into human disease process. 2015 , 4, e001733	52
1110	Relationship of Age With Stroke and Death in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: AMADEUS Trial. 2015 , 46, 3202-7	10
1109	Smoothing the Bumpy Road to Antiarrhythmic Drug Development. <i>Circulation</i> , 2015 , 132, 2195-7	16.7
1108	Observing the Obvious. 2015 , 66, 1008-10	
1107	Radiofrequency Ablation to Prevent Sudden Cardiac Death. 2015 , 11, 121-8	3
1106	Economic evaluation of a randomized controlled trial of pharmacist-supervised patient self-testing of warfarin therapy. 2015 , 40, 14-9	12
1105	Advances in stroke prevention. 2015 , 1338, 1-15	22
1104	Underuse of oral anticoagulation for individuals with atrial fibrillation in a nursing home setting in France: comparisons of resident characteristics and physician attitude. 2015 , 63, 71-6	62
1103	Rate control versus rhythm control in atrial fibrillation: lessons learned from clinical trials of atrial fibrillation. 2015 , 58, 168-76	5
1102	Are We Ready for Mass Screening to Detect Atrial Fibrillation?. <i>Circulation</i> , 2015 , 131, 2167-8	16.7 14
1101	Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation. 2015 , 17, 61	11
1100	Associations of obesity and body fat distribution with incident atrial fibrillation in the biracial health aging and body composition cohort of older adults. 2015 , 170, 498-505.e2	33
1099	Role of Endovascular Closure of the Left Atrial Appendage in Stroke Prevention for Atrial Fibrillation. 2015 , 17, 65	2
1098	Anticoagulation for Atrial Fibrillation in Patients with Cerebral Microbleeds. 2015 , 17, 47	14
1097	The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism. 2015 , 8, 1048-56	106
1096	Left Ventricular Systolic Dysfunction by Longitudinal Strain Is an Independent Predictor of Incident Atrial Fibrillation: A Community-Based Cohort Study. 2015 , 8, e003520	31

1095	Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapy. 2015 , 18, 1041-9	2
1094	Sex differences in clinical characteristics and inpatient outcomes among 2442 hospitalized Chinese patients with nonvalvular atrial fibrillation: The Nanchang Atrial Fibrillation Project. 2015 , 201, 195-9	5
1093	The risk of atrial fibrillation in the general male population: a lifetime follow-up of 50-year-old men. 2015 , 17, 1018-22	23
1092	Increasing incidence of non-valvular atrial fibrillation in the UK from 2001 to 2013. 2015 , 101, 1748-54	35
1091	Vagal atrial fibrillation: What is it and should we treat it?. 2015 , 201, 415-21	36
1090	Incidence of Atrial Fibrillation and Relationship With Cardiovascular Events, Heart Failure, and Mortality: A Community-Based Study From the Netherlands. 2015 , 66, 1000-7	153
1089	Management of device-detected atrial high-rate episodes. 2015 , 7, 515-25	7
1088	Discrepancy between guidelines for stroke prevention in atrial fibrillation and practice patterns in primary care. The nationwide French AFIGP survey. 2015 , 108, 544-53	14
1087	Continuous vagal nerve stimulation affects atrial neural remodeling and reduces atrial fibrillation inducibility in rabbits. 2015 , 24, 395-8	5
1086	Validation of PR interval length as a criterion for development of atrial fibrillation in non-Hispanic whites, African Americans and Hispanics. 2015 , 48, 703-9	6
1085	Assessment of Degree of Anticoagulation Control in Patients With Atrial Fibrillation in Primary Health Care in Galicia, Spain: ANFAGAL Study. 2015 , 68, 753-60	5
1084	Evaluaci3n del grado de anticoagulaci3n de pacientes con fibrilaci3n auricular en el 3mbito de atenci3n primaria de Galicia. Estudio ANFAGAL. 2015 , 68, 753-760	36
1083	Catheter Ablation for Long-Standing Persistent Atrial Fibrillation. 2015 , 11, 87-93	9
1082	A bridge too far? Findings of bridging anticoagulation use and outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>Circulation</i> , 2015 , 131, 448-50	16.7 6
1081	Stroke prophylaxis in atrial fibrillation: searching for management improvement opportunities in the emergency department: the HERMES-AF study. 2015 , 65, 1-12	28
1080	Early results with the LARIAT device for left atrial appendage exclusion in patients with atrial fibrillation at high risk for stroke and anticoagulation. 2015 , 86, 121-7	48
1079	Management of Atrial Fibrillation. 2015 , 30, 484-98	5
1078	Comparison of costs and discharge outcomes for patients hospitalized for ischemic or hemorrhagic stroke with or without atrial fibrillation in the United States. 2015 , 39, 508-15	9

1077	Rationale and design of Triple AXEL: trial for early anticoagulation in acute ischemic stroke patients with nonvalvular atrial fibrillation. 2015 , 10, 128-33	33
1076	Current trends in preoperative, intraoperative, and postoperative care of the adult cardiac surgery patient. 2015 , 52, 531-69	30
1075	Oral anticoagulants and status of antidotes for the reversal of bleeding risk. 2015 , 21, 105-14	15
1074	The Educational Needs of Clinicians Regarding Anticoagulation Therapy for Prevention of Thromboembolism and Stroke in Patients With Atrial Fibrillation. 2016 , 31, 38-46	6
1073	Atrial Fibrillation, Cognitive Decline And Dementia. 2016 , 11, 49-53	43
1072	Attitudes toward anticoagulant treatment among nonvalvular atrial fibrillation patients at high risk of stroke and low risk of bleed. 2016 , 10, 795-805	8
1071	Stroke Prevention in Atrial Fibrillation and Valvular Heart Disease. 2016 , 10, 110-6	5
1070	Atrial fibrillation and silent stroke: links, risks, and challenges. 2016 , 12, 65-74	28
1069	Five years of keeping a watch on the left atrial appendage-how has the WATCHMAN fared?. 2016 , 8, E1726-E1733	6
1068	Incidence and Risk Factors for Atrial Fibrillation in Korea: the National Health Insurance Service Database (2002-2010). 2016 , 46, 515-21	43
1067	Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials. 2016 , 116, S33-S40	7
1066	Relationship between plasma level of vitamin D and post operative atrial fibrillation in patients undergoing CABG. 2016 , 32, 900-4	6
1065	Global Epidemiology and Incidence of Cardiovascular Disease. 2016 , 57-96	3
1064	Radiofrequency Catheter Ablation Improves the Quality of Life Measured with a Short Form-36 Questionnaire in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis. 2016 , 11, e0163755	22
1063	Atrial Fibrillation: The Science behind Its Defiance. 2016 , 7, 635-656	10
1062	Recent Advances in the Pharmacological Management of Atrial Fibrillation. 2016 , 23, e118-38	2
1061	The Role of Pharmacogenetics in Atrial Fibrillation Therapeutics: Is Personalized Therapy in Sight?. 2016 , 67, 9-18	13
1060	Hybrid Procedure (Endo/Epicardial) versus Standard Manual Ablation in Patients Undergoing Ablation of Longstanding Persistent Atrial Fibrillation: Results from a Single Center. 2016 , 27, 524-30	42

1059	The Impact of Duration of Atrial Fibrillation Recurrences on Measures of Health-Related Quality of Life and Symptoms. 2016 , 39, 166-72	14
1058	2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. 2016 , 68, 525-568	38
1057	2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. 2016 , 9, 443-88	23
1056	No Decline in the Risk of Stroke Following Incident Atrial Fibrillation Since 2000 in the Community: A Concerning Trend. 2016 , 5,	23
1055	Detection of atrial fibrillation with seismocardiography. 2016 , 2016, 4369-4374	3
1054	Renal sympathetic stimulation in patients with controlled hypertension and paroxysmal atrial fibrillation. 2016 , 224, 394-397	4
1053	Correlation between impedance cardiography and 6' min walk distance in atrial fibrillation patients. 2016 , 16, 133	2
1052	Synthesis of a highly water-soluble acacetin prodrug for treating experimental atrial fibrillation in beagle dogs. 2016 , 6, 25743	18
1051	High prevalence of modifiable stroke risk factors identified in a pharmacy-based screening programme. 2016 , 3, e000515	32
1050	Associations of Epicardial, Abdominal, and Overall Adiposity With Atrial Fibrillation. 2016 , 9,	75
1049	Spectral Analysis of Baseline Electrocardiogram During Atrial Fibrillation Predicts Response to Antiarrhythmic Drug Therapy in Patients With Persistent Atrial Fibrillation. 2016 , 27, 1312-1318	1
1048	Atrial electrocardiography in obesity and hypertension: Clinical insights from the Polish-Norwegian Study (PONS). 2016 , 24, 2608-2614	12
1047	2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. 2016 , 115, 893-952	76
1046	Surgical Weight Loss and Atrial Fibrillation: A Convenient Paradigm to Evaluate a Complex Problem. 2016 , 68, 2505-2507	10
1045	TBX5 loss-of-function mutation contributes to atrial fibrillation and atypical Holt-Oram syndrome. 2016 , 13, 4349-56	11
1044	Epidemiologã de la fibrilaciã auricular. 2016 , 16, 2-7	1
1043	Asymmetric dimethylarginine, related arginine derivatives, and incident atrial fibrillation. 2016 , 176, 100-6	6
1042	Residential exposure to traffic noise and risk of incident atrial fibrillation: A cohort study. 2016 , 92-93, 457-63	36

1041	Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. 2016 , 5,	144
1040	Atrial fibrillation burden and atrial fibrillation type: Clinical significance and impact on the risk of stroke and decision making for long-term anticoagulation. 2016 , 83, 26-35	48
1039	Cost comparison of radiofrequency catheter ablation versus cryoablation for atrial fibrillation in hospitals using both technologies. 2016 , 19, 959-64	13
1038	Efficacy and Safety of Percutaneous Left Atrial Appendage Occlusion for Stroke Prevention in Nonvalvular Atrial Fibrillation: A Meta-analysis of Contemporary Studies. 2016 , 25, 1107-1117	8
1037	Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. 2016 , 13, 321-32	150
1036	Left Atrial Appendage Closure for Atrial Fibrillation Is Safe and Effective After Intracranial or Intraocular Hemorrhage. 2016 , 32, 349-54	12
1035	The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. 2016 , 37, 2869-2878	144
1034	Atrial fibrillation: In the light of new hypothesis. 2016 , 86, 10-3	0
1033	Left Atrial Appendage and Closure: Who, When, and How. 2016 , 9, e002942	21
1032	[Atrial fibrillation - Update 2016]. 2016 , 158 Spec No 1, 20-28	
1031	Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. 2016 , 18, 1135-42	18
1030	Relation of Body Mass Index With Adverse Outcomes Among Patients With Atrial Fibrillation: A Meta-Analysis and Systematic Review. 2016 , 5,	55
1029	Dynamic ECG features for atrial fibrillation recognition. 2016 , 136, 143-50	15
1028	Genetic basis of atrial fibrillation. 2016 , 3, 257-262	17
1027	New Oral Anticoagulants in Nonvalvular Atrial Fibrillation. 2016 , 39, 739-746	10
1026	Hypertension and Sudden Cardiac Death. 2016 , 279-308	
1025	Initial experience with the WATCHMAN® left atrial appendage system for stroke prevention in atrial fibrillation: A single-centre registry. 2016 , 109, 689-695	
1024	Evaluation of a Prediction Model for the Development of Atrial Fibrillation in a Repository of Electronic Medical Records. 2016 , 1, 1007-1013	32

1023	Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. 2016 , 150, 1302-1312	165
1022	The changing face of cardiovascular disease 2000-2012: An analysis of the world health organisation global health estimates data. 2016 , 224, 256-264	154
1021	Non-vitamin K oral anticoagulant treatment in elderly patients with atrial fibrillation and coronary heart disease. 2016 , 222, 1079-1083	9
1020	Chronic anticoagulation in non-valvular atrial fibrillation: Where things stand. 2016 , 222, 615-619	4
1019	Management of atrial fibrillation: when are invasive approaches useful?. 2016 , 77, 460-6	
1018	Atrial Fibrillation Patients Treated With Long-Term Warfarin Anticoagulation Have Higher Rates of All Dementia Types Compared With Patients Receiving Long-Term Warfarin for Other Indications. 2016 , 5,	33
1017	Short Stay Management of Atrial Fibrillation. 2016 ,	1
1016	The changing circumstance of atrial fibrillation - progress towards precision medicine. 2016 , 279, 412-27	20
1015	A Bridge to Nowhere? Benefits and Risks for Periprocedural Anticoagulation in Atrial Fibrillation. 2016 , 18, 101	2
1014	Atrial Fibrillation Associated Genetic Variants and Left Atrial Histology: Evaluation for Molecular Sub-Phenotypes. 2016 , 27, 1264-1270	1
1013	Outcomes of Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. 2016 , 68, 895-904	47
1012	A Fresh Perspective on Atrial Fibrillation. 2016 , 68, 905-7	
1011	Use of Direct Oral Anticoagulants in Special Populations. 2016 , 30, 1053-71	3
1010	Atrial fibrillation is associated with an increased risk of myocardial infarction: Insights from a meta-analysis. 2016 , 254, 1-7	12
1009	Discontinuation of Dofetilide From QT Prolongation and Ventricular Tachycardia in the 'Real World'. 2016 , 2, 777-781	9
1008	Strategies for Risk Analysis and Disease Classification in Atrial Fibrillation. 2016 , 27, 1271-1273	
1007	Prevention of stroke: a strategic global imperative. 2016 , 12, 501-12	117
1006	Left Atrial Sphericity Index Predicts Early Recurrence of Atrial Fibrillation After Direct-Current Cardioversion: An Echocardiographic Study. 2016 , 39, 406-12	14

1005	Monitoring and detecting atrial fibrillation using wearable technology. 2016 , 2016, 3394-3397	55
1004	Intra-Operative Modeling of the Left Atrium: A Simulation Approach Using Poisson Surface Reconstruction. 2016 , 354-365	
1003	New perspectives on atrial fibrillation and stroke. 2016 , 102, 1788-1792	17
1002	Cryoablation of atrial fibrillation. 2016 , 120, 101-109	2
1001	Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives. 2016 , 18, 1507-1513	7
1000	An ECG Index of P-Wave Force Predicts the Recurrence of Atrial Fibrillation after Pulmonary Vein Isolation. 2016 , 39, 1191-1197	3
999	Left atrial appendage closure versus oral anticoagulation for preventing stroke in people with atrial fibrillation. 2016 ,	78
998	The effect of a dual or a triple antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model: An open-label, controlled, sequential study. 2016 , 95, e4145	1
997	Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation. 2016 , 175, 9-17	6
996	Invited Commentary: Initial Experience with Direct Oral Anticoagulants in the Perioperative Setting. 2016 , 4, 88-92	
995	Atrial fibrillation and gastroesophageal reflux disease: the cardiogastric interaction. 2017 , 19, 16-20	25
994	A comparison of the CHARGE-AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study. 2016 , 178, 45-54	42
993	Cardiovascular risk profile and management of atrial fibrillation in India: Real world data from RealiseAF survey. 2016 , 68, 663-670	12
992	Clinical Implications of Leaks Following Left Atrial Appendage Ligation With the LARIAT Device. 2016 , 9, 1051-7	31
991	Percutaneous closure of left atrial appendage for stroke prevention. 2016 , 58, e250-e260	1
990	Capítulo 6. Utilidad del mapeo tridimensional en la ablación de la fibrilación auricular paroxística. 2016 , 23, 35-37	
989	Prevalence and associating factors of atrial fibrillation in patients with hypertension: a nation-wide study. 2016 , 16, 57	18
988	Risk factor changes and incident atrial fibrillation among middle-aged men in the Malmö Preventive Project cohort. 2016 , 2, 81-7	9

987	Usual blood pressure, atrial fibrillation and vascular risk: evidence from 4.3 million adults. 2017 , 46, 162-172	32
986	E-health in patients with atrial fibrillation. 2016 , 15, 200-2	3
985	Obstructive Sleep Apnea Treatment and Atrial Fibrillation: A Need for Definitive Evidence. 2016 , 27, 1001-10	16
984	Left atrial appendage isolation using percutaneous (endocardial/epicardial) devices: Pre-clinical and clinical experience. 2016 , 26, 182-99	10
983	Temporal Patterns and Predictors of Rate vs Rhythm Control in Patients Attending a Multidisciplinary Atrial Fibrillation Clinic. 2016 , 32, 1247.e7-1247.e13	
982	Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. <i>Circulation</i> , 2016 , 133, e38-360	16.7 4504
981	Adequacy of ESC atrial fibrillation guidelines in the elderly population: Analysis of practices from an internal medicine department. 2016 , 7, 23-27	1
980	Atrial fibrillation and arterial hypertension: A common duet with dangerous consequences where the renin angiotensin-aldosterone system plays an important role. 2016 , 206, 71-6	30
979	Underuse of anticoagulation in patients with atrial fibrillation. 2016 , 128, 191-200	26
978	Direct Oral Anticoagulants for the Management of Thromboembolic Disorders: The Importance of Adherence and Persistence in Achieving Beneficial Outcomes. 2016 , 22, 605-16	16
977	Comorbidity of atrial fibrillation and heart failure. 2016 , 13, 131-47	88
976	Secondary Prevention After Cardioembolic Stroke. 2016 , 111-135	
975	Are There Deleterious Cardiac Effects of Acute and Chronic Endurance Exercise?. 2016 , 96, 99-125	122
974	Diabetes mellitus is an independent risk factor for atrial fibrillation in a general Chinese population. 2016 , 7, 791-6	11
973	Health Care Resource Utilization, Costs, and Persistence in Patients Newly Diagnosed as Having Nonvalvular Atrial Fibrillation and Newly Treated With Dabigatran versus Warfarin in the United States. 2016 , 38, 545-56.e1-6	24
972	Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?. 2016 , 16, 183-200	52
971	PDGF-B/PDGFR- β Signaling: A New Potential Therapeutic Target of Atrial Fibrillation. 2016 , 134, 19-21	0
970	Detection of Atrial Fibrillation After Surgical Ablation: Conventional Versus Continuous Monitoring. 2016 , 101, 42-7; discussion 47-8	24

969	Is atrial fibrillation a risk factor for contrast-induced nephropathy in patients with ST-elevation myocardial infarction?. 2016 , 67, 327-30	10
968	Differentiation between atrial fibrillation and atrial flutter using 1d Poincare maps based on endocardial bipolar intracardiac electrograms extracted from the right atria. 2016 ,	0
967	The Effects of Radiofrequency or Cryothermal Ablation on Biomechanical Properties of Isolated Human or Swine Cardiac Tissues. 2016 , 4, 1900105	138
966	Diagnostic Evaluation and Follow-Up of Patients with Atrial Fibrillation. 2016 , 12, 179-91	
965	Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions. 2017 , 38, 1294-1302	124
964	Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study. 2016 , 176, 10-6	5
963	Risk Factors and Genetics of Atrial Fibrillation. 2016 , 12, 157-66	24
962	Body mass index and the risk of new-onset atrial fibrillation in middle-aged adults. 2016 , 173, 41-8	36
961	Variations in the emergency department management of atrial fibrillation: Lessons to be learned. 2016 , 173, 159-60	3
960	Validation of the Framingham Heart Study and CHARGE-AF Risk Scores for Atrial Fibrillation in Hispanics, African-Americans, and Non-Hispanic Whites. 2016 , 117, 76-83	28
959	Effect of Intensive Blood Pressure Lowering on Incident Atrial Fibrillation and P-Wave Indices in the ACCORD Blood Pressure Trial. 2016 , 29, 1276-1282	22
958	The role of obesity in atrial fibrillation. 2016 , 37, 1565-72	115
957	Hyperuricemia is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. 2016 , 39, 159-67	25
956	Atrial arrhythmogenesis in obstructive sleep apnea: Therapeutic implications. 2016 , 26, 87-94	50
955	Choice of Health Options In prevention of Cardiovascular Events for people with Atrial Fibrillation (CHOICE-AF): A pilot study. 2016 , 15, 39-46	6
954	Early impairment in left ventricular longitudinal systolic function is associated with an increased risk of incident atrial fibrillation in patients with type 2 diabetes. 2017 , 31, 413-418	19
953	Genetic Risk Scores for Atrial Fibrillation: Do They Improve Risk Estimation?. 2017 , 33, 422-424	6
952	National Trends in Atrial Fibrillation Hospitalization, Readmission, and Mortality for Medicare Beneficiaries, 1999-2013. <i>Circulation</i> , 2017 , 135, 1227-1239	16.7 70

951	Right Ventricular Structure and Function Are Associated With Incident Atrial Fibrillation: MESA-RV Study (Multi-Ethnic Study of Atherosclerosis-Right Ventricle). 2017 , 10,	9
950	Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. <i>Circulation</i> , 2017 , 135, e146-e603	16.7 5568
949	Interleukin-37 elevation in patients with atrial fibrillation. 2017 , 40, 66-72	9
948	The burden of proof: The current state of atrial fibrillation prevention and treatment trials. 2017 , 14, 763-782	23
947	Sinus Node Dysfunction and Atrial Fibrillation: A Reversible Phenomenon?. 2017 , 40, 442-450	34
946	Incidence of Idiopathic Ventricular Arrhythmias: A Population-Based Study. 2017 , 10,	27
945	Electrocardiographic intervals associated with incident atrial fibrillation: Dissecting the QT interval. 2017 , 14, 654-660	2
944	Is Atrial Fibrillation a Preventable Disease?. 2017 , 69, 1968-1982	61
943	Update about atrial fibrillation genetics. 2017 , 32, 246-252	8
942	Upregulation of sestrins protect atriums against oxidative damage and fibrosis in human and experimental atrial fibrillation. 2017 , 7, 46307	22
941	What Is the Appropriate Lesion Set for Ablation in Patients with Persistent Atrial Fibrillation?. 2017 , 19, 35	7
940	Cardiac troponin-I as a predictor of mortality in patients with first episode acute atrial fibrillation. 2017 , 110, 507-511	9
939	Risk and Prediction of Sudden Cardiac Death and Ventricular Arrhythmias for Patients with Atrial Fibrillation - A Nationwide Cohort Study. 2017 , 7, 46445	23
938	Circulating ceruloplasmin, ceruloplasmin-associated genes, and the incidence of atrial fibrillation in the atherosclerosis risk in communities study. 2017 , 241, 223-228	3
937	Low incidence of left atrial delayed enhancement with MRI in patients with AF: a single-centre experience. 2017 , 4, e000546	10
936	A deep learning approach to monitoring and detecting atrial fibrillation using wearable technology. 2017 ,	65
935	Treatment of Patients With Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2017 , 135, 1547-1563	16.7 54
934	Pericardial fat volume and incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis and Jackson Heart Study. 2017 , 25, 1115-1121	26

933	Ablation of Advanced Subtypes of Atrial Fibrillation: Highlighting the Art of When and When Not to Perform Additional Ablation. 2017 , 11, 1	1
932	Should Ablation Be First-Line Therapy for Patients with Paroxysmal AF?. 2017 , 19, 38	
931	Who Should Be Referred for Left Atrial Appendage Occlusion Therapy?. 2017 , 19, 42	
930	Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care. 2017 , 6,	127
929	Impact of atrial fibrillation detected by extended monitoring-A population-based cohort study. 2017 , 22,	10
928	Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. 2017 , 120, 1501-1517	370
927	Perspectives and challenges of antioxidant therapy for atrial fibrillation. 2017 , 390, 1-14	21
926	Normalization of Testosterone Levels After Testosterone Replacement Therapy Is Associated With Decreased Incidence of Atrial Fibrillation. 2017 , 6,	30
925	Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience. 2017 , 18, 467-477	6
924	Abnormal P-Wave Axis and Ischemic Stroke: The ARIC Study (Atherosclerosis Risk In Communities). 2017 , 48, 2060-2065	27
923	Real-practice thromboprophylaxis in atrial fibrillation. 2017 , 67, 227-236	2
922	Socioeconomic status and the development of atrial fibrillation in Hispanics, African Americans and non-Hispanic whites. 2017 , 40, 770-776	8
921	State of the Art Review: Atrial Fibrillation in Athletes. 2017 , 26, 983-989	38
920	Atrial fibrillation inducibility during cavo-tricuspid isthmus dependent atrial flutter ablation for the prediction of clinical atrial fibrillation. 2017 , 240, 246-250	3
919	Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial). 2017 , 119, 1989-1996	61
918	Effect of ablation pattern on mechanical function in the atrium. 2017 , 40, 648-654	8
917	Hypertension and Atrial Fibrillation: An Intimate Association of Epidemiology, Pathophysiology, and Outcomes. 2017 , 30, 733-755	37
916	Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. 2017 , 4, CD008600	31

915	Insufficient Leaflet Remodeling in Patients With Atrial Fibrillation: Association With the Severity of Mitral Regurgitation. 2017 , 10,	59
914	Conventional versus 3-D Echocardiography to Predict Arrhythmia Recurrence After Atrial Fibrillation Ablation. 2017 , 28, 651-658	11
913	Quantized Segmentation of Fibrotic Tissue of Left Atrial from Delay-Enhancement MRI Images Using Level-Set and Graph-Cut. 2017 ,	1
912	Short- and long-term clinical predictors of pharmacological cardioversion of persistent atrial fibrillation by dofetilide: A retrospective cohort study of 160 patients. 2017 , 40, 474-479	3
911	Latin American Clinical Epidemiology Network Series - Paper 2: Apixaban was cost-effective vs. acenocoumarol in patients with nonvalvular atrial fibrillation with moderate to severe risk of embolism in Chile. 2017 , 86, 75-83	6
910	Retrospective Cohort Study Examining Reduced Intensity and Duration of Anticoagulant and Antiplatelet Therapy Following Left Atrial Appendage Occlusion with the WATCHMAN Device. 2017 , 26, 477-485	8
909	Genetic Obesity and the Risk of Atrial Fibrillation: Causal Estimates from Mendelian Randomization. <i>Circulation</i> , 2017 , 135, 741-754	16.7 62
908	Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know. 2017 , 37, 236-248	67
907	Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study. 2017 , 185, 74-84	41
906	Pro-arrhythmic atrial phenotypes in incrementally paced murine Pgc1 α hearts: effects of age. 2017 , 102, 1619-1634	8
905	Diminished Expression Is Associated With Increased Risk of Atrial Fibrillation and Shortening of the Cardiac Action Potential. 2017 , 10,	20
904	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. 2017 , 194, 132-140	104
903	Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study. 2017 , 194, 99-106	25
902	Atrial fibrillation and the risk of myocardial infarction: a nation-wide propensity-matched study. 2017 , 7, 12716	33
901	Effect of eicosapentaenoic acid and pitavastatin on electrophysiology and anticoagulant gene expression in mice with rapid atrial pacing. 2017 , 14, 2310-2316	2
900	Anatomical and electrical remodeling with incomplete left atrial appendage ligation: Results from the LAALA-AF registry. 2017 , 28, 1433-1442	8
899	Refining Prediction of Atrial Fibrillation Risk in the General Population With Analysis of P-Wave Axis (from the Atherosclerosis Risk in Communities Study). 2017 , 120, 1980-1984	16
898	Emergency Department, Hospital Inpatient, and Mortality Burden of Atrial Fibrillation in the United States, 2006 to 2014. 2017 , 120, 1966-1973	31

897	Screening of older patients for atrial fibrillation in general practice: Current evidence and its implications for future practice. 2017 , 23, 246-253	11
896	Homocysteine in non-valvular atrial fibrillation: Role and clinical implications. 2017 , 475, 85-90	12
895	Symptom challenges after atrial fibrillation ablation. 2017 , 46, 425-431	10
894	Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures: a prospective, open-label, single-arm phase 3b study. 2017 , 106, 777-786	18
893	Novel composite scoring system to predict unknown atrial fibrillation in acute ischemic stroke patients. 2017 , 1674, 36-41	3
892	Ca/calmodulin-dependent kinase II-dependent regulation of atrial myocyte late Na current, Ca cycling, and excitability: a mathematical modeling study. 2017 , 313, H1227-H1239	18
891	Atrial Fibrillation Ablation. 2017 , 143-155	
890	Temporal Trends in the Incidence, Prevalence, and Survival of Patients With Atrial Fibrillation From 2004 to 2016. 2017 , 120, 1961-1965	25
889	Screening for atrial fibrillation in Canadian pharmacies: an economic evaluation. 2017 , 5, E653-E661	16
888	Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation. 2017 , 37, 1221-1230	60
887	Cardiovascular Catheter With an Expandable Origami Structure. 2017 , 11,	6
886	Different Implications of Heart Failure, Ischemic Stroke, and Mortality Between Nonvalvular Atrial Fibrillation and Atrial Flutter-a View From a National Cohort Study. 2017 , 6,	39
885	Is antithrombotic therapy necessary for short self-limiting episodes of atrial fibrillation?. 2017 , 18 Suppl 1, e166-e169	
884	Effect of Bariatric Surgery on Emergency Department Visits and Hospitalizations for Atrial Fibrillation. 2017 , 120, 947-952	26
883	Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. 2017 , 192, 19-25	28
882	Proteinuria Detected by Urine Dipstick Test as a Risk Factor for Atrial Fibrillation: A Nationwide Population-Based Study. 2017 , 7, 6324	10
881	Atrioventricular reciprocating tachycardia in a girl with atrial fibrillation. 2017 , 59, 1029-1031	
880	Efficacy and safety of driver-guided catheter ablation for atrial fibrillation: A systematic review and meta-analysis. 2017 , 28, 1371-1378	27

879	Recent Advances in Stroke Prevention in Patients with Atrial Fibrillation and End-Stage Renal Disease. 2017 , 7, 207-217	12
878	Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study. 2017 , 6,	23
877	Can Implantable Cardiac Devices Be Used to Lower Risk of Stroke?. 2017 , 11, 1	
876	Outcomes in Pelvic Organ Prolapse Surgery in Women Using Chronic Antithrombotic Therapy. 2017 , 23, 372-376	1
875	Association Between Leukocyte Telomere Length and the Risk of Incident Atrial Fibrillation: The Framingham Heart Study. 2017 , 6,	10
874	Atrioesophageal Fistula: Clinical Presentation, Procedural Characteristics, Diagnostic Investigations, and Treatment Outcomes. 2017 , 10,	53
873	Age-dependent atrial arrhythmic phenotype secondary to mitochondrial dysfunction in Pgc-1 α deficient murine hearts. 2017 , 167, 30-45	12
872	Treating Specialty and Outcomes in Newly Diagnosed Atrial Fibrillation: From the TREAT-AF Study. 2017 , 70, 78-86	35
871	High molecular weight fibroblast growth factor-2 as a promising prognostic biomarker to predict the occurrence of heart failure in atrial fibrillation patients. 2017 , 32, 1506-1512	1
870	A New Algorithm for Predicting the Progression from Paroxysmal to Persistent Atrial Fibrillation. 2017 ,	1
869	Long Sleep Duration Is an Independent Risk Factor for Incident Atrial Fibrillation in a Chinese Population: A Prospective Cohort Study. 2017 , 7, 3679	15
868	Assessing the Safety of Early U.S. Commercial Application of Left Atrial Appendage Closure. 2017 , 69, 262-264	8
867	Endocardial voltage mapping of pulmonary veins with an ultra-high-resolution system to evaluate atrial myocardial extensions. 2017 , 106, 293-299	7
866	The burden and implications of preoperative atrial fibrillation in Australian heart valve surgery patients. 2017 , 227, 100-105	3
865	Atrial fibrillation in highly trained endurance athletes - Description of a syndrome. 2017 , 226, 11-20	48
864	Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and therapeutics. 2017 , 176, 32-39	35
863	Serum brain-derived neurotrophic factor and risk of atrial fibrillation. 2017 , 183, 69-73	6
862	Update on atrial fibrillation. 2017 , 27, 14-25	22

861	The Impact of First Procedure Success Rate on the Economics of Atrial Fibrillation Ablation. 2017 , 3, 129-138	21
860	Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice. 2017 , 11, 105-120	5
859	Cosmetic Procedures and Office Based Sedation. 2017 , 319-328	
858	Body mass index is an independent predictor of major bleeding in non-valvular atrial fibrillation patients taking dabigatran. 2017 , 228, 771-778	13
857	Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective. 2017 , 17, 123-133	10
856	Pulmonary Vein Isolation with the Cryoballoon Technique: Feasibility, Procedural Outcomes, and Adoption in the Real World: Data from One Shot Technologies TO Pulmonary Vein Isolation (1STOP) Project. 2017 , 40, 46-56	19
855	ANMCO/AIAC/SICI-GISE/SIC/SICCH Consensus Document: percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation patients: indications, patient selection, staff skills, organisation, and training. 2017 , 19, D333-D353	21
854	Association between serum uric acid and atrial fibrillation: a cross-sectional community-based study in China. 2017 , 7, e019037	18
853	A new algorithm for short term prediction of persistent atrial fibrillation. 2017 ,	1
852	Long-term aspirin does not lower risk of stroke and increases bleeding risk in low-risk atrial fibrillation ablation patients. 2017 , 28, 1241-1246	2
851	Feasibility and Usability of a Mobile Application to Assess Symptoms and Affect in Patients with Atrial Fibrillation: A Pilot Study. 2017 , 10, 1672	6
850	Recent advances in rhythm control for atrial fibrillation. 2017 , 6, 1796	8
849	Phase Analysis of Endoatrial Electrograms for 3D Rotor Detection in Atrial Fibrillation. 2017 ,	2
848	Advances in anticoagulation management of patients undergoing cardioversion of nonvalvular atrial fibrillation. 2017 , 37, 277-285	1
847	Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study. 2017 , 167, 845-854	33
846	Exposure to a chronic high-fat diet promotes atrial structure and gap junction remodeling in rats. 2017 , 40, 217-225	14
845	Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. 2017 , 117, 837-850	78
844	Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation. 2017 , 23, 980-988	23

843	Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation. 2017 , 23, 1191-1201	16
842	An integrated epidemiological and neural net model of the warfarin effect in managed care patients. 2017 , 9, 55-64	1
841	Antiarrhythmic drug therapy among patients presenting to emergency department with symptomatic atrial fibrillation - a prospective nationwide cohort. 2017 , 25, 81	2
840	Self-detection of atrial fibrillation in an aged population: three-year follow-up of the LietoAF intervention study. 2017 , 17, 218	5
839	Surgical Weight Loss to Treat Atrial Fibrillation Risk and Progression. 2017 , 11, 1	1
838	Review of screening studies for atrial fibrillation in rural populations of 11 countries. 2017 , 30, 280-285	3
837	Arterial stiffness and atrial fibrillation: a new and intriguing relationship. 2017 , 19, B35-B39	2
836	Effectiveness and safety of simultaneous hybrid thoracoscopic endocardial catheter ablation of atrial fibrillation in obese and non-obese patients. 2017 , 9, 3087-3096	1
835	Novel Fingertip Image-Based Heart Rate Detection Methods for a Smartphone. 2017 , 17,	16
834	The Trends of Atrial Fibrillation-Related Hospital Visit and Cost, Treatment Pattern and Mortality in Korea: 10-Year Nationwide Sample Cohort Data. 2017 , 47, 56-64	59
833	Atrial Fibrillation in Heart Failure: a Therapeutic Challenge of Our Times. 2017 , 47, 644-662	26
832	Anticoagulation therapy in the elderly with non-valvular atrial fibrillation: a double-edged sword. 2017 , 3,	1
831	Long-Term Exposure to Traffic-Related Air Pollution and Risk of Incident Atrial Fibrillation: A Cohort Study. 2017 , 125, 422-427	49
830	The significance of the left atrial volume index in prediction of atrial fibrillation recurrence after electrical cardioversion. 2017 , 9, 54-59	21
829	First results of the Brazilian Registry of Percutaneous Left Atrial Appendage Closure. 2017 , 109, 440-447	7
828	Catheter Ablation versus Thoracoscopic Surgical Ablation in Long Standing Persistent Atrial Fibrillation (CASA-AF): study protocol for a randomised controlled trial. 2018 , 19, 117	5
827	Modified CHADS and CHADS-VASc scores to predict atrial fibrillation in acute ischemic stroke patients. 2018 , 51, 35-38	8
826	Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. 2018 , 3, CD008980	24

825	Association of Atrial Fibrillation With Cognitive Decline and Dementia Over 20 Years: The ARIC-NCS (Atherosclerosis Risk in Communities Neurocognitive Study). 2018 , 7,	59
824	Sex Differences in Cardiac Arrhythmias. 2018 , 247-269	
823	Relation of Obesity to New-Onset Atrial Fibrillation and Atrial Flutter in Adults. 2018 , 121, 1072-1075	25
822	Default Mode Network Disruption in Stroke-Free Patients with Atrial Fibrillation. 2018 , 45, 78-84	7
821	Increasing trends in hospital care burden of atrial fibrillation in Korea, 2006 through 2015. 2018 , 104, 2010-2017	69
820	American Heart Association's Life Simple 7 and Risk of Atrial Fibrillation in a Population Without Known Cardiovascular Disease: The ARIC (Atherosclerosis Risk in Communities) Study. 2018 , 7,	26
819	20-year trends of characteristics and outcomes of stroke patients with atrial fibrillation. 2018 , 13, 707-716	6
818	Association between lifetime risk of atrial fibrillation and mortality in the oldest old. 2018 , 41, 634-639	2
817	State of play and future direction with NOACs: An expert consensus. 2018 , 106, 9-21	7
816	Management and prognosis of atrial fibrillation in diabetic patients: an EORP-AF General Pilot Registry report. 2018 , 4, 172-179	24
815	Pharmacists detecting atrial fibrillation (PDAF) in primary care during the influenza vaccination season: a multisite, cross-sectional screening protocol. 2018 , 8, e021121	8
814	Atrial Fibrillation in Patients with Heart Failure: Current State and Future Directions. 2018 , 18, 347-360	5
813	Bleeding Edge Technology: Retroperitoneal Hemorrhage and Its Implications for Transradial Access. 2018 , 11, e006320	
812	Impact of Atrial Fibrillation During ST-Segment-Elevation Myocardial Infarction on Infarct Characteristics and Prognosis. 2018 , 11, e006955	10
811	When is Device-Detected Atrial Fibrillation Actionable?. 2018 , 10, 75-85	2
810	Obesity is associated with incident atrial fibrillation independent of gender: A meta-analysis. 2018 , 29, 725-732	31
809	Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. <i>Circulation</i> , 2018 , 137, e67-e492	16.7 3848
808	Ambulatory blood pressure and long-term risk for atrial fibrillation. 2018 , 104, 1263-1270	13

807	Concomitant Use of Antiplatelets and Anticoagulants in Patients with Coronary Heart Disease and Atrial Fibrillation: What Do Recent Clinical Trials Teach Us?. 2018 , 20, 4	6
806	Stress Signaling JNK2 Crosstalk With CaMKII Underlies Enhanced Atrial Arrhythmogenesis. 2018 , 122, 821-835	35
805	Troponin assessment in patients admitted to the emergency department with atrial fibrillation: which role in daily clinical practice?. 2018 , 13, 319-320	2
804	Efficacy of Warfarin Anticoagulation and Incident Dementia in a Community-Based Cohort of Atrial Fibrillation. 2018 , 93, 145-154	34
803	Association of lipoprotein-associated phospholipase A and risk of incident atrial fibrillation: Findings from 3 cohorts. 2018 , 197, 62-69	3
802	Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. 2018 , 361, k1453	110
801	Burden of Atrial Fibrillation-Associated Ischemic Stroke in the United States. 2018 , 4, 618-625	36
800	10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population. 2018 , 202, 20-26	71
799	Variations of Prevalence and Incidence of Atrial Fibrillation and Oral Anticoagulation Rate According to Different Analysis Approaches. 2018 , 8, 6856	13
798	Real-Time Pathophysiologic Correlates of Left Atrial Appendage Thrombus in Patients Who Underwent Transesophageal-Guided Electrical Cardioversion for Atrial Fibrillation. 2018 , 121, 1540-1547	7
797	Associations of Obstructive Sleep Apnea With Atrial Fibrillation and Continuous Positive Airway Pressure Treatment: A Review. 2018 , 3, 532-540	133
796	Atrial Infarction-Induced Spontaneous Focal Discharges and Atrial Fibrillation in Sheep: Role of Dantrolene-Sensitive Aberrant Ryanodine Receptor Calcium Release. 2018 , 11, e005659	13
795	Sex Differences in Cardiac Arrhythmias: Clinical and Research Implications. 2018 , 11, e005680	24
794	Selective screening for atrial fibrillation using multivariable risk models. 2018 , 104, 1492-1499	13
793	Long-term outcomes following percutaneous left atrial appendage closure in patients with atrial fibrillation and contraindications to anticoagulation. 2018 , 52, 53-59	14
792	Hospital and clinical care costs associated with atrial fibrillation for Medicare beneficiaries in the Cardiovascular Health Study and the Framingham Heart Study. 2018 , 6, 2050312118759444	23
791	Transcatheter closure of the left atrial appendage: A focused update on the Watchman closure device. 2018 , 92, E28-E34	1
790	Atrial Fibrillation Detection via Accelerometer and Gyroscope of a Smartphone. 2018 , 22, 108-118	70

789	Increased stroke risk among patients with open-angle glaucoma: a 10-year follow-up cohort study. 2018 , 102, 338-343	11
788	The impact of lifestyle intervention on atrial fibrillation. 2018 , 33, 14-19	16
787	Atrial fibrillation and cognitive decline: Another piece for a big puzzle. 2018 , 15, 173-174	2
786	Lifetime Risks, Projected Numbers, and Adverse Outcomes in Asian Patients With Atrial Fibrillation: A Report From the Taiwan Nationwide AF Cohort Study. 2018 , 153, 453-466	65
785	Anticoagulant Therapy in Atrial Fibrillation for Stroke Prevention: Assessment of Agreement Between Clinicians' Decision and CHA2DS2-VASc and HAS-BLED Scores. 2018 , 25, 61-64	4
784	Low cardiovascular event rate and high atrial fibrillation recurrence rate one year after electrical cardioversion. 2018 , 60, e246-e250	2
783	Safety profiles of percutaneous left atrial appendage closure devices: An analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE) database from 2009 to 2016. 2018 , 29, 5-13	26
782	Screening for atrial fibrillation in hospitalised geriatric patients. 2018 , 104, 588-593	15
781	Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation. 2018 , 34, 275-284	1
780	Evaluating the potential for pharmacists to prescribe oral anticoagulants for atrial fibrillation. 2018 , 151, 51-61	3
779	Sex Differences in Atrial Fibrillation. 2018 , 34, 429-436	33
778	The stress kinase JNK regulates gap junction Cx43 gene expression and promotes atrial fibrillation in the aged heart. 2018 , 114, 105-115	33
777	Incident Atrial Fibrillation and the Risk of Congestive Heart Failure, Myocardial Infarction, End-Stage Kidney Disease, and Mortality Among Patients With a Decreased Estimated GFR. 2018 , 71, 191-199	22
776	Coronary artery calcium score and the long-term risk of atrial fibrillation in patients undergoing non-contrast cardiac computed tomography for suspected coronary artery disease: a Danish registry-based cohort study. 2018 , 19, 926-932	9
775	Atrial Fibrillation Ablation. 2018 , 69, 53-63	8
774	MicroRNA-34a mediates atrial fibrillation through regulation of Ankyrin-B expression. 2018 , 17, 8457-8465	13
773	Association Between Blood Lipid Profiles and Atrial Fibrillation: A Case-Control Study. 2018 , 24, 3903-3908	12
772	Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial. 2018 , 5, e000908	4

771	Atrial fibrillation in patients with first-ever stroke: Incidence trends and antithrombotic therapy before the event. 2018 , 13, e0209198	2
770	2018 Korean Guideline of Atrial Fibrillation Management. 2018 , 48, 1033-1080	68
769	Gene and Protein Expression Profile of Selected Molecular Targets Mediating Electrophysiological Function in Deficient Murine Atria. 2018 , 19,	3
768	Comparison of real-world clinical and economic outcomes between the ThermoCool SF and ThermoCool catheters in patients undergoing radiofrequency catheter ablation for atrial fibrillation. 2018 , 10, 587-599	0
767	Obstructive Sleep Apnea as a Risk Factor for Atrial Fibrillation: A Meta-Analysis. 2018 , 7,	42
766	Automatic Detection of Atrial Fibrillation and Other Arrhythmias in ECG Recordings Acquired by a Smartphone Device. 2018 , 7, 199	8
765	Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges. 2018 , 48, 873-889	7
764	Cognitive dysfunction in atrial fibrillation. 2018 , 15, 744-756	36
763	Validation of Conventional Thromboembolic Risk Factors in a Korean Atrial Fibrillation Population - Suggestion for a Novel Scoring System, CHADS-VAK. 2018 , 82, 2970-2975	8
762	Relationship between P-wave duration and the risk of atrial fibrillation. 2018 , 16, 837-843	15
761	Effects of a reminder to initiate oral anticoagulation in patients with atrial fibrillation/atrial flutter discharged from the emergency department: REMINDER study. 2018 , 20, 841-849	3
760	Staged hybrid procedure versus radiofrequency catheter ablation in the treatment of atrial fibrillation. 2018 , 13, e0205431	4
759	Differences in amiodarone efficacy in relation to ejection fraction and basal rhythm in patients with implantable cardioverter defibrillators. 2018 , 51, 1111-1115	2
758	Epidemiology and Prognostic Importance of Atrial Fibrillation in Kidney Transplant Recipients: A Meta-Analysis. 2018 , 7,	6
757	Collagen Biomarkers and Incidence of New Onset of Atrial Fibrillation in Subjects With No Overt Cardiovascular Disease at Baseline: The Multi-Ethnic Study of Atherosclerosis. 2018 , 11, e006557	13
756	Treatment of Atrial Fibrillation in Patients with Co-existing Heart Failure and Reduced Ejection Fraction: Time to Revisit the Management Guidelines?. 2018 , 7, 91-94	11
755	Structured care delivery in the management of cardiac arrhythmias. 2018 , 21, 117-119	0
754	Predictors of new oral anticoagulant drug initiation as opposed to warfarin in elderly adults: a retrospective observational study in Southern Italy. 2018 , 14, 1907-1914	3

753	APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN. 2018 , 14, 441-450	
752	Nonalcoholic Fatty Liver Disease Is Associated with Increased Atrial Fibrillation Risk in an Elderly Chinese Population: A Cross-Sectional Study. 2018 , 2018, 5628749	10
751	Cross-Sectional Associations between Homocysteine, Intermediate Phenotypes, and Atrial Fibrillation in the Community-The Gutenberg Health Study. 2018 , 8,	3
750	Thrombogenic and Arrhythmogenic Roles of the Left Atrial Appendage in Atrial Fibrillation. <i>Circulation</i> , 2018 , 138, 2036-2050	16.7 17
749	Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review. 2018 , 169, 774-787	15
748	Association of Healthcare Plan with atrial fibrillation prescription patterns. 2018 , 41, 1136-1143	2
747	Patient Diversity and Population Health-Related Cardiovascular Outcomes Associated with Warfarin Use in Atrial Fibrillation: An Analysis Using Administrative Claims Data. 2018 , 35, 2069-2080	1
746	Automatic Detection of Atrial Fibrillation Based on Continuous Wavelet Transform and 2D Convolutional Neural Networks. 2018 , 9, 1206	50
745	Effects of the short-term exposure to ambient air pollution on atrial fibrillation. 2018 , 41, 1441-1446	17
744	Safety and efficacy of uninterrupted versus minimally interrupted periprocedural DOACs for implantation of cardiac devices in patients with AF. 2018 , 41, 1481-1483	
743	Aging, Obesity, and the Incidence of Diverticulitis: A Population-Based Study. 2018 , 93, 1256-1265	22
742	Feasibility of intracardiac echocardiography imaging from the left superior pulmonary vein for left atrial appendage occlusion. 2018 , 34, 1571-1579	8
741	Relevance of Dementia in Atrial Fibrillation Patients within a Specific European Health Care Area. 2018 , 51, 11-18	3
740	Association of Burden of Atrial Fibrillation With Risk of Ischemic Stroke in Adults With Paroxysmal Atrial Fibrillation: The KP-RHYTHM Study. 2018 , 3, 601-608	124
739	Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants?. 2018 , 50, 1633-1642	1
738	Trend of Prevalence of Atrial Fibrillation and use of Oral Anticoagulation Therapy in Patients With Atrial Fibrillation in South Korea (2002-2013). 2018 , 28, 81-87	13
737	Estimated prevalence of undiagnosed atrial fibrillation in the United States. 2018 , 13, e0195088	68
736	Frequency of Cardiac Rhythm Abnormalities in a Half Million Adults. 2018 , 11, e006273	73

735	Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation. 2018 , 115, 287-294	11
734	Screening for undiagnosed atrial fibrillation. 2018 , 16, 591-598	8
733	Von Willebrand Factor and Thrombosis. 2018 , 225-241	
732	Is atrial fibrillation a risk factor for in-hospital cardiac arrest?: a Swedish retrospective cohort study. 2018 , 8, e022092	3
731	National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. 2018 , 27, 1209-1266	122
730	Left Atrial Appendages Occlusion: Current Status and Prospective. 2018 , 48, 692-704	15
729	Differences in Cardiovascular Aging in Men and Women. 2018 , 1065, 389-411	30
728	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. 2018 , 209, 356-362	32
727	A Pilot Randomized Trial of Oral Magnesium Supplementation on Supraventricular Arrhythmias. 2018 , 10,	8
726	Rebleeding vs Thromboembolism After Hospitalization for Gastrointestinal Bleeding in Patients on Direct Oral Anticoagulants. 2018 , 16, 1893-1900.e2	25
725	Case-Based Discussion Regarding Challenges in Patient Selection and Procedural Planning in Left Atrial Appendage Occlusion. 2018 , 93, 630-638	2
724	Age as a Critical Determinant of Atrial Fibrillation: A Two-sided Relationship. 2018 , 34, 1396-1406	21
723	Recent Trends in Oral Anticoagulant Use and Post-Discharge Complications Among Atrial Fibrillation Patients with Acute Myocardial Infarction. 2018 , 10, 1749	2
722	Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure. 2018 , 71, 2603-2611	58
721	The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly. 2018 , 265, 118-124	13
720	Hemodynamic impact of percutaneous left atrial appendage closure in patients with paroxysmal atrial fibrillation. 2018 , 53, 151-157	4
719	Safety of Direct Oral Anticoagulants and Vitamin K Antagonists in Oldest Old Patients: A Prospective Study. 2018 , 19, 936-941	9
718	Stroke Prevention in Nonvalvular Atrial Fibrillation: A Stakeholder Perspective. 2018 , 71, 2790-2801	33

717	Atrial fibrillation in young patients. 2018 , 16, 489-500	12
716	Mechanisms and Drug Development in Atrial Fibrillation. 2018 , 70, 505-525	38
715	Heart failure and the development of atrial fibrillation in Hispanics, African Americans and non-Hispanic Whites. 2018 , 271, 186-191	2
714	Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin. 2019 , 54, 73-80	3
713	Atrial Fibrillation and Deterioration in Cognitive Function. 2019 , 44, 100386	3
712	Refining the Association Between Body Mass Index and Atrial Fibrillation: G-Formula and Restricted Mean Survival Times. 2019 , 8, e013011	6
711	The Role of Novel Oral Anticoagulants and Antiplatelet Therapy after Percutaneous Coronary Intervention: Individualizing Therapy to Optimize Outcomes. 2019 , 49, 645-656	2
710	Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis. 2019 , 17, 13	3
709	Geometrical Patterning and Constituent Cell Heterogeneity Facilitate Electrical Conduction Disturbances in a Human Induced Pluripotent Stem Cell-Based Platform: An Disease Model of Atrial Arrhythmias. 2019 , 10, 818	8
708	The prevalence of atrial fibrillation on 48-hour ambulatory electrocardiography in African Americans compared to Whites: The Atherosclerosis Risk in Communities (ARIC) study. 2019 , 216, 1-8	9
707	Changes in atrial electrophysiological and structural substrate and their relationship to histology in a long-term chronic canine atrial fibrillation model. 2019 , 42, 930-936	5
706	Percutaneous devices for left atrial appendage occlusion: A contemporary review. 2019 , 11, 57-70	15
705	Rapid Atrial Pacing Promotes Atrial Fibrillation Substrate in Unanesthetized Instrumented Rats. 2019 , 10, 1218	9
704	Risk of Recurrent Bleeding Events in Nonvalvular Atrial Fibrillation Treated with Vitamin K Antagonists: A Clinical Practice Research Datalink Study. 2019 , 3, e316-e324	2
703	External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis. 2019 ,	78
702	Development and Validation of a Prediction Model for Atrial Fibrillation Using Electronic Health Records. 2019 , 5, 1331-1341	24
701	Safety of catheter ablation for atrial fibrillation in the octogenarian population. 2019 , 30, 2686-2693	7
700	A review of the epidemiology of atrial fibrillation in sub-Saharan Africa. 2019 , 30, 3006-3016	6

699	The role of microRNAs in the development, regulation, and treatment of atrial fibrillation. 2019 , 55, 297-305	7
698	Economic impact of contact force sensing in catheter ablation for atrial fibrillation. 2019 , 30, 2302-2309	1
697	Atrial Fibrillation in Older People: Concepts and Controversies. 2019 , 6, 175	30
696	Meta-analysis of Effect of Modest (â‰¤10%) Weight Loss in Management of Overweight and Obese Patients With Atrial Fibrillation. 2019 , 124, 1568-1574	7
695	Long-term outcomes of dialysis in patients with chronic kidney disease and new-onset atrial fibrillation: A population-based cohort study. 2019 , 14, e0222656	0
694	An Update on the Development and Feasibility Assessment of Canadian Quality Indicators for Atrial Fibrillation and Atrial Flutter. 2019 , 1, 198-205	4
693	Usefulness of Left Atrial Volume as an Independent Predictor of Development of Heart Failure in Patients With Atrial Fibrillation. 2019 , 124, 1430-1435	4
692	Stroke Risk as a Function of Atrial Fibrillation Duration and CHADS-VASc Score. <i>Circulation</i> , 2019 , 140, 1639-1646	16.7 87
691	The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study. 2019 , 18, 128	31
690	Atrial fibrosis in non-atrial fibrillation individuals and prediction of atrial fibrillation by use of late gadolinium enhancement magnetic resonance imaging. 2019 , 30, 550-556	25
689	Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation. 2019 , 211, 77-89	37
688	Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. <i>Circulation</i> , 2019 , 139, e56-e528	16.7 3937
687	Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. 2019 , 132, 749-757.e5	34
686	Risk of Hospital Admissions in Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis. 2019 , 35, 1332-1343	16
685	Atrial fibrillation, not atrial cardiopathy, is associated with stroke: A single center retrospective study. 2019 , 402, 69-73	2
684	A Novel Deep Arrhythmia-Diagnosis Network for Atrial Fibrillation Classification Using Electrocardiogram Signals. 2019 , 7, 75577-75590	23
683	Application-based management of perioperative anticoagulant therapy: description of POPACTApp. 2019 , 404, 633-645	1
682	Comprehensive metabolomic and proteomic analyses reveal candidate biomarkers and related metabolic networks in atrial fibrillation. 2019 , 15, 96	9

681	Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: the FAI Project. 2019 , 21, 1468-1475	52
680	Obesity Surgery and Anesthesiology Risks: a Review of Key Concepts and Related Physiology. 2019 , 29, 2670-2677	18
679	Impact of coronary artery disease and revascularization on recurrence of atrial fibrillation after catheter ablation: Importance of ischemia in managing atrial fibrillation. 2019 , 30, 1491-1498	7
678	P Wave Indices-Advancing Our Understanding of Atrial Fibrillation-Related Cardiovascular Outcomes. 2019 , 6, 53	13
677	Plasma total testosterone and risk of incident atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. 2019 , 125, 5-10	5
676	Electrophysiologic and molecular mechanisms of a frameshift NPPA mutation linked with familial atrial fibrillation. 2019 , 132, 24-35	13
675	Atrial Transcriptional Profiles of Molecular Targets Mediating Electrophysiological Function in Aging and Deficient Murine Hearts. 2019 , 10, 497	2
674	Improving performance of 3D speckle tracking in arterial hypertension and paroxysmal atrial fibrillation by using novel strain parameters. 2019 , 9, 7382	5
673	Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: The mAFA (mAF-App) II randomised trial. 2019 , 73, e13352	36
672	Oral anticoagulation in patients with "hemorrhagic-prone" vasculopathies: Overestimated risk?. 2019 , 92, 981-982	1
671	Changes in Anticoagulant Utilization Among United States Nursing Home Residents With Atrial Fibrillation From 2011 to 2016. 2019 , 8, e012023	33
670	Cardiac CT: Electrophysiological Applications. 2019 , 531-552	
669	Empowering podiatrists to perform pulse checks for opportunistic atrial fibrillation detection during annual diabetes foot checks. 2019 , 6, e000795	2
668	Low-Carbohydrate Diets and Risk of Incident Atrial Fibrillation: A Prospective Cohort Study. 2019 , 8, e011955	11
667	Noninvasive peripheral vascular function and atrial fibrillation in the general population. 2019 , 37, 928-934	7
666	Effectiveness of screening for atrial fibrillation and its determinants. A meta-analysis. 2019 , 14, e0213198	19
665	Atrial Fibrillation and Brain Magnetic Resonance Imaging Abnormalities. 2019 , 50, 783-788	12
664	Sex differences in rate and rhythm control for atrial fibrillation. 2019 , 21, 690-697	7

- 663 Predictores de mortalidad en pacientes hospitalizados con fibrilación auricular en un hospital universitario. **2019**, 26, 322-327
- 662 Catheter Ablation for Atrial Fibrillation: Lessons Learned From CABANA. **2019**, 321, 1255-1257 8
- 661 Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. **2019**, 321, 1261-1274 472
- 660 Ablation of Persistent and Long-Standing Persistent Atrial Fibrillation. **2019**, 292-304.e4
- 659 Obesity and Atrial Fibrillation: Epidemiology, Pathophysiology and Novel Therapeutic Opportunities. **2019**, 8, 28-36 46
- 658 Divergent Temporal Trends in Morbidity and Mortality Related to Heart Failure and Atrial Fibrillation: Age, Sex, Race, and Geographic Differences in the United States, 1991-2015. **2019**, 8, e010756 17
- 657 Left Atrial Appendage Occlusion in High Bleeding Risk Patients. **2019**, 2019, 6704031 8
- 656 Can atrial fibrillation be caused or triggered by air pollution? An epidemiological perspective. **2019**, 26, 1205-1207
- 655 Second-Generation Cryoballoon Atrial Fibrillation Ablation in Patients With Persistent Left Superior Caval Vein. **2019**, 5, 590-598 3
- 654 Increasing trends in hospitalisations due to atrial fibrillation in Australia from 1993 to 2013. **2019**, 105, 1358-1363 27
- 653 Atrial Fibrillation Ablation Should Be First-Line Therapy in Heart Failure Patients: CON. **2019**, 37, 197-206
- 652 Does Left Ventricular Systolic Function Matter? Treating Atrial Fibrillation in HFrEF Versus HFpEF. **2019**, 37, 157-166 1
- 651 Atrial fibrillation: risk factors and comorbidities in a tertiary center in Jeddah, Saudi Arabia. **2019**, 12, 71-77 7
- 650 Association of atrial fibrillation and gastroesophageal reflux disease: Natural and therapeutic linkage of the two common diseases. **2019**, 35, 43-51 9
- 649 Risk factor modification: another win for our fight against atrial fibrillation. **2019**, 21, 527-528 2
- 648 A forecasting model of disease prevalence based on the McKendrick-von Foerster equation. **2019**, 311, 31-38 4
- 647 The Year in Electrophysiology: Selected Highlights From 2018. **2019**, 33, 1771-1777 1
- 646 Sex Differences in Risk Factors for Incident Atrial Fibrillation (from the Reasons for Geographic and Racial Differences in Stroke [REGARDS] Study). **2019**, 123, 1453-1457 11

645	Peridevice Leak After Left Atrial Appendage Closure: Incidence, Risk Factors, and Clinical Impact. 2019 , 35, 405-412	24
644	INADEQUACY OF VITAMIN K ANTAGONIST USE IN PATIENTS WITH ATRIAL FIBRILLATION - OVERVIEW OF EVERYDAY CLINICAL PRACTICE AT THE MERKUR UNIVERSITY HOSPITAL IN ZAGREB, CROATIA. 2019 , 58, 744-750	
643	Left atrial dimension and cardiovascular outcomes in patients with and without atrial fibrillation: a systematic review and meta-analysis. 2019 , 105, 1884-1891	22
642	Cardiac MRI and Fibrosis Quantification. 2019 , 11, 537-549	5
641	Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: Sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. 2019 , 30, 2823-2833	8
640	Annual rate of newly treated atrial fibrillation by age and gender in France, 2010-2016. 2020 , 35, 1139-1147	5
639	Impact of Atrial Fibrillation on In-Hospital Outcomes in Patients With Diabetic Ketoacidosis. 2019 , 358, 350-356	1
638	Association between elevated blood glucose level and non-valvular atrial fibrillation: a report from the Guangzhou heart study. 2019 , 19, 270	1
637	Pre-Screening for Atrial Fibrillation Using the Electronic Health Record. 2019 , 5, 1342-1343	0
636	Cardiac remodeling in obesity and after bariatric and metabolic surgery; is there a role for gastro-intestinal hormones?. 2019 , 17, 771-790	5
635	Epidemiology of atrial fibrillation in patients with cirrhosis and clinical significance: a meta-analysis. 2019 , 31, 514-519	14
634	Racial Differences in Atrial Fibrillation Epidemiology, Management, and Outcomes. 2019 , 21, 85	8
633	Digital Medicine and Evolution of Remote Patient Monitoring in Cardiac Electrophysiology: A State-of-the-Art Perspective. 2019 , 21, 92	9
632	The Role of Cardiovascular and Metabolic Comorbidities in the Link between Atrial Fibrillation and Cognitive Impairment: An Appraisal of Current Scientific Evidence. 2019 , 55,	6
631	Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study. 2019 , 207, 66-75	204
630	Temperature variability and hospitalization for cardiac arrhythmia in Brazil: A nationwide case-crossover study during 2000-2015. 2019 , 246, 552-558	14
629	Impact of Atrial Fibrillation Ablation on Recurrent Hospitalization: A Nationwide Cohort Study. 2019 , 5, 330-339	9
628	Relation of the CHADS-VASc Score to Risk of Thrombotic and Embolic Stroke in Community-Dwelling Individuals Without Atrial Fibrillation (From The Atherosclerosis Risk in Communities [ARIC] Study). 2019 , 123, 402-408	11

627	Is it safe to stop oral anticoagulation after catheter ablation for atrial fibrillation?. 2019 , 17, 31-41	2
626	Sex-differences in post-discharge outcomes among patients hospitalized for atrial fibrillation. 2019 , 42, 84-92	2
625	Electronic Decision support for Improvement of Contemporary Therapy for Stroke Prevention. 2019 , 28, 569-573	2
624	Cryoballoon ablation of atrial fibrillation is effectively feasible without previous imaging of pulmonary vein anatomy: insights from the 1STOP project. 2019 , 55, 267-275	6
623	Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis. 2019 , 81, 209-214	28
622	Prevalence and Incidence of Atrial Fibrillation in the General Population Based on National Health Insurance Special Health Checkups - TAMA MED Project-AF. 2019 , 83, 524-531	10
621	Stroke prevention in atrial fibrillation: Closing the gap. 2019 , 210, 29-38	6
620	A Simple Clinical Risk Score (CHEST) for Predicting Incident Atrial Fibrillation in Asian Subjects: Derivation in 471,446 Chinese Subjects, With Internal Validation and External Application in 451,199 Korean Subjects. 2019 , 155, 510-518	64
619	Nonvalvular atrial fibrillation in high-hemorrhagic-risk patients: state of the art of percutaneous left atrial appendage occlusion. 2019 , 20, 1-9	5
618	Trends in the Incidence and In-Hospital Outcomes of Patients With Atrial Fibrillation Complicated by Non-ST-Segment Elevation Myocardial Infarction. 2019 , 70, 317-324	0
617	Refining Prediction of Atrial Fibrillation-Related Stroke Using the P-CHADS-VASc Score. <i>Circulation</i> , 2019 , 139, 180-191	16.7 45
616	The management of atrial fibrillation: An integrated team approach - insights of the 2016 European Society of Cardiology guidelines for the management of atrial fibrillation for nurses and allied health professionals. 2019 , 18, 88-95	10
615	Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients. 2019 , 35, 653-660	6
614	Echocardiographic Guidance of AMPLATZER Amulet Left Atrial Appendage Occlusion Device Placement. 2019 , 23, 248-255	2
613	Outcomes of Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Analysis of National Inpatient Sample. 2020 , 21, 14-19	4
612	Kidney function stratified outcomes of percutaneous left atrial appendage occlusion in patients with atrial fibrillation and high bleeding risk. 2020 , 75, 312-320	6
611	Short and Intermediate Term Outcomes of the Convergent Procedure: Initial Experience in a Tertiary Referral Center. 2020 , 26, 13-21	9
610	Free thyroxine within the normal reference range predicts risk of atrial fibrillation. 2020 , 31, 18-29	6

609	Impact of atrial fibrillation/flutter on the in-hospital mortality of ischemic stroke patients. 2020 , 17, 383-390	7
608	One-year all-cause mortality risk among atrial fibrillation patients in Middle East with and without diabetes: The Gulf SAFE registry. 2020 , 302, 47-52	3
607	Atrial fibrillation and stroke: chicken or egg? Does it really matter?. 2020 , 22, 509-510	2
606	Prevalence, risk factors, and type of sleep apnea in patients with paroxysmal atrial fibrillation. 2020 , 26, 100447	14
605	Catheter ablation of atrial fibrillation reduces the risk of dementia and hospitalization during a very long-term follow-up. 2020 , 304, 75-81	11
604	Impact of pre-existing hypertension and control status before atrial fibrillation onset on cardiovascular prognosis in patients with non-valvular atrial fibrillation: A real-world database analysis in Japan. 2020 , 22, 431-437	8
603	Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation. 2020 , 40, 40-54	43
602	Cardiac Computed Tomography for Atrial Fibrillation Patients Undergoing Ablation: Implications for the Prediction of Early Recurrence. 2020 , 35, 186-192	3
601	Novel three-dimensional imaging approach for cryoballoon navigation and confirmation of pulmonary vein occlusion. 2020 , 43, 269-277	2
600	Cerebrovascular Dysfunction in Atrial Fibrillation. 2020 , 11, 1066	6
599	Proteomic Analysis of Atrial Appendages Revealed the Pathophysiological Changes of Atrial Fibrillation. 2020 , 11, 573433	2
598	National Physician Survey for Nonvalvular Atrial Fibrillation (NVAf) Anticoagulation Comparing Knowledge, Attitudes and Practice of Cardiologist to PCPs. 2020 , 26, 1076029620952550	1
597	Utilization of anticoagulants and predictors of treatment among hospitalized patients with atrial fibrillation in the USA. 2020 , 23, 1389-1400	1
596	"One-stop shop": safety and efficacy of combining atrial septal defect occlusion and left atrial appendage closure for patients with atrial septal defect and atrial fibrillation. 2020 , 20, 444	0
595	Prevention and Treatment of Bleeding with Direct Oral Anticoagulants. 2020 , 80, 1293-1308	2
594	Effect of combined renal denervation and pulmonary vein isolation in atrial fibrillation recurrence in hypertensive patients: A meta-analysis. 2020 , 43, 866-874	4
593	Anticoagulation in Patients with Aortic Stenosis and Atrial Fibrillation. 2020 , 4, 360-368	1
592	Impact of timing of atrial fibrillation, CHADS-VASc score and cancer therapeutics on mortality in oncology patients. 2020 , 7,	1

591	Educational interventions to improve outcomes in patients with atrial fibrillation-a systematic review. 2020 , 74, e13629	0
590	Utilizing biomarkers associated with cardiovascular events in atrial fibrillation: informing a precision medicine response. 2020 , 5, 331-345	
589	Evaluation of the Incremental Healthcare Economic Burden of Patients with Atrial Fibrillation Treated with Direct-Acting Oral Anticoagulants and Hospitalized for Major Bleeds in the USA. 2020 , 37, 3942-3953	1
588	Reduction in Pulmonary Vein Stenosis and Collateral Damage With Pulsed Field Ablation Compared With Radiofrequency Ablation in a Canine Model. 2020 , 13, e008337	13
587	Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990-2017: results from the Global Burden of Disease Study 2017. 2021 , 7, 574-582	29
586	Frailty and Anticoagulant Therapy in Patients Aged 65 Years or Older with Atrial Fibrillation. 2020 , 4, 153-161	1
585	Prevalence of Atrial Fibrillation Subtypes in Italy and Projections to 2060 for Italy and Europe. 2020 , 68, 2534-2541	4
584	Trends in excess mortality associated with atrial fibrillation over 45 years (Framingham Heart Study): community based cohort study. 2020 , 370, m2724	10
583	Major bleed costs of atrial fibrillation patients treated with factor Xa inhibitor anticoagulants. 2020 , 23, 1409-1417	
582	The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. 2020 , 36, 1847-1948	82
581	Clinically Meaningful Change in Quality of Life and Associated Factors Among Older Patients With Atrial Fibrillation. 2020 , 9, e016651	2
580	Association of Atrial Fibrillation With Incidence of Extracranial Systemic Embolic Events: The ARIC Study. 2020 , 9, e016724	3
579	Left ventricular dysfunction in atrial fibrillation and heart failure risk. 2020 , 7, 3694	1
578	Trends in Atrial Fibrillation Incidence Rates Within an Integrated Health Care Delivery System, 2006 to 2018. 2020 , 3, e2014874	18
577	Impact of atrial fibrillation/flutter on the in-hospital mortality of surgical patients - Results from the German nationwide cohort. 2020 , 196, 526-535	1
576	Atrial fibrillation and stroke prevention: state of the art-epidemiology and pathophysiology: new risk factors, concepts and controversies. 2020 , 22, O1-O13	4
575	Outcomes of oesophageal variceal bleeding among patients with atrial fibrillation: a propensity-matched analysis of a nationwide inpatient sample. 2020 , 5, e255-e262	
574	Watch-PAT is Useful in the Diagnosis of Sleep Apnea in Patients with Atrial Fibrillation. 2020 , 12, 1115-1121	12

573	Relationship between predicting bleeding complication in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score and mortality among patients with atrial fibrillation undergoing percutaneous coronary intervention. 2021 , 98, 838-845	0
572	Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms. 2020 , 11, 581837	8
571	Racial/Ethnic Disparities in Atrial Fibrillation Treatment and Outcomes among Dialysis Patients in the United States. 2020 , 31, 637-649	5
570	Comparison of healthcare costs among patients with non-valvular atrial fibrillation treated with warfarin who switched to a novel oral anticoagulant. 2020 , 11, 133-140	1
569	More data to motivate hospital volume standards for catheter ablation of atrial fibrillation. 2020 , 31, 1920-1922	2
568	Tetrodotoxin-Sensitive Neuronal-Type Na Channels: A Novel and Druggable Target for Prevention of Atrial Fibrillation. 2020 , 9, e015119	1
567	CPAP is associated with decreased risk of AF recurrence in patients with OSA, especially those younger and slimmer: a meta-analysis. 2020 , 58, 369-379	4
566	Efficacy and Safety of Same-Day Discharge for Atrial Fibrillation Ablation. 2020 , 6, 609-619	26
565	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. 2020 , 23, 1147-1148	25
564	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. 2020 , 23, 1147-1148	11
563	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. 2020 , 17, e269-e316	7
562	Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights. 2020 , 127, 4-20	143
561	Machine Learning in Cardiology-Ensuring Clinical Impact Lives Up to the Hype. 2020 , 25, 379-390	5
560	Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. 2020 , 80, 1065-1083	13
559	The Euro Heart Survey and EURObservational Research Programme (EORP) in atrial fibrillation registries: contribution to epidemiology, clinical management and therapy of atrial fibrillation patients over the last 20 years. 2020 , 15, 1183-1192	16
558	Drivers of hospitalization in atrial fibrillation: A contemporary review. 2020 , 17, 1991-1999	4
557	Central sleep apnea and atrial fibrillation: A review on pathophysiological mechanisms and therapeutic implications. 2020 , 30, 100527	8
556	Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2020 , 141, e750-e772	16.7 80

555	Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants. 2020 , 9, 603-614	24
554	Left Atrial Dynamics Is Altered in Young Adults With Cryptogenic Ischemic Stroke: A Case-Control Study Utilizing Advanced Echocardiography. 2020 , 9, e014578	9
553	Accuracy of Smartphone Camera Applications for Detecting Atrial Fibrillation: A Systematic Review and Meta-analysis. 2020 , 3, e202064	30
552	Differences in Epidemiology and Risk Factors for Atrial Fibrillation Between Women and Men. 2020 , 7, 3	11
551	The Genetic Puzzle of Familial Atrial Fibrillation. 2020 , 7, 14	9
550	Bariatric surgery to alleviate Occurrence of Atrial Fibrillation Hospitalization-BLOC-AF. 2020 , 1, 96-102	2
549	Plasma Ceramides and Sphingomyelins in Relation to Atrial Fibrillation Risk: The Cardiovascular Health Study. 2020 , 9, e012853	11
548	Serum Galectin-3 level and recurrence of atrial fibrillation post-ablation - Systematic review and meta-analysis. 2020 , 20, 64-69	7
547	Exercise-Related Acute Cardiovascular Events and Potential Deleterious Adaptations Following Long-Term Exercise Training: Placing the Risks Into Perspective-An Update: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2020 , 141, e705-e736	16.7 70
546	Positioning an ECG electrode to the dorsal side can record higher amplitude of CMAPs during cryoballoon ablation. 2020 , 36, 328-334	0
545	Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies. 2020 , 7, 54	9
544	Prevalence of cardiovascular risk factors and financial burden in younger adults hospitalized with atrial fibrillation. 2020 , 49, 393-397	6
543	Rhythm versus rate control strategies regarding anticoagulant use in elderly non-valvular atrial fibrillation patients: Subanalysis of the ANAFIE (All Nippon AF In the Elderly) Registry. 2020 , 76, 87-93	4
542	AGE-RAGE Stress in the Pathophysiology of Atrial Fibrillation and Its Treatment. 2020 , 29, 72-80	6
541	Age-Related Differences in the Clinical Characteristics and Treatment of Elderly Patients With Atrial Fibrillation in Japan - Insight From the ANAFIE (All Nippon AF In Elderly) Registry. 2020 , 84, 388-396	4
540	Correlation between P-selectin rs1800807 and rs1800808 Gene polymorphisms and plasma soluble P-selectin concentrations in patients with atrial fibrillation complicated with thromboembolism in Xinjiang, China. 2020 , 99, e18937	
539	Convergent epicardial-endocardial ablation for treatment of long-standing persistent atrial fibrillation: A review of literature. 2020 , 35, 1306-1313	4
538	Differences in treatment and prognosis by the experience of falls or bone fracture in elderly patients with atrial fibrillation. 2020 , 35, 1234-1242	1

537	The NCDR Left Atrial Appendage Occlusion Registry. 2020 , 75, 1503-1518	92
536	Development of a Risk Score for Atrial Fibrillation in Adults With Diabetes Mellitus (from the ACCORD Study). 2020 , 125, 1638-1643	4
535	Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation. 2020 , 9, 2048004020915406	2
534	Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation. 2020 , 35, 1125-1134	6
533	Non-genetic risk factors for atrial fibrillation are equally important in both young and old age: A nationwide population-based study. 2020 , 2047487320915664	17
532	The Safety and Efficacy of Rivaroxaban Compared with Warfarin in Patients with Atrial Fibrillation and Diabetes: A Systematic Review and Meta-analysis. 2021 , 21, 51-61	4
531	Obesity and atrial fibrillation: making inroads through fat. 2021 , 7, 59-67	8
530	GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. 2021 , 17, 19-38	6
529	Automated Atrial Fibrillation Detection using a Hybrid CNN-LSTM Network on Imbalanced ECG Datasets. 2021 , 63, 102194	42
528	New methodological approaches to atrial fibrillation drug discovery. 2021 , 16, 319-329	
527	Circulating long noncoding RNA, GAS5, as a novel biomarker for patients with atrial fibrillation. 2021 , 35, e23572	5
526	Impact of Sleep Apnea on Cardioembolic Risk in Patients With Atrial Fibrillation: Data From the ESADA Cohort. 2021 , 52, 712-715	2
525	Age-specific incidence rates of atrial fibrillation and risk factors for the future development of atrial fibrillation in the Japanese general population. 2021 , 77, 88-92	2
524	Early neurological deterioration in cardiogenic cerebral embolism due to nonvalvular atrial fibrillation: Predisposing factors and clinical implications. 2021 , 11, e01985	1
523	No causal association between plasma homocysteine levels and atrial fibrillation: A Mendelian randomization study. 2021 , 31, 587-591	2
522	Sex-stratified analysis of the safety of percutaneous left atrial appendage occlusion. 2021 , 97, 885-892	8
521	Prevalence and incidence rates of atrial fibrillation in Norway 2004-2014. 2021 , 107, 201-207	6
520	Clinical and cardiac structural predictors of atrial fibrillation persistence. 2021 , 51, e13395	1

519	Catheter ablation superiority over the pharmacological treatments in atrial fibrillation: a dedicated review. 2021 , 53, 551-557	2
518	Impact of Atrial Fibrillation on Survival in Adults with Congenital Heart Disease: a Retrospective Population-based Study. 2021 , 36, e43	2
517	CT-Guided 3D Super-Resolution Method for Left Atrial Model. 2021 ,	
516	Anticoagulation in Elderly Patients with Atrial Fibrillation Authors. 2021 , 131-147	
515	Drug-Drug Interaction with DOACs. 2021 , 41-69	
514	Epidemiology and Prevalence. 2021 , 9-29	
513	Oxidized CaMKII and O-GlcNAcylation cause increased atrial fibrillation in diabetic mice by distinct mechanisms. 2021 , 131,	14
512	Regulatory role of cardiomyocyte metabolism via AMPK activation in modulating atrial structural, contractile, and electrical properties following atrial fibrillation. 2021 , 99, 36-41	1
511	Relationship between lipoproteins, thrombosis and atrial fibrillation. 2021 ,	2
510	Comparison of fibrin sealants in peripheral vascular surgery: A systematic review and network meta-analysis. 2021 , 61, 161-168	3
509	Diabetes mellitus and atrial fibrillation—Untying the Gordian Knot. 2021 , 95-121	1
508	The relationship between heart disease and cognitive impairment. 2021 , 177, 377-391	1
507	Using 5D flow MRI to decode the effects of rhythm on left atrial 3D flow dynamics in patients with atrial fibrillation. 2021 , 85, 3125-3139	4
506	Actin-granule formation is an additional step in cardiac myofibroblast differentiation. 2021 , 9, 165	2
505	Premature ventricular contraction is associated with increased risk of atrial fibrillation: a nationwide population-based study. 2021 , 11, 1601	7
504	A virtual platform to deliver ambulatory care for patients with atrial fibrillation.. 2021 , 2, 63-70	1
503	Alterations of 'housekeeping' proteins in human aged and diseased hearts. 2021 , 473, 351-362	1
502	Deep learning and the electrocardiogram: review of the current state-of-the-art. 2021 , 23, 1179-1191	19

501	Neutrophil degranulation interconnects over-represented biological processes in atrial fibrillation. 2021 , 11, 2972	1
500	Diabetes and atrial fibrillation in hospitalized patients in the United States. 2021 , 44, 340-348	2
499	Opportunities and perspectives of stereotactic radiosurgery for non-invasive arrhythmology interventions. 2021 , 27, 33-41	2
498	Sex-specific contemporary trends in incidence, prevalence and survival of patients with non-valvular atrial fibrillation: A long-term real-world data analysis. 2021 , 16, e0247097	3
497	Relationship Between Body Mass Index and Incidence of Atrial Fibrillation in Young Japanese Men - The Nishimura Health Survey. 2021 , 85, 243-251	1
496	Pre-procedural proton pump inhibition is associated with fewer peri-oesophageal lesions after cryoballoon pulmonary vein isolation. 2021 , 11, 4728	1
495	The efficacy and safety of cryoballoon catheter ablation in patients with paroxysmal atrial fibrillation. 2021 , 1	3
494	Shared medical appointments: Translating research into practice for patients treated with ablation therapy for atrial fibrillation. 2021 , 16, e0246861	
493	The affordability of adding a direct-acting oral anticoagulant to the national list of essential medicine for patients with non-valvular atrial fibrillation in Thailand: a budget impact analysis. 2021 , 1-8	1
492	Novel mapping techniques for rotor core detection using simulated intracardiac electrograms. 2021 , 32, 1268-1280	3
491	Postoperative atrial fibrillation in pneumonectomy for primary lung cancer. 2021 , 13, 789-802	2
490	Active esophageal cooling for the prevention of thermal injury during atrial fibrillation ablation: a randomized controlled pilot study. 2021 , 1	10
489	Impact of age on the outcome of cryoballoon ablation as the primary approach in the interventional treatment of atrial fibrillation: Insights from a large all-comer study. 2021 , 32, 949-957	3
488	Long-term results of thoracoscopic ablation of paroxysmal atrial fibrillation: is the glass half full or half empty?. 2021 , 60, 850-856	0
487	National rates and trends of tobacco and substance use disorders among atrial fibrillation hospitalizations. 2021 , 50, 244-251	1
486	A STUDY ON CLINICAL PROFILE OF PATIENTS WITH ATRIAL FIBRILLATION. 2021 , 42-43	
485	Atrial Fibrillation in Inherited Channelopathies. 2021 , 13, 155-163	0
484	Deep learning assisted heart arrhythmia detection. 2021 , 1817, 012011	

483	Plasma EB and EB PUFA Concentrations and Risk of Atrial Fibrillation: The Multi-Ethnic Study of Atherosclerosis. 2021 , 151, 1479-1486	2
482	Integrated Care in Atrial Fibrillation: A Road Map to the Future. 2021 , 14, e007411	3
481	Adverse effects of PM on cardiovascular diseases. 2021 ,	2
480	Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population. 2021 , 37, 881-890	5
479	Bioengineering approaches to mature induced pluripotent stem cell-derived atrial cardiomyocytes to model atrial fibrillation. 2021 , 246, 1816-1828	2
478	Real-world persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis. 2021 , 37, 891-902	1
477	Handheld ECG Tracking of in-hospital Atrial Fibrillation (HECTO-AF): A Randomized Controlled Trial. 2021 , 8, 681890	0
476	Genetics of atrial fibrillation-practical applications for clinical management: if not now, when and how?. 2021 , 117, 1718-1731	1
475	Cohort Design and Natural Language Processing to Reduce Bias in Electronic Health Records Research: The Community Care Cohort Project.	1
474	ATTICUS: Ambient-Intelligent Tele-monitoring and Telemetry for Incepting and Catering Over hHuman Sustainability. 2021 , 3,	2
473	Accelerometer-derived physical activity and risk of atrial fibrillation. 2021 , 42, 2472-2483	9
472	Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAf) Patients with Obesity and Polypharmacy in the United States (US). 2021 , 38, 3771-3788	1
471	Importance of Paroxysmal Atrial Fibrillation and Sex Differences in the Prevention of Embolic Stroke in Hypertrophic Cardiomyopathy. 2021 , 3, 273-278	0
470	Guía ESC 2020 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración de la European Association of Cardio-Thoracic Surgery (EACTS). 2021 , 74, 437.e1-437.e116	3
469	A Web-Based Integrated Management Program for Improving Medication Adherence and Quality of Life, and Reducing Readmission in Patients With Atrial Fibrillation: Randomized Controlled Trial (Preprint).	
468	Percutaneous left atrial appendage occlusion: A review of current devices, clinical evidence, patient selection, and post procedural antithrombotic management. 2021 , 66, 92-100	1
467	From electrophysiological exploration to management of heart arrhythmias: Economic analysis of practices in a high-volume French hospital over two different time periods. 2021 , 79, 255-265	
466	Different Influence of Blood Pressure on New-Onset Atrial Fibrillation in Pre- and Postmenopausal Women: A Nationwide Population-Based Study. 2021 , 77, 1500-1509	7

- 465 Arrhythmia Recurrence After Atrial Fibrillation Ablation: Impact of Warfarin vs. Non-Vitamin K Antagonist Oral Anticoagulants. **2021**, 1
- 464 The Role of α 7nAChR-Mediated Cholinergic Anti-Inflammatory Pathway in Vagal Nerve Regulated Atrial Fibrillation. **2021**, 62, 607-615 1
- 463 Surveillance for Outcomes Selected as Atrial Fibrillation Quality Indicators in Canada: 10-Year Trends in Stroke, Major Bleeding, and Heart Failure. **2021**, 3, 609-618
- 462 Who is at risk of atrial fibrillation?. **2021**, 18, 853-854
- 461 Relations between left atrial appendage contrast retention and thromboembolic risk in patients with atrial fibrillation. **2021**, 1 3
- 460 Refractory Atrial Fibrillation With Rapid Ventricular Rate in a Patient With Small Cell Carcinoma of the Lung Encasing the Right Pulmonary Artery: A Case Report and Insight Into Therapeutic Options. **2021**, 13, e16027
- 459 Mapping atrial fibrillation : An overview of potential mechanisms underlying atrial fibrillation. **2021**, 46, 305-311 0
- 458 Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants. **2021**, 1 1
- 457 Incidence and Mortality Trends of Atrial Fibrillation/Atrial Flutter in the United States 1990 to 2017. **2021**, 148, 78-83 2
- 456 Incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes. **2021**, 20, 123 2
- 455 Geriatric nutritional risk index as a predictor of arrhythmia recurrence after catheter ablation of atrial fibrillation. **2021**, 31, 1798-1808 0
- 454 Molecular basis of ventricular arrhythmogenicity in a Pgc-1 β deficient murine model. **2021**, 27, 100753 0
- 453 Midterm results of stand-alone thoracoscopic epicardial ablation with box lesion for atrial fibrillation. **2021**, 33, 354-361
- 452 The Association between the PRECISE-DAPT Score and New-Onset Atrial Fibrillation in Patients with ST-Elevation Myocardial Infarction.. **2021**, 16, 20-25 0
- 451 An automated method for detecting atrial fat using convolutional neural network. **2021**, 235, 1329-1334 0
- 450 Update on the efficacy of statins in primary and secondary prevention of atrial fibrillation. **2021**, 40, 509-518
- 449 Temporal trends in cause-specific mortality among individuals with newly diagnosed atrial fibrillation in the Framingham Heart Study. **2021**, 19, 170 0
- 448 Update on the efficacy of statins in primary and secondary prevention of atrial fibrillation. **2021**, 40, 509-518

447	Clinical Significance of Atrial Fibrillation Status in Patients With Percutaneous Coronary Intervention.. 2021 , 3, 1357-1364	0
446	Atrial Fibrillation Is Associated with Cognitive Impairment, All-Cause Dementia, Vascular Dementia, and Alzheimer's Disease: a Systematic Review and Meta-Analysis. 2021 , 36, 3122-3135	4
445	Dis�� y caracter��sticas basales del estudio REGUEIFA (Registro Gallego Interch��trico de Fibrilaci�� Auricular). 2021 , 56, 197-207	1
444	Anticoagulation After Ischemic Stroke or Transient Ischemic Attack (TIA) in the Time of Direct Oral Anticoagulation (DOAC) and Thrombectomy. 2021 , 13, e17392	
443	Length of stay following percutaneous left atrial appendage occlusion: Data from the prospective, multicenter Amplatzer Amulet Occluder Observational Study. 2021 , 16, e0255721	1
442	Trends in Cardiovascular Mortality Related to Atrial Fibrillation in the United States, 2011 to 2018. 2021 , 10, e020163	8
441	2020 Clinical guidelines for Atrial fibrillation and atrial flutter. 2021 , 26, 4594	31
440	Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy. 2021 , 10, 1235-1250	1
439	Deep Learning of Left Atrial Structure and Function Provides Link to Atrial Fibrillation Risk.	1
438	Differences in the Clinical Profile and Management of Atrial Fibrillation According to Gender. Results of the REgistro GallEgo Interch��trico de Fibrilaci�� Auricular (REGUEIFA) Trial. 2021 , 10,	1
437	Clinical Characteristics and Outcomes of Hospitalized Patients With Heart Failure From the Large-Scale Japanese Registry Of Acute Decompensated Heart Failure (JROADHF). 2021 , 85, 1438-1450	10
436	Oral Anticoagulant Use in Morbid Obesity and Post Bariatric Surgery: A Review. 2021 ,	1
435	Use of Smartphones and Wearables for Arrhythmia Monitoring. 2021 , 13, 509-522	1
434	Comparative Clinical Effectiveness of Population-Based Atrial Fibrillation Screening Using Contemporary Modalities: A Decision-Analytic Model. 2021 , 10, e020330	1
433	A Web-Based Integrated Management Program for Improving Medication Adherence and Quality of Life, and Reducing Readmission in Patients With Atrial Fibrillation: Randomized Controlled Trial. 2021 , 23, e30107	1
432	Long-Term Exposures to Air Pollution and the Risk of Atrial Fibrillation in the Women's Health Initiative Cohort. 2021 , 129, 97007	1
431	Outcomes and predictors of readmission after implantation of a percutaneous left atrial appendage occlusion device in the United States: A propensity score-matched analysis from The National Readmission Database. 2021 , 32, 2961-2970	0
430	Low incidence of major complications after the first six hours post atrial fibrillation ablation: Is same-day discharge safe and feasible in most patients?. 2021 , 32, 2953-2960	3

429	Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Non-Valvular Atrial Fibrillation Patients: Results of A Real-World Study in a Metropolitan Area of Northern Italy. 2021 , 10,	0
428	Batch enrollment for an artificial intelligence-guided intervention to lower neurologic events in patients with undiagnosed atrial fibrillation: rationale and design of a digital clinical trial. 2021 , 239, 73-79	5
427	Artificially Created Reentry Circuit by Laser Irradiation Causes Atrial Tachycardia to Persist in Murine Atria. 2021 ,	2
426	Association of Left Atrial Metrics with Atrial Fibrillation Rehospitalization and Adverse Cardiovascular Outcomes in Patients with Nonvalvular Atrial Fibrillation following Index Hospitalization. 2021 , 34, 1046-1055.e3	3
425	Atrial Fibrillation (Part 1): Pathophysiology, Risk Factors, and Therapeutic Basis. 2021 , 116, 129-139	3
424	Overexpression of MiR-29b-3p Inhibits Atrial Remodeling in Rats by Targeting PDGF-B Signaling Pathway. 2021 , 2021, 3763529	3
423	Neurologic complications of atrial fibrillation: Pharmacologic and interventional approaches to stroke prevention. 2021 , 177, 143-149	0
422	Changing the Paradigm to Understand and Manage Atrial Fibrillation. 2014 , 127-164	1
421	LARIAT: The Endo-Epicardial Technique for Left Atrial Appendage Exclusion. 2016 , 205-223	1
420	The Economic Impact of Atrial Fibrillation in the US. 2016 , 27-40	1
419	A Smartphone-Based Virtual Agent for Atrial Fibrillation Education and Counseling. 2016 , 120-127	14
418	Proarrhythmic atrial calcium cycling in the diseased heart. 2012 , 740, 1175-91	11
417	Pathophysiology of Cardioembolism. 2020 , 105-111	1
416	Atrial Fibrillation. 2012 , 825-844	3
415	Beyond Pulmonary Vein Isolation in Nonparoxysmal Atrial Fibrillation: Posterior Wall, Vein of Marshall, Coronary Sinus, Superior Vena Cava, and Left Atrial Appendage. 2020 , 12, 219-231	3
414	Prevalence of atrial fibrillation and outcomes in older long-term care residents: a systematic review. 2021 , 50, 744-757	2
413	Atrial Fibrillation. 2009 , 1069-1132	5
412	Prognostic value of Tc-ECD brain perfusion SPECT in patients with atrial fibrillation and dementia. 2020 , 10, 3	5

411	Epidemiology and long-term prognosis of atrial fibrillation in rural African patients. 2019 , 71, 6	3
410	Prevalence of atrial fibrillation in Thai elderly. 2016 , 13, 270-3	12
409	Real-world characteristics of hospitalized frail elderly patients with atrial fibrillation: can we improve the current prescription of anticoagulants?. 2016 , 13, 226-32	25
408	Predisposing factors for atrial fibrillation in the elderly. 2017 , 14, 179-184	27
407	Atrial fibrillation: the current epidemic. 2017 , 14, 195-203	125
406	Effect of advanced age on plasma homocysteine levels and its association with ischemic stroke in non-valvular atrial fibrillation. 2017 , 14, 743-749	12
405	Atrial fibrillation in the elderly. 2019 , 16, 49-53	15
404	Screening of unknown atrial fibrillation through handheld device in the elderly. 2020 , 17, 495-501	1
403	Heart Failure in Atrial Fibrillation - An Update on Clinical and Echocardiographic Implications. 2020 , 84, 1212-1217	5
402	Atrio-Esophageal Fistula: A Case Series and Literature Review. 2017 , 18, 847-854	12
401	Expanding use of new oral anticoagulants. 2014 , 6, 93	15
400	Whole Exome Sequencing in Atrial Fibrillation. 2016 , 12, e1006284	24
399	The expression levels of plasma microRNAs in atrial fibrillation patients. 2012 , 7, e44906	81
398	Virtual electrophysiological study of atrial fibrillation in fibrotic remodeling. 2015 , 10, e0117110	88
397	Association of Smoking, Alcohol, and Obesity with Cardiovascular Death and Ischemic Stroke in Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study and Cardiovascular Health Study (CHS). 2016 , 11, e0147065	32
396	Shensongyangxin Capsules for Paroxysmal Atrial Fibrillation: A Systematic Review of Randomized Clinical Trials. 2016 , 11, e0151880	8
395	Whole Blood Gene Expression Differentiates between Atrial Fibrillation and Sinus Rhythm after Cardioversion. 2016 , 11, e0157550	10
394	Presence of atrial fibrillation is associated with liver stiffness in an elderly Finnish population. 2017 , 12, e0173855	10

393	Efficacy and safety of oral anticoagulation in elderly patients with atrial fibrillation. 2018 , 19, 67-71	17
392	A novel score in the prediction of rhythm outcome after ablation of atrial fibrillation: The SUCCESS score. 2019 , 21, 142-149	7
391	Lifestyle of Patients with Atrial Fibrillation Following Self-Management Interventions: a Randomized Clinical Trial. 2019 , 8, 83-88	4
390	Achieving metrics during beating-heart ex-maze procedures improves outcomes. 2008 , 11, E237-42	3
389	Relationship between the long-term preventive effect of combined treatment with antiarrhythmic drugs plus angiotensin-converting enzyme inhibitors and circadian variation in the onset of paroxysmal atrial fibrillation. 2010 , 51, 331-6	1
388	Anticoagulation in Atrial Fibrillation. 2012 , 1, 12-16	2
387	Targeting Stable Rotors to Treat Atrial Fibrillation. 2012 , 1, 34-38	3
386	The Future of Pulmonary Vein Isolation - Single-shot Devices, Remote Navigation or Improving Conventional Radiofrequency Delivery by Contact Monitoring and Lesion Characterisation?. 2013 , 2, 59-64	2
385	Closed Chest Convergent Epicardial-Endocardial Ablation of Non-paroxysmal Atrial Fibrillation - A Case Series and Literature Review. 2013 , 2, 65-8	16
384	The Use of Gene Therapy for Ablation of Atrial Fibrillation. 2014 , 3, 139-44	13
383	Evaluating the Cost-effectiveness of Catheter Ablation of Atrial Fibrillation. 2014 , 3, 177-83	13
382	Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy. 2017 , 6, 63-68	10
381	Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation: Assessment, Monitoring and Treatment Reversal. 2016 , 11, 118-122	2
380	[The prevalence of atrial fibrillation in Hungary]. 2012 , 153, 339-42	2
379	Novel Biomarkers in Cardiovascular Disease: A Review. 2010 , 2, 66	1
378	Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets. 2017 , 8, 60673-60683	10
377	Catheter Ablation of Atrial Fibrillation: A Review of the Current Status and Future Directions. 2017 , 8, 2907-2917	4
376	Posterior Wall Isolation in Atrial Fibrillation Ablation. 2018 , 9, 3186-3194	8

375	Apple Watch, Wearables, and Heart Rhythm: where do we stand?. 2019 , 7, 417	53
374	Ticagrelor or prasugrel . clopidogrel in combination with anticoagulation for treatment of acute coronary syndrome in patients with atrial fibrillation. 2019 , 7, 406	4
373	Biomarkers of Atrial Fibrillation in Hypertension. 2019 , 26, 888-897	5
372	Understanding Atrial Fibrillation: The Signal Processing Contribution, Part I. 2008 , 3, 1-129	5
371	Atrial fibrillation in the cardiometabolic patient. 2019 , 110, 157-167	9
370	Stroke prevention in patients with atrial fibrillation and comorbidities. 2018 , 15, 55-59	1
369	Atrial fibrillation: its prevalence and risk factor profile in the German general population. 2012 , 109, 293-9	47
368	Cost-Effectiveness of Rate- and Rhythm-Control Drugs for Treating Atrial Fibrillation in Korea. 2019 , 60, 1157-1163	2
367	Analysis of costs of treatment of patients with atrial fibrillation in the Czech Republic. 2008 , 50, 23-27	4
366	Surgical Delay Is Not Warranted for Patients With Hip Fractures Receiving Non-Warfarin Anticoagulants. 2019 , 42, e331-e335	7
365	The role of transcription factors in atrial fibrillation. 2015 , 7, 152-8	12
364	Adjunct ablation strategies for persistent atrial fibrillation-beyond pulmonary vein isolation. 2015 , 7, 178-84	5
363	Putative Role of Right Atrial Ablation in Atrial Fibrillation. 2014 , 6, 1085	3
362	Retrospective Evaluation Of Novel Percutaneous Left Atrial Appendage Ligation Using The LARIAT Suturing Device: Single Center Initial Experience. 2014 , 7, 1106	2
361	Von Willebrand Factor Plasma Levels Variability In Nonvalvular Atrial Fibrillation. 2014 , 7, 1124	4
360	Clinical and Economic Implications of AF Related Stroke. 2016 , 8, 1279	14
359	Baseline Demographics, Safety, and Patient Acceptance of an Insertable Cardiac Monitor for Atrial Fibrillation Screening: The REVEAL-AF Study. 2017 , 9, 1551	6
358	California study of Ablation (CAABL):early utilization after index hospitalization for non-valvular atrial fibrillation. 2017 , 10, 1599	1

357	Management of Stroke risk in atrial fibrillation patients with bleeding on Oral Anticoagulation Therapy-Role of Left Atrial Appendage Closure, Octreotide and more. 2017 , 10, 1729	2
356	Life's Simple 7 Approach to Atrial Fibrillation Prevention. 2018 , 11, 2051	2
355	Atrial Fibrillation at an Internal Medicine Ward: Clinical and Prognostic Implications. 2012 , 5, 343	2
354	Success of Radiofrequency Catheter Ablation of Atrial Fibrillation: Does Obesity Influence the Outcomes?. 2008 , 1, 36	3
353	Preventative Measures of Stroke in Patients With Atrial Fibrillation. 2012 , 4, 399	2
352	Atrial Fibrillation and Metabolic Syndrome: Understanding the Connection. 2012 , 5, 647	6
351	The Temporal Relationship Between Atrial Fibrillation and Ischemic Stroke. 2013 , 5, 738	1
350	Atrial Fibrillation and Heart Failure: A Review of the Intersection of Two Cardiac Epidemics. 2013 , 6, 751	12
349	The Role Of Renin Angiotensin System In Atrial Fibrillation. 2014 , 6, 972	15
348	Reducing Stroke Risk in Atrial Fibrillation: Adherence to Guidelines Has Improved, but Patient Persistence with Anticoagulant Therapy Remains Suboptimal. 2019 , 49, 883-907	18
347	Atrial Fibrillation in Middle Eastern Arabs and South Asians: Summary of Published Articles in the Arabian Gulf. 2019 , 20, 158-165	1
346	Contemporary therapy of atrial fibrillation. 2012 , 02, 111-117	2
345	Comparison of cardiac computed tomography angiography and transoesophageal echocardiography for device surveillance after left atrial appendage closure. 2019 , 15, 663-670	29
344	Geometry of left atrial appendage assessed with multidetector-row computed tomography: implications for transcatheter closure devices. 2014 , 10, 364-71	23
343	EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. 2015 , 10, 1109-1125	64
342	Improving outpatient warfarin use for hospitalized patients with atrial fibrillation. 2008 , 6, 43-50	4
341	Prognostic impact of atrial fibrillation on clinical outcomes of acute coronary syndromes, heart failure and chronic kidney disease. 2015 , 7, 397-403	11
340	NOACs Added to WHO's Essential Medicines List: Recommendations for Future Policy Actions. 2020 , 15, 67	2

338	Prediction of mid-term outcome after cryo-balloon ablation of atrial fibrillation using post-procedure high-sensitivity troponin level. 2015 , 26, 165-70	16
-----	------------------------------------------------------------------------------------------------------------------------------------------------------------------	----

- 321 Surgical Treatment for Isolated Atrial Fibrillation Minimally Invasive vs Classic Cut and Sew Maze. **2011**, 6, 373-377
- 320 Novel therapies for treating atrial fibrillation. **2012**, 02, 242-259
- 319 Catheter Ablation for Atrial Fibrillation. **2012**, 1345-1360
- 318 Diagnostic Aspects of Implantable Devices. **2012**, 1265-1279
- 317 Left Atrial Appendage Closure and Stroke. **2012**, 623-634
- 316 Atrial Fibrillation. **2012**, 559-624 1
- 315 Atrial Fibrillation: Current and Forthcoming Antithrombotic Therapies. 285-305
- 314 Atrial Fibrillation. 143-173
- 313 Assessment of the adherence of cardiologists to guidelines for the treatment of atrial fibrillation. **2013**, 101, 127-33 7
- 312 Improvement of left ventricular function in patients with persistent atrial tachyarrhythmia induced cardiomyopathy undergoing radiofrequency ablation. **2013**, 03, 529-535
- 311 Non-surgical Treatment and Prevention of Atrial Fibrillation. **2013**, 543-559
- 310 Common Clinical Indications for Anticoagulation. **2013**, 7-31
- 309 Stroke in Atrial Fibrillation - Long-term Follow-up of Cardiovascular Events. **2013**, 2, 105-8 3
- 308 THE INCIDENCE AND POSSIBLE CAUSES OF ATRIAL FIBRILLATION IN HOSPITALIZED PATIENTS DURING 1985â2010. **2013**, 19, 109-116 1
- 307 Surgical Minimally Invasive Pulmonary Vein Isolation for Lone Atrial Fibrillation. **2013**, 8, 410-415
- 306 Epidemiology, Burden and Unmet Needs in Atrial Fibrillation. **2014**, 1-22
- 305 Image-Guided Cardiac Electrophysiology Procedures Focusing on MRI Guidance. **2014**, 701-724
- 304 Understanding the Genetic Basis of Atrial Fibrillation: Towards a Pharmacogenetic Approach for Arrhythmia Treatment. **2014**, 65-75

303 Left Atrial Occluders/Isolation. **2014**, 1325-1332

302 Atrial Fibrillation in the Elderly: Management Strategies to Achieve Performance Measures. **2014**, 25, 205-212

1

301 Hybrid therapy in the management of atrial fibrillation. **2015**, 11, 167-79

1

300 Atrial Fibrillation and Related Disorders. **2015**, 227-239

299 Clinical Differences between Subtypes of Atrial Fibrillation and Flutter: Cross-Sectional Registry of 407 Patients. **2015**, 105, 3-10

7

298 When Should Ablation Be Considered in the Treatment of Atrial Fibrillation âA Clinicianâs View. **2015**, 349-359

297 Basic knowledge of oral anticoagulant therapy. **2015**, 34, 46-50

0

296 The Left Atrial Appendage in Health and Disease. **2015**, 1,

0

295 Left Atrial Volumes and Function: Evaluation With Real-Time 3D Echocardiography in an Acute Care Setting. **2015**, 3,

294 Radiofrequency ablation and antiarrhythmic therapy in the treatment of patients with paroxysmal and persistent atrial fibrillation: clinical effects. **2015**, 6, 38-47

2

293 Thromboprophylaxis in Patients with Atrial Fibrillation: A Real Practice Analysis. **2016**, 3, GRHTA.5000203a

292 Emergency Medical Services and Atrial Fibrillation. **2016**, 43-49

291 A Molecular Genetic Perspective on Atrial Fibrillation. **2016**, 227-245

290 Atrial Fibrillation and Stroke Epidemiology. **2016**, 3-16

289 Amplatzer Cardiac Plug and Amulet. **2016**, 181-193

288 Anticoagulation for the prevention of stroke in non-valvular AF in general practice: room for improvement. **2016**, 5, 212295

3

287 [Prevalence of atrial fibrillation and predictors of its occurrence in patients with dual-chamber pacemakers]. **2016**, 86, 214-20

1

286 Cost-Effectiveness of Cardiac Radiosurgery for Atrial Fibrillation: Implications for Reducing Health Care Morbidity, Utilization, and Costs. **2016**, 8, e720

5

285 Recurrence of Stroke in Patients with AF Using NOACs. **2017**, 11-23

284 Atrial Fibrillation in the Elderly. **2017**, 149-163

283 Klinische und apparative Diagnostik. **2017**, 41-66

282 Frailty and Heart Disease. **2017**, 41-58

281 Cardioembolic Stroke. **2017**, 23, 111-132

9

280 A Pilot Randomized Trial of Oral Magnesium Supplementation on Supraventricular Arrhythmias.

279 Imaging-derived Biomarkers Associated with Atrial FIBROsis, Structural Remodeling and the Risk of Cardioembolic Events in Patients with Atrial Fibrillation â€”The FIBROS Study. **2017**, 2, 31-35

1

278 ??????????????????????????????. **2018**, 26, 35-41

277 Letter from the Editor in Chief. **2018**, 9, A7

276 Management of Common Arrhythmia in the Neurological Intensive Care Unit. **2018**, 11, 7-12

275 [Comparison of the efficacy and safety of dronedarone and flecainide as maintenance antiarrhythmic therapy for sinus rhythm in atrial fibrillation]. **2018**, 88, 204-211

2

274 Rate Versus Rhythm Control in Patients with Normal to Mild Left Atrial Enlargement: Insights from the AFFIRM Trial. **2018**, 11, 2067

0

273 Left Atrial Scarring Segmentation from Delayed-Enhancement Cardiac MRI Images: A Deep Learning Approach. **2018**, 109-130

1

272 Determination of the effects of cryoablation for atrial fibrillation on esophageal functions. **2020**, 23, 223-227

271 Recent Advances for Stroke Prevention in Patients With Atrial Fibrillation and Advanced Kidney Disease. **2019**, 736-740.e2

270 Heart Rhythm Qualitative Analysis Using Low-Cost and Open Source Electrocardiography: A Study Based on Atrial Fibrillation Detection. **2019**, 198-217

269 Atria score to predict atrial fibrillation in acute ischemic stroke patients.

268 The Impact of Repeated Cardioversions for Atrial Fibrillation on Stroke, Hospitalizations, and Catheter Ablation Outcomes. **2019**, 11, 2164

- 267 Prevention of gastrointestinal bleeding in patients receiving oral anticoagulants: focus on proton pump inhibitors. **2019**, 18, 128-137
- 266 [How to maintain an adherence to oral anticoagulant in a patient with atrial fibrillation?]. **2019**, 59, 76-83
- 265 A Molecular Genetic Perspective on Atrial Fibrillation. **2020**, 287-305
- 264 Identification of atrial fibrillation in secondary care diabetes and vascular clinics: a pilot study. **2020**, 16, 179-188
- 263 Interleukin-22 is elevated in the atrium and plasma of patients with atrial fibrillation and increases collagen synthesis in transforming growth factor- β -treated cardiac fibroblasts via the JNK pathway. **2020**, 20, 1012-1020 o
- 262 National Trends of Arrhythmia Hospitalizations and Comorbid Alcohol Use Disorders in the United States. **2020**, 12, e8835 o
- 261 The convergent procedure: a hybrid approach for long lasting persistent atrial fibrillation ablation. **2020**, 61, 369-375 1
- 260 Catheter Ablation vs. Medical Treatment in Patients With Atrial Fibrillation. **2020**, 12, e9700
- 259 Thoracoscopic surgical ablation versus catheter ablation as first-line treatment for long-standing persistent atrial fibrillation: the CASA-AF RCT. **2021**, 8, 1-122 1
- 258 Prevention of Atrial Fibrillation. **2021**, 541-580
- 257 Deep Learning Based Prediction of Atrial Fibrillation Disease Progression with Endocardial Electrograms in a Canine Model. **2020**, 47, o
- 256 Arrhythmia in tumor lysis syndrome and associated in-hospital mortality: A nationwide inpatient analysis. **2021**, 37, 121-127 1
- 255 Obesity and Atrial Fibrillation. **2020**, 473-478
- 254 Modern aspects of surgical treatment of patients with atrial fibrillation. Development of uniform criteria for selecting patients for radiofrequency ablation. **2020**, 58-64
- 253 Atrial Fibrillation. **2020**, 141-168
- 252 Pharmacologic Management of Atrial Fibrillation and Flutter. **2020**, 359-407
- 251 O-GlcNAcylation, oxidation and CaMKII contribute to atrial fibrillation in type 1 and type 2 diabetes by distinct mechanisms. 1
- 250 Obesity and Atrial Fibrillation: Epidemiology, Pathogenesis and Effect of Weight Loss. **2021**, 10, 159-164 1

249	Systematic review of renal denervation for the management of cardiac arrhythmias. 2021 , 1	0
248	Senescence and Arrhythmogenesis. 2008 , 247-260	
247	Age-Specific Association Between Body Mass Index and the Incidence of Atrial Fibrillation in Japanese Men. 2020 , 2, 466-470	1
246	Commentary: An ounce of prevention may not be worth a pound of cure—postoperative atrial fibrillation. 2020 , 3, 86-87	
245	Alternative medicine in atrial fibrillation treatment-Yoga, acupuncture, biofeedback and more. 2015 , 7, 185-92	9
244	Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation. 2009 , 5, 783-91	1
243	GENE AND CELL THERAPY FOR LIFE-THREATENING CARDIAC ARRHYTHMIAS. 2009 , 14, 44-51	3
242	Atrial fibrillation (chronic). 2008 , 2008,	
241	The Utility of Ambulatory Electrocardiographic Monitoring for Detecting Silent Arrhythmias and Clarifying Symptom Mechanism in an Urban Elderly Population with Heart Failure and Hypertension: Clinical Implications. 2010 , 3, 193	9
240	Is AF Ablation Cost Effective?. 2010 , 3, 286	3
239	Atrial fibrillation (chronic). 2011 , 2011,	1
238	Esophageal injury following left atrial ablation. 2012 , 8, 414-6	5
237	Drug therapy in atrial fibrillation management: where do we stand in 2010?. 2010 , 5, 172-8	
236	Management of refractory atrial fibrillation post surgical ablation. 2014 , 3, 91-7	13
235	Atrial fibrillation. 2013 , 82, 135-40	0
234	New oral anticoagulants for atrial fibrillation: are they worth the risk?. 2014 , 39, 54-64	9
233	Role of neural modulation in the pathophysiology of atrial fibrillation. 2014 , 139, 512-22	2
232	Temporal and Spatial Indices of AF Regularization Predict Intraprocedural AF Termination and Outcome. 2012 , 4, 507	

231	Use Of Rate And Rhythm Control Drugs In Patients Younger Than 65 Years With Atrial Fibrillation. 2014 , 7, 1062	3
230	Atrial fibrillation (chronic). 2015 , 2015,	1
229	Elevated glycated hemoglobin levels may increase the risk of atrial fibrillation in patients with diabetes mellitus. 2015 , 8, 3271-80	6
228	Atrial fibrillation and physical activity: Should we exercise caution?. 2015 , 61, 1061-70	7
227	Atrial fibrillation and sleep-disordered breathing. 2015 , 7, E575-84	20
226	C-Reactive Protein Gene Polymorphisms and the Risk of Atrial Fibrillation in a Chinese Population in Taiwan. 2013 , 29, 208-16	4
225	Atrial Fibrillation and Stroke - Increasing Stroke Risk With Intervention. 2013 , 6, 966	
224	Optimization Of Stroke Prophylaxis Strategies In Nonvalvular AF -Drugs, Devices Or Both?. 2015 , 8, 1156	
223	PURLs: Should you bypass anticoagulant "bridging" before and after surgery?. 2015 , 64, 794-800	
222	Stroke Prevention in Atrial Fibrillation. 2010 , 3, 279	1
221	Commentary on: Pericardial Fat is Independently Associated with Human Atrial Fibrillation by Al Chekakie et al. 2010 , 3, 318	
220	Efficacy And Safety of Dabigatran Etexilate Utilization With Concomitant Dual Antiplatelet Therapy In Atrial Fibrillation. 2014 , 6, 1001	
219	Dabigatran, A Direct Thrombin Inhibitor, In Atrial Fibrillation: Is It Already Time For A Change In Oral Anticoagulation Therapy?. 2010 , 2, 234	
218	Experimental Evidence Of The Role Of Renal Sympathetic Denervation For Treating Atrial Fibrillation. 2014 , 7, 1128	0
217	The Optimal Treatment For Atrial Fibrillation In Less Developed Countries. 2014 , 7, 1147	2
216	Cost-Effectiveness of Dabigatran Exilate in Treatment of Atrial Fibrillation. 2015 , 7, 1223	
215	The Cost Effectiveness of LAA Exclusion. 2016 , 8, 1374	2
214	Symptoms In Atrial Fibrillation: A Contemporary Review And Future Directions. 2016 , 9, 1422	10

213	Complications From Left Atrial Appendage Exclusion Devices. 2014 , 7, 1034	10
212	Managing Antiplatelet Therapy and Anticoagulants in Patients with Coronary Artery Disease and Atrial Fibrillation. 2015 , 8, 1318	5
211	Integrated Chronic Care Management For Patients With Atrial Fibrillation - A Rationale For Redesigning Atrial Fibrillation Care. 2015 , 7, 1177	6
210	Sex Differences In Outcomes Of Ablation Of Atrial Fibrillation. 2014 , 6, 1024	8
209	Catheter Ablation Of Atrial Fibrillation In The Elderly: Risk Benefit Analysis. 2014 , 7, 1116	1
208	Necessity of Repeat Ablations to Eliminate Atrial Fibrillation. 2012 , 4, 469	
207	Adverse Outcomes from Atrial Fibrillation;Mechanisms, Risks, and Insights Learned from Therapeutic Options. 2012 , 4, 477	
206	Age as a Risk factor for Atrial Fibrillation and Flutter after Coronary Artery Bypass Grafting. 2012 , 4, 482	1
205	Left Atrial Appendage Occlusion for Stroke Prevention in Patients with Nonrheumatic Atrial Fibrillation. 2013 , 6, 923	
204	Ablation of Atrial Fibrillation in the Elderly: Current Evidence and Evolving Trends. 2011 , 4, 341	
203	Surgery for Atrial Fibrillation: Selecting the Procedure for the Patient. 2013 , 6, 743	
202	Thinking outside the Box: Rotor Modulation in the Treatment of Atrial Fibrillation. 2013 , 6, 811	
201	Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old Agents. 2013 , 6, 825	
200	Catheter Ablation of Atrial Fibrillation in Females. 2013 , 6, 893	1
199	Atrial Fibrillation Associated with Heart Failure, Stroke and Mortality. 2012 , 5, 467	7
198	Prevention of Stroke in Patients With Atrial Fibrillation. 2011 , 4, 447	
197	New Stroke Prophylaxis Options in Atrial Fibrillation Patients. 2013 , 5, 462	
196	The Role of Pericardial and Epicardial Fat in Atrial Fibrillation Pathophysiology and Ablation Outcomes. 2013 , 5, 790	2

- 195 Primary Prevention of Atrial Fibrillation where are we in 2012?. **2012**, 5, 608 2
- 194 Structural and Functional Remodeling of the Left Atrium: Clinical and Therapeutic Implications for Atrial Fibrillation. **2013**, 6, 986 9
- 193 Body Mass Index, Quality of Life, and Catheter Ablation in Patients with Atrial Fibrillation. **2012**, 5, 426
- 192 How Does Alcohol Intake Relate to the Risk of Atrial Fibrillation?. **2012**, 5, 433
- 191 Co-existence of Atrial Fibrillation with Myocardial Infarction - Unhealthy Combination. **2012**, 5, 666
- 190 Ischemic Conditioning and Atrial Fibrillation: Hope for a New Therapy?. **2013**, 5, 753 1
- 189 Atrial Fibrillation Complicating Acute Coronary Syndromes. **2012**, 5, 611 2
- 188 AF and Venous Thromboembolism - Pathophysiology, Risk Assessment and CHADS-VASc score. **2012**, 5, 649 8
- 187 Treatment Considerations for a Dual Epidemic of Atrial Fibrillation and Heart Failure. **2013**, 6, 740 3
- 186 Connexin Remodeling Contributes to Atrial Fibrillation. **2013**, 6, 839 4
- 185 Rate Versus Rhythm Control Pharmacotherapy For Atrial Fibrillation: Where are We in 2008?. **2008**, 1, 21 6
- 184 Mechanical discordance between left atrium and left atrial appendage. **2018**, 21, 82-84
- 183 Coronary Artery Dominance May Predict Future Risk of Atrial Fibrillation. **2018**, 34, 344-351 4
- 182 Treatment of atrial fibrillation in nursing homes: A place for direct acting oral anticoagulants?. **2018**, 4, 15-19 3
- 181 Efficacy and Safety of Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation Undergoing Elective Surgical Procedures: A Meta-analysis. **2021**, 19, 19-25
- 180 Atrial appendage closure in patients with heart failure and atrial fibrillation: industry-independent single-centre study. **2021**, 1
- 179 Risk factor management of atrial fibrillation using mHealth: The Atrial Fibrillation - Helping Address Care with Remote Technology (AF-HEART) Pilot Study.. **2022**, 3, 14-20
- 178 A tale of two balloons: technical and procedural difference between cryoballoon systems. **2022**, 37, 62-67 0

177	Proposal for a Home Sleep Monitoring Platform Employing a Smart Glove. 2021 , 21,	0
176	QT prolongation in patients with index evaluation for seizure or epilepsy is predictive of all-cause mortality. 2021 ,	0
175	Pharmacological Management of Atrial Fibrillation: A Century of Expert Opinions in Cecil Textbook of Medicine.. 2022 , 29, e18-e25	1
174	Comparing Patient and Provider Experiences with Atrial Fibrillation to Highlight Gaps and Opportunities for Improving Care.. 2022 , 1	
173	Ambient nitrogen dioxide is associated with emergency hospital visits for atrial fibrillation: a population-based case-crossover study in Reykjavik, Iceland.. 2022 , 21, 2	0
172	Epicardial adipose tissue as a mediator of cardiac arrhythmias. 2021 ,	2
171	CLINICAL FACTORS ASSOCIATED WITH NON-VALVULAR ATRIAL FIBRILLATION. 2019 , 8-13	0
170	Efficacy and Safety of Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation Undergoing Elective Surgical Procedures: A Meta-analysis. 2021 , 19, 19-25	1
169	Quantifying Risk Factors for Atrial Fibrillation: Retrospective Review of a Large Electronic Patient Database.. 2020 , 13, 2365	
168	Electrical Remodeling of Left Atrium Is a Better Predictor for Recurrence Than Structural Remodeling in Atrial Fibrillation Patients Undergoing Radiofrequency Catheter Ablation.. 2021 ,	1
167	Atrial Fibrillation With Decompensated Heart Failure Complicated With Non-ST Elevation Myocardial Infarction.. 2022 , 14, e21050	
166	Catheter ablation for atrial fibrillation. 2022 , 2022,	
165	Associations of Atrial Fibrillation Patterns With Mortality and Cardiovascular Events: Implications of the MISOAC-AF Trial.. 2022 , 27, 10742484211069422	0
164	Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation.. 2021 , 12, 812018	1
163	Atrial ischemia: An underappreciated piece of the atrial fibrillation mosaic.. 2022 ,	
162	Atrial Fibrillation Is Not an Independent Determinant of Mortality Among Critically Ill Acute Ischemic Stroke Patients: A Propensity Score-Matched Analysis From the MIMIC-IV Database.. 2021 , 12, 730244	0
161	The Determinants of the 13-Year Risk of Incident Atrial Fibrillation in a Russian Population Cohort of Middle and Elderly Age.. 2022 , 12,	0
160	Systematic review and meta-analysis of randomized controlled trials on safety and effectiveness of oral anticoagulants for atrial fibrillation in older people.. 2022 , 1	0

- 159 Similarity Score for the Identification of Active Sites in Patients With Atrial Fibrillation.. **2021**, 12, 767190 1
- 158 The comparison of catheter ablation on hard outcomes versus medical treatment for atrial fibrillation patients: A meta-analysis of randomized, controlled trials with trial sequential analysis.. **2022**, 17, e0262702 0
- 157 Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration.. *Circulation*, **2022**, 145, 392-409 16.7 4
- 156 Comparison of oral anticoagulation use and adherence among Medicare beneficiaries enrolled in stand-alone prescription drug plans vs Medicare Advantage prescription drug plans.. **2022**, 28, 266-274
- 155 Increased atrial effectiveness of flecainide conferred by altered biophysical properties of sodium channels.. **2022**, 166, 23-35 0
- 154 Cardio-Ankle Vascular Index is Associated with Prevalence and New-Appearance of Atrial Fibrillation in Japanese Urban Residents: A Retrospective Cross-Sectional and Cohort Study.. **2022**, 18, 5-15 1
- 153 Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs) as a Platform for Modeling Arrhythmias. **2022**, 1-19
- 152 Joint efficacy of the three biomarkers SNCA, GYPB and HBG1 for atrial fibrillation and stroke: Analysis via the support vector machine neural network.. **2022**, 1
- 151 Human Tissue Analysis of Left Atrial Adipose Tissue and Atrial Fibrillation after Cox Maze Procedure.. **2022**, 11,
- 150 MEDEX South Carolina: a progress report. **1975**, 71, 337-8
- 149 Endovascular occlusion of the left atrialaud in patients with atrial fibrillations. Experience of city hospital. **2022**, 8, 24-32
- 148 Impact of atrial fibrillation and the clinical outcomes in patients with acute myocardial infarction from the K-ACTIVE registry.. **2022**, 0
- 147 New cerebral microbleeds in AF patients on non-vitamin K oral anticoagulants or warfarin: One-year follow-up.. **2022**, 101, e25836 0
- 146 Decreasing time between first diagnosis of paroxysmal atrial fibrillation and cryoballoon ablation positively affects long-term consequences.. **2022**, 1 2
- 145 Left Atrioventricular Coupling for Early Prediction of Incident Atrial Fibrillation.. **2022**, 213293
- 144 Association between oral health and atrial fibrillation: A systematic review. **2022**, 8, e09161 1
- 143 Incidence of atrial fibrillation in elderly patients with type 2 diabetes mellitus.. **2022**, 10, 0
- 142 Association Between Atrial Fibrillation and the Risk of Cardiovascular Mortality Among Elderly Adults With Ischemic Stroke in Northeast China: A Community-Based Prospective Study.. **2022**, 14, 836425 1

141	Healthcare resource utilization in patients with newly diagnosed atrial fibrillation in the United States.. 2022 ,	1
140	Adherence to Anticoagulation Interruption Guidelines in Patients with Atrial Fibrillation.. 2022 , 1-17	
139	Comparison of the Mid-Term Outcomes of Robotic Magnetic Navigation-Guided Radiofrequency Ablation versus Cryoballoon Ablation for Persistent Atrial Fibrillation.. 2022 , 9,	2
138	Are 2 Left Atrial Appendage Guards Better Than 1? The Amulet IDE Randomized Trial.. <i>Circulation</i> , 2022 , 145, 739-741	16.7 0
137	Prediction of Atrial Fibrillation in Hospitalized Elderly Patients With Coronary Heart Disease and Type 2 Diabetes Mellitus Using Machine Learning: A Multicenter Retrospective Study.. 2022 , 10, 842104	
136	Self-reported Sleep Quality Before and After Atrial Fibrillation Ablation.. 2022 ,	
135	Identification of Incident Atrial Fibrillation From Electronic Medical Records.. 2022 , e023237	2
134	Cohort design and natural language processing to reduce bias in electronic health records research.. 2022 , 5, 47	2
133	Interpretable risk models for Sleep Apnea and Coronary diseases from structured and non-structured data. 2022 , 200, 116955	
132	End-to-End Optimized Arrhythmia Detection Pipeline using Machine Learning for Ultra-Edge Devices. 2021 ,	
131	Atrial branch coronary artery stenosis as a mechanism for atrial fibrillation.. 2021 ,	0
130	NT Pro-BNP can be used as a risk predictor of clinical atrial fibrillation with or without left atrial enlargement.. 2021 ,	4
129	Polarization-sensitive optical coherence tomography monitoring of percutaneous radiofrequency ablation in left atrium of living swine.. 2021 , 11, 24330	2
128	Thirty-Year Trends in the Incidence of Atrial Fibrillation: The ARIC Study.. 2022 , e023583	0
127	Detection of Common Arrhythmias by the Watch-PAT: Expression of Electrical Arrhythmias by Pulse Recording.. 2022 , 14, 751-763	
126	Image_1.TIF. 2019 ,	
125	Image_2.TIF. 2019 ,	
124	Image_3.TIF. 2019 ,	

123 Image_4.TIF. **2019**,

122 Image_5.TIF. **2019**,

121 Image_6.TIF. **2019**,

120 Image_7.TIF. **2019**,

119 Video_1.AVI. **2019**,

118 Video_10.AVI. **2019**,

117 Video_11.AVI. **2019**,

116 Video_2.AVI. **2019**,

115 Video_3.AVI. **2019**,

114 Video_4.AVI. **2019**,

113 Video_5.AVI. **2019**,

112 Video_6.AVI. **2019**,

111 Video_7.AVI. **2019**,

110 Video_8.AVI. **2019**,

109 Video_9.AVI. **2019**,

108 Image_1.pdf. **2019**,

107 Image_2.pdf. **2019**,

106 Table_1.docx. **2019**,

105 Table_2.docx. **2019**,

104 Table_3.docx. **2019**,

103 Use of anticoagulant drugs in patients with atrial fibrillation. Does adherence to therapy have a prognostic impact?. **2022**, 150, 113002

102 The WATCHMAN device and post-implantation anticoagulation management. A review of key studies and the risk of device-related thrombosis.. **2021**, 11, 714-722

101 Left atrial appendage closure with Watchman device: Insights from the first-ever Tunisian experience and six-year follow-up.. **2021**, 99, 525-530

100 STUDY ON RELATIONSHIP BETWEEN OBESITY & LIPID PROFILE IN NORMAL POPULATION OF CENTRAL UTTAR PRADESH. **2022**, 27-30

99 Temporal trends and patterns in atrial fibrillation incidence: A population-based study of 374 million individuals. **2022**, 100386 2

98 Machine learning based potentiating impacts of 12-lead ECG for classifying paroxysmal versus non-paroxysmal atrial fibrillation. **2022**, 23,

97 Sex-Differences in Atrial Fibrillation Patients: Bias or Proper Management?. **2022**, 18, 347-358 o

96 Prospective evaluation of the effect of smartphone electrocardiogram usage on anticoagulant medication compliance.. **2022**, 1

95 Impact of treatment adherence on the effectiveness and safety of oral anticoagulants in patients with atrial fibrillation: A retrospective cohort study.. **2022**,

94 The Chinese burden of atrial fibrillation review of atrial fibrillation studies in China.. **2022**, o

93 Percutaneous transhepatic venous access for left atrial appendage closure in a patient with left sided inferior vena cava with hemiazygos continuation. **2022**,

92 Improvement in the Management of Oral Anticoagulation in Patients with Atrial Fibrillation in Primary Health Care. **2022**, 19, 6746

91 Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants. **2022**, 5, e2214321 o

90 Beneficial Effect of Edoxaban on Preventing Atrial Fibrillation and Coagulation by Reducing Inflammation via HBG1/HBD Biomarkers. 13,

89 Automated Indicator of Atrial Fibrillations Risk Using Machine Learning. **2021**,

88 Automatic Cardiac Arrhythmia Classification Using Residual Network Combined with Long Short-term Memory. **2022**, 1-1 1

- 87 DIFFERENCES IN OUTCOMES AMONG PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING CATHETER ABLATION WITH VERSUS WITHOUT INTRACARDIAC ECHOCARDIOGRAPHY. 1
- 86 Patient Clusters and Cost Trajectories in Atrial Fibrillation: Evidence from the Swiss Atrial Fibrillation Cohort.
- 85 Association between serum apolipoprotein B and atrial fibrillation: a caseâcontrol study. **2022**, 12, 1
- 84 Incidence and clinical relevance of upper gastrointestinal pathology during preprocedural endoscopy in patients undergoing pulmonary vein isolation. 0
- 83 Impact of Medication Adherence on the Association Between Oral Anticoagulant Use and Risk of Dementia: A Retrospective Cohort Study using the Japanese Claims Database. 0
- 82 Feasible approaches and implementation challenges to atrial fibrillation screening: a qualitative study of stakeholder views in 11 European countries. **2022**, 12, e059156 0
- 81 Automated detection of atrial fibrillation based on vocal features analysis.
- 80 Atrial Fibrillation With Myocardial Infarction Presenting as a Progressive Worsening Fatigue in a Young Male. **2022**,
- 79 Association of atrial fibrillation burden with in-hospital outcomes in patients with Takotsubo cardiomyopathy. **2022**, 0
- 78 Long-Term Outcomes of Preoperative Atrial Fibrillation in Cardiac Surgery. **2022**,
- 77 Quantitative Analysis Using Consecutive Time Window for Unobtrusive Atrial Fibrillation Detection Based on Ballistocardiogram Signal. **2022**, 22, 5516
- 76 Geographic and temporal variation in the treatment and outcomes of atrial fibrillation: a population-based analysis of national quality indicators. **2022**, 10, E702-E713 0
- 75 Safety and long-term efficacy of cryoballoon ablation for atrial fibrillation in octogenarians: a multicenter experience.
- 74 Impact of Catheter Ablation on Brain Microstructure and Blood Flow Alterations for Cognitive Improvements in Patients with Atrial Fibrillation: A Pilot Longitudinal Study. **2022**, 11, 4346 0
- 73 Impact of Atrial Fibrillation on Patients With Inflammatory Bowel Disease Admitted for Colectomy. **2022**,
- 72 Assessment of Left Atrial Structure and Function by Echocardiography in Atrial Fibrillation. **2022**, 12, 1898
- 71 The blanking period after atrial fibrillation ablation: an European Heart Rhythm Association survey on contemporary definition and management. 0
- 70 Impact of Catheter Ablation on Long-Term Outcomes in Patients With Atrial Fibrillation: A Meta-Analysis. **2022**, 1

- 69 Higher Na⁺-Ca²⁺ Exchanger Function and Triggered Activity Contribute to Male Predisposition to Atrial Fibrillation. **2022**, 23, 10724 ○
- 68 Incidence and Complications of Atrial Fibrillation in a Low Socioeconomic and High Disability United States (US) Population: A Combined Statistical and Machine Learning Approach. **2022**, 2022, 1-14 ○
- 67 Vagal milieu or electrophysiologic substrate? The link between atrial fibrillation and obstructive sleep apnea. 153537022211202 ○
- 66 Targeting autonomic nervous system as a biomarker of well-ageing in the prevention of stroke. 14, ○
- 65 A subspace projection approach to quantify respiratory variations in the f-wave frequency trend. 13, ○
- 64 Sex-based differences in atrial fibrillation ablation adverse events. heartjnl-2022-321192 ○
- 63 Impact of ABCB1 C3435T Polymorphism on Treatment Response of Vitamin K Antagonists: A Systematic Review and Meta-analysis. **2022**, 32, 238-250 ○
- 62 Nine-Year Trends in Prevention of Thromboembolic Complications in Elderly Patients with Atrial Fibrillation Treated with NOACs. **2022**, 19, 11938 ○
- 61 Development and validation of a nomogram for predicting atrial fibrillation in patients with acute heart failure admitted to the ICU: A retrospective cohort study. ○
- 60 Health care utilization in a nurse practitioner-led atrial fibrillation clinic. 1139-1148 ○
- 59 Implementation of Time-Frequency Moments for the Classification of Atrial Fibrillation Sequences Through a Bidirectional Long-Short Term Memory Network. **2022**, 201-214 ○
- 58 Associations of Atrial Fibrillation with Mild Cognitive Impairment and Dementia: An Investigation Using SPRINT Research Materials. **2022**, 11, 5800 ○
- 57 Sex-specific time trends in incident atrial fibrillation and the contribution of risk factors: the Tromsø Study 1994-2016. 1
- 56 Mechanisms and clinical manifestations of cognitive decline in atrial fibrillation patients: potential implications for preventing dementia. **2022**, ○
- 55 Patient Perspectives on Performance of a Smartphone App for Atrial Fibrillation Self-Management. Volume 16, 2799-2810 ○
- 54 Prevalence and Incidence Rates of Atrial Fibrillation in Denmark 2004-2018. Volume 14, 1193-1204 ○
- 53 Cannabis, cocaine, methamphetamine, and opiates increase the risk of incident atrial fibrillation. ○
- 52 Advancing anticoagulation stewardship: A call to action for stewardship from the US-based anticoagulation forum. **2022**, 100125 ○

- 51 Efficacy of a Novel Bipolar Radiofrequency Clamp: An Acute Porcine Model. 155698452211265 ○
- 50 U-shaped association between the triglyceride-glucose index and atrial fibrillation incidence in general people without known cardiovascular disease. ○
- 49 Intravenous metoprolol versus diltiazem for atrial fibrillation with concomitant heart failure. **2022**, 62, 49-54 ○
- 48 Introduction to Atrial Fibrillation. **2008**, 3-32 ○
- 47 Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs) as a Platform for Modeling Arrhythmias. **2022**, 875-893 ○
- 46 Some good reasons to proceed with the occlusion of the auricle. **2022**, 24, 157-160 ○
- 45 Screening strategies for atrial fibrillation in the elderly population: a systematic review and network meta-analysis. ○
- 44 Patient clusters and cost trajectories in the Swiss Atrial Fibrillation cohort. heartjnl-2022-321520 ○
- 43 Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Economic Evaluations. **2023**, 33, 99-108 ○
- 42 Time trends in antithrombotic therapy prescription patterns: Real-world monocentric study in hospitalized patients with atrial fibrillation. 14, 576-598 ○
- 41 Association of chronic kidney disease with all-cause mortality in patients hospitalized for atrial fibrillation and impact of clinical and socioeconomic factors on this association. 9, ○
- 40 Comprehensive nationwide incidence and prevalence trends of atrial fibrillation in Finland. **2022**, 9, e002140 ○
- 39 Machine learning for atrial fibrillation risk prediction in patients with sleep apnea and coronary artery disease. 9, ○
- 38 Development and validation of a nomogram for predicting atrial fibrillation in patients with acute heart failure admitted to the ICU: a retrospective cohort study. **2022**, 22, ○
- 37 Atrial fibrillation: Epidemiology, pathophysiology, and clinical complications (literature review). 1
- 36 Temporal trends in admissions for atrial fibrillation and severe bleeding in England: an 18-year longitudinal analysis. **2023**, 57, 40-47 ○
- 35 Left Atrial Mechanical Dysfunction and the Risk for Ischemic Stroke in People Without Prevalent Atrial Fibrillation or Stroke. 1
- 34 Atrial fibrillation and stroke. 1

33	The Aging Heart: A Molecular and Clinical Challenge. 2022 , 23, 16033	2
32	Comparative Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin Among Adults With Cancer and Atrial Fibrillation. 2022 , 15,	0
31	Association of obesity with incident atrial fibrillation in Korea and the United Kingdom.	0
30	What has sex got to do with it?. 2023 ,	0
29	Role of Heat Shock Proteins in Atrial Fibrillation: From Molecular Mechanisms to Diagnostic and Therapeutic Opportunities. 2023 , 12, 151	0
28	COVID-19 and atrial fibrillation: Intercepting lines. 10,	0
27	Autonomic nervous system and cardiac neuro-signaling pathway modulation in cardiovascular disorders and Alzheimer's disease. 14,	0
26	Pulmonary vein isolation-induced vagal nerve injury and gastric motility disorders.	0
25	Atrial fibrillation in real clinical practice at the outpatient stage. 2023 , 30, 5-10	0
24	The role of protein glycosylation in the occurrence and outcome of acute ischemic stroke. 2023 , 106726	0
23	A Smart IoT Gateway Capable of Prescreening for Atrial Fibrillation. 2022 , 111-123	0
22	Anteriolateral versus anterior-posterior electrodes in external cardioversion of atrial fibrillation: A systematic review and meta-analysis of clinical trials. 2023 , 46, 359-375	0
21	Surgical volume and outcomes of surgical ablation for atrial fibrillation: a nationwide population-based cohort study. 2023 , 23,	0
20	Automated analysis framework for in vivo cardiac ablation therapy monitoring with optical coherence tomography. 2023 , 14, 1228	0
19	Sex differences in atrial fibrillation ablation in-hospital outcomes from the National Inpatient Sample database 2016-2019. 2023 , 39, 149-158	0
18	Sex Differences in the Association Between Hypertension and Incident Atrial Fibrillation. 2023 , 12,	0
17	Utility of short-term telemetry heart rhythm monitoring and CHA2DS2-VASc stratification in patients presenting with suspected cerebrovascular accident. 15, 56-63	0
16	Mitochondrial Dysfunction in Cardiac Arrhythmias. 2023 , 12, 679	1

- 15 Kinase Inhibitors and Atrial Fibrillation. **2023**, ○
- 14 H2ARDD score as a feasible predictor of heart failure events in patients with atrial fibrillation: a validation study. ○
- 13 Wavelet transform and vector machines as emerging tools for computational medicine. **2023**, 14, 4595-4605 ○
- 12 Association of accelerometer-derived circadian abnormalities and genetic risk with incidence of atrial fibrillation. **2023**, 6, ○
- 11 The Integration of Artificial Intelligence Into Patient Care: A Case of Atrial Fibrillation Caught by a Smartwatch. **2023**, ○
- 10 Subject-specific factors affecting particle residence time distribution of left atrial appendage in atrial fibrillation: A computational model-based study. 10, ○
- 9 Buscando Novos Parâmetros Não Invasivos para Prever a Fibrilação Atrial após Ablação por Cateter de Radiofrequência. **2023**, 120, ○
- 8 Is Age Associated with Complications of Atrial Fibrillation Catheter Ablation?. **2023**, 36, ○
- 7 Machine learning-based analysis of risk factors for atrial fibrillation recurrence after Cox-Maze IV procedure in patients with atrial fibrillation and chronic valvular disease: A retrospective cohort study with a control group. 10, ○
- 6 Stroke in Atrial Fibrillation and Other Atrial Dysrhythmias. ○
- 5 Latest incidence and electrocardiographic predictors of atrial fibrillation: a prospective study from China. **2023**, 136, 313-321 ○
- 4 Association of obesity with incident atrial fibrillation in Korea and the United Kingdom. **2023**, 13, ○
- 3 Atrial fibrillation as a contributor to the mortality in patients with dementia: A nationwide cohort study. 10, ○
- 2 Challenges of Anticoagulant Therapy in Atrial Fibrillation—Focus on Gastrointestinal Bleeding. **2023**, 24, 6879 ○
- 1 Associations of Community and Individual Social Determinants of Health With Medication Adherence in Patients With Atrial Fibrillation: A Retrospective Cohort Study. **2023**, 12, ○